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ABSTRACT
BACKGROUND
Severe infection with Respiratory Syncytial Vims (RSV) is an important cause of respiratory 
failure in infants and young children. Pulmonary surfactant is a surface-active complex of 
phospholipids and proteins which lines the alveolar surface of the lung. Clinical similarities of 
severe RSV infection to Respiratory Distress Syndrome of the newborn (RDS) and Adult 
Respiratory Distress Syndrome (ARDS) suggest that surfactant abnormalities may be involved 
in the pathogenesis of the disease.
HYPOTHESIS
The hypothesis tested in this study is that the pulmonary surfactant system is dysfunctional in 
severe RSV infection, due to deficiency, abnormal composition, damage or inhibition.
PATIENTS AND METHODS 
Patients
Non-bronchoscopic bronchoalveolar lavage was performed on 18 children ventilated for severe 
RSV infection and 16 children ventilated for surgical procedures and post operative care. 
Sequential daily samples were collected from those patients ventilated for more than 1 day. 
Methods
Bronchoalveolar lavage fluid was examined for surfactant function, surfactant content and 
composition, indices of surfactant damage and evidence of surfactant inhibition as follows: 
Surfactant function
1. Surfactant activity in whole BAL sample - shake and click tests
2. Surface activity of an organic extract of BAL fluid - pulsating bubble surfactometer 
(PBS)
Surfactant content and composition
1. Surfactant proteins A,B and D - enzyme-linked immunosorbent assays (ELISA)
2. Total phospholipid - gas chromatography-mass spectrometry (GC-MS)
3. Phospholipid classes - high performance thin layer chromatography (HPTLC) and 
scanning densitometry
4. Phospholipid long chain fatty acids - GC-MS 
Indices o f surfactant damage
1. Maiondialdehyde (a lipid peroxidation product) - higli performance liquid 
chromatography
2. Nitrotyrosine (an index of damage by peroxynitrite) - ELISA
3. Lysophosphatidylcholine and glycolipids - HPTLC 
Surfactant inhibitors and inhibitory capacity of BAL proteins
1. Total protein - Lowry method
2. Albumin (a surfactant inhibitor) - immunoturbimetry
3. C-reactive protein (a surfactant inhibitor) - immunoturbimetry
4. D-dimer fibrin degradation product (a surfactant inhibitor) - ELISA
5. Surface activity of bovine surfactant plus proteins from 40,000g supernatant of 
BAL fluid - PBS
RESULTS
Tire following results were found in ventilated patients with RSV infection compared to 
controls:
Surfactant function
1. Surfactant activity in the whole BAL sample, measured by shake and click tests was 
reduced.
2. Surfactometer studies of organic extracts of BAL fluid (adjusted to ImM phospholipid) 
showed no evidence of functional impairment. This measurement assessed surfactant 
function in isolation from surfectant inhibition or deficiency.
Surfactant content and composition
1. Surfactant proteins A, B and D were reduced. The reduction in protein A was small but 
significant. Median surfactant protein A concentration was lower on the first day of 
ventilation than on the last in children with RSV infection. No pattern was evident for 
surfactant proteins B or D
2. Surfactant protein B was reduced when expressed per pg phospholipid
3. Total phospholipid content of BAL was reduced.
4. The combined fi-action of phosphatidylcholine and sphingomyelin (PC&S - which could not 
be separately distinguished by densitometry) was reduced. Phosphatidylserine and 
phosphatidylglycerol (PG) fractions were increased. There was no difference between groups 
in the proportion of phosphatidylinositol detected. The changes in PC&S and in PG were 
small. Phosphatidylinositol and PG varied reciprocally throught the illness in patients with 
RSV. The proportion of phosphatidylethanolamaine (PE) present in BAL fluid could not be i 
assessed, as PE co-migrated with a glycolipid fraction in samples from the RSV group.
5. The 14:0, 16:0 and 16:1 species of phospholipid fatty acids were reduced. The 18:0 and 18:1 
species were increased. No difference was found in 18:2 and 20:4 species between groups.
Indices o f surfactant damage
1. Maiondialdehyde was reduced and nitrotyrosine was increased.
2. Lysophosphatidylcholine and glycolipids were increased.
Evidence for surfactant inhibition
1. Total BAL protein was elevated, as was the D-dimer fibrin degradation product.
2. There was no difference in BAL albumin between patients with RSV and controls.
3. C-reactive protein was not detected in any BAL samples
4. Pulsating bubble surfectometer studies showed that 1 mg/ml of BAL supernatant proteins 
from
patients with RSV inhibited bovine surfactant more than 1 mg/ml of BAL supernatant 
proteins
from controls.
CONCLUSIONS
It was concluded that in children with severe RSV infection, surfactant was dysfunctional.
Tliere was evidence that two mechanisms contributed to this:
1. Pulmonary surfactant proteins and phospholipids were deficient.
2. Surfactant surface activity was inhibited.
Surfactant phospholipid and fatty acid composition was abnormal, and surfactant damage was 
present. However, the surface active properties of an organic extract of BAL fluid were intact.
This indicated that damage to surfactant and change in composition did not reduce surface 
activity. There was minimal damage to lipids by peroxidation.
In conclusion, the pulmonary surfactant system is abnonnal in children with severe RSV 
infection. Surfiictant abnormality may be an important factor leading to respiratory failure in 
these children.
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1. INTRODUCTION
1.1. RESPIRATORY SYNCYTIAL VIRUS INFECTION
1.1.1. EPIDEMIOLOGY AND DIAGNOSIS
Epidemiology
Respiratory Syncytial Virus (RSV) is one o f the most important viral pathogens of 
infancy and early childhood. It causes annual epidemics of respiratory disease mainly in 
children under one year o f age. Epidemics are of 3-5 months in duration and occur 
most commonly in winter and early spring (Kim et al. 1973). The disease is widespread 
in the community, and, during an epidemic, 44% of families with young children may 
be affected (Hall et al. 1976). I f  a child becomes infected with RSV, the risk of 
hospitalisation is between 1 and 2 percent (Sims et al. 1976). Usually, if hospital 
admission is required, the infection has spread from the upper respiratory tract to the 
small airways (bronchiolitis) or the lung parenchyma and alveoli (pneumonia).
Although only a small percentage of children who contract RSV infection become ill 
enough to require hospital care, during an epidemic, cases of RSV bronchiolitis and 
pneumonia account for a sizeable proportion of the workload in a children’s hospital.
In one study, nearly 85% of children admitted to hospital with respiratory disease in an 
"epidemiologic’ year (ie. from the beginning of one epidemic to the beginning of the 
next) had viral bronchiolitis or pneumonia (Mufson et al. 1973). When infants are 
hospitalised with these conditions, RSV is the pathogen involved in over 70% of cases
18
Diagnosis
Culture of RSV may be difficult, as the virus is labile. Diagnostic tests based on the 
detection of viral antigens in respiratory epithelial cells by immunofluorescence are 
now both very rapid and highly sensitive and specific. Such tests have replaced culture- 
based systems. Recent work has been directed towards more efficient methods o f viral 
sampling (Mackie et al. 1991) and to the development of near-patient diagnostic tests. 
Molecular techniques based on polymerase chain reaction are also now available. The 
increased sensitivity of testing methods may reveal that an even greater proportion of 
bronchiolitis and pneumonia is due to RSV infection than has hitherto been 
documented.
(Sims et al. 1976). While severe infection can occasionally be fatal, especially in infants 
with underlying disease such as congenital heart defects and immunosuppression, 
mortality rates for hospitalised children with the virus are now around 1% (Wang et al. » 
1995; Navas et al. 1992)
.iff
1.1.2. CLINICAL COURSE
The clinical course and severity of RSV infection varies greatly. Typically, the illness 
starts with rhinoixhoea and pharyngitis which persist for one to three days before the
'development of a cough. Narrowing of the small airways is a characteristic of the
■
disease, and this gives rise to an audible wheeze. Rhinorrhoea and intermittent low 
grade pyrexia persist throughout the illness. The clinical condition may worsen, with 
increased coughing, wheezing and crepitations accompanied by intercostal recession
:
and hyperexpansion (Ackerman and Salva, 1994).
19
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Information on the histopathological changes which accompany severe RSV infection 
has been gleaned from animal studies and from post mortem studies of lung sections 
from patients who died of the disease.
20
At the most severe end o f the spectrum, small airways become obstructed by plugs of 
mucus and cellular debris, giving rise to atelectasis and increased pulmonary shunting. /
Airway resistance increases, work o f breathing is increased, and respiratory failure with 
hypoxaemia and metabolic acidosis may supervene. In such children, poor air entry, 
central cyanosis, tachypnoea, listlessness and, occasionally, periods of apnoea herald a 
need for urgent ventilatory support. The support required ranges from continuous 
positive airways pressure to full intermittent positive pressure ventilation or, in very 
severe cases, extracorporeal membrane oxygenation.
»
1.1.3. PATHOLOGICAL CHANGES IN SEVERE RSV INFECTION
At a microscopic level, the consequences of severe RSV infection involve damage to 
the respiratory epithelium, increased mucus secretion, a fibrinous exudate and invasion 
of the alveoli and bronchi by inflammatory cells.
Human studies
While RSV infection is common, pathological data are surprisingly sparse. The 
available data on the human lung come mainly from fixed post-mortem specimens. The 
series are small (Holzel et al. 1963; Wright et al. 1997; Gardner et al. 1970), often 
being case reports of one or two fatal cases.
.i i* 'liî
pathological picture in the group with pneumonia was heterogeneous, with different 
features prominent in each patient.
Another case report from Halzel et al (1963) reported desquamation of cilated
21
Aheme and colleagues (1970) studied post mortem lung tissue from 9 patients in
.  ■which RSV was recovered, and who were classed as having RSV bronchiolitis or 
pneumonia. In all these patients, there was necrosis of the bronchiolar epithelium and a 
peribronchiolar infiltrate of lymphocytes. Small airways were blocked by plugs of 
mucus, cell debris and fibrin, leading to subsegments of alveolar collapse. These 
patients were considered to have 'bronchiolitis'. In four patients, in addition to the 
changes of bronchiolitis, the process extended to the alveoli (pneumonia), and in these 
patients, pathological features included inflammatory infiltration of the air spaces and 
parenchyma, alveolar oedema and exudate and focal necrosis of areas o f lung. The
-ÎGardner et al (1970) reported post mortem findings from two infants who died within 
two hours of onset o f lower respiratory tract symptoms. Lung sections from these 
patients showed 'acute bronchiolitis' with epithelial necrosis, peribronchiolar infiltration 
of lymphocytes, increased mucus secretion and thick plugs o f fibrin in the bronchioles. 
In these children, the alveoli were enlarged - presumably due to gas trapping behind 
partially obstructed small airways - but contained no cellular infiltrate. In a third child 
who died after 5 days of'suspected pneumonia', an inflammatory exudate containing 
mononuclear cells was seen in the small bronchioles, alveoli and alveolar ducts, and 
cellular infiltration of interstitial tissue was evident.
columnar epithelium, lymphocytic infiltration of bronchial walls, and small areas of
consolidation in a post mortem lung specimen from a 10 month old boy who had died 
from RSV bronchiolitis.
Recently, Wright and colleagues (1997) reported findings from immunostaining of post 
mortem lung tissue from two patients who had died of 'severe RSV pneumonitis'. In 
both cases, viral antigen staining was demonstrated in bronchial and bronchiolar 
epithelial cells. Alveolar pneumocytes staining positive for viral antigens were seen 
lining distorted alveolar spaces in one o f the two cases with no distinction being made 
between type I and type II pneumocytes. In the second case, staining was confined to 
small airways. The number of antigen positive cells varied from airway to airway in 
both cases.
To date, only one study has reported on bronchoalveolar lavage (BAL) findings.
Lavage fluid from ventilated infants with severe RSV infection was examined, and 
found to contain around 80% neutrophils, 10% lymphocytes and 10% mononuclear 
phagocytes. Eosinophils accounted for less than 1% of cells seen (Everard et al. 1994). 
These findings seem to be at odds with the peribronchiolar infiltrate of lymphocytes 
described by previous authors (Aherne et al. 1970; Holzel et al. 1963; Gardner et al. 
1970) who studied post mortem tissue sections. However, Everard and colleagues 
(1994) suggest that this discrepancy may be explained by rapid migration of 
neutrophils into the airway lumen in vivo.
Animal studies
As yet, no fully satisfactory animal model of human RSV infection has been developed. 
It is difficult to reproduce the clinical picture of severe RSV infection by inoculating
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animais with human RSV, and responses to bovine RSV vary between species. There
- i
are, however, enough histopathological similarities between human RSV and animal
models for the latter to be of some use in understanding human disease.  ^ i
within the alveolar spaces (Meehan et al. 1994).
I
Infection with Respiratory Syncytial Virus is followed by the clinical symptoms o f a
lower respiratory tract illness only in large animals. For example, calves infected with
the bovine strain of the virus develop necrosis of the bronchiolar epithelium and an i
extensive peribronchiolar infiltrate of inflammatory cells. In these animals, viral
»
antigens can be demonstrated by immunofluorescence in the cells of alveolar walls and 
bronchiolar epithelium. However, infection of calves with a human isolate of RSV does 
not lead to development of the clinical signs of respiratory disease (Stott and Taylor,
1985). Lambs experimentally infected with bovine RSV have been found to develop 
focal areas of lung consolidation, necrosis of pulmonary epithelial cells and
■Iaccumulation of cell debris (Cutlip and Lehmkuhl, 1979). In adult sheep exposed to 
bovine RSV, viral antigen has been found in bronchiolar epithelium. Type I 
pneumocytes, Type II pneumocytes, alveolar macrophages and mononuclear cells
Experimental RSV pneumonia has been reproduced in monkeys after inoculation with 
a strain of RSV known to cause severe pulmonary infection in humans. These animals 
developed areas of consolidation with thickening of the alveolar walls which were 
infiltrated by polymorphonuclear leukocytes and mononuclear inflammatory cells.
Multinucleated giant cells (syncytia) with eosinophilic cytoplasmic inclusions were I
present in the alveoli along with proteinaceous fluid and inflammatory cells. In these 
primates, viral antigen was detected by immunofluorescence in occasional tracheal
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epithelial cells, and, more extensively in alveolar cells, lung parenchyma and 
bronchiolar epithelium (Richardson et al. 1978).
By contrast, attempts to inoculate small animals eg. mice, rats, guinea pigs and ferrets 
with human RS V have not produced clinical signs of lower respiratory tract disease 
(Graham et al. 1988; Prince et al. 1978; Hegele et al. 1993; Stott and Taylor, 1985).
1.2. THE PULMONARY SURFACTANT SYSTEM
1.2.1. INTRODUCTION
Pulmonary surfactant is a surface-active complex of proteins and phospholipids which 
lines the alveolar surface of the lung. Surfactant helps to maintain alveolar patency 
throughout the respiratory cycle, and thus allows adequate pulmonary gas exchange. 
Other functions attributed to pulmonary surfactant include protection of cell surfaces, 
assistance in keeping the alveoli free of fluid, participation in the defence against 
micro-organisms and maintenance of small airway patency.
1.2.2. SURFACTANT FHOSHOLIPIDS
The surfactant lipid-protein complex consists of approximately 90% lipids and 5-10% 
surfactant-specific proteins (King et al. 1973). Phospholipids account for 80-90% of 
the surfactant lipids, with the remaining 10-20% comprising cholesterol, 
triacylglycerols and free fatty acids (King, 1984).
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Phospholipid classes
Six different phospholipid classes have been isolated from pulmonary surfactant. In 
humans, phosphatidylcholine (PC) is the most abundant, at around 60 - 80% of total 
phospholipids, with phosphatidylglycerol (PG) the next most abundant at around 10 - I
20%. In adult humans, the relative proportions of phospholipids vary considerably 
between studies (reviewed by Ratjen et al (1996)). Recently, Ratjen and colleagues 
(1996), using high performance liquid chromatography (HPLC), characterised 
phospholipid classes in normal children between 3 and 15 years of age. In this age 
group, children had a higher proportion of PC (>80%) and a lower proportion of PG 
(<10%) than adults. There are at present no data on the phospholipid classes present in 
surfactant from normal children under 3 years old.
%
'C:>
The other surfactant phospholipid classes, which are less abundant than PC and PG in
humans, are phosphatidylinositol (PI), phosphatidylethanolamine (PE),
.phosphatidylserine (PS) and sphingomyelin (S). Each of these classes individually 
accounts for less than 10% of the total phospholipid complement of lung lavage fluid 
in humans (Ratjen et al. 1996).
In other animal species, PC is also the most abundant class. However, it can be seen 
from Table 1 that PG accounts for a relatively small proportion of surfactant 
phospholipid in some animals (chicken, monkey, cat and pig).
Total fatty acid composition of surfactant phospholipids
Several analyses have been performed on the total fatty acid composition (as opposed 
to individual molecular species) o f PC and PG in humans and animals (Tables 2 and 3).
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The results of these analyses show that 16:0 is the predominant fatty acid in human PC, 
at around 73%. Human neonates have less 16:0 (58.9%) and more 18:1 and 18:2. 
Palmitic acid is also the predominant fatty acid in other species of animals (accounting 
for between 64 and 87% of total PC lipid). The predominant fatty acids of PG can be 
seen from Table 3 to be 16:0 and 18:1.
Phospholipid species - PC
All phospholipids in surfactant are composed of a charged, hydrophilic head group, 
and two hydrophobic hydrocarbon tails. The hydrocarbon tails vary with age, between 
different samples, and between animal species.
Hunt and colleagues (1991), using HPLC, examined the molecular species of lavage 
PC from adults undergoing bronchoscopy, and found 67.6% to consist of the 
16:0/16:0 (dipalmitoylphosphatidylcholine - DPPC) species, 12.7% to be 14:0/16:0, 
7.9% 16:0/16:1,6.1% 16:0/18:2 and 5.8% 16:0/18:1. Lavage PC was enriched in 
14:0/16:0 and 16:0/16:0 compared to lung tissue PC and contained less 16:0/18:1 and 
16:0/18:2 than tissue PC. There is evidence of variation with age in that in lavage PC 
from neonates, the same authors found 51.1% 16:0/16:0, 12.4% 14:0/16:0, 16.0% 
16:0/16:1, 8.2% 16:0/18:2 and 12.7% 16:0/18:1.
The dipalmitoyl species is also a major component of animal surfactant PC. Work done 
on rabbit surfactant indicates that the dipalmitoyl (16:0/16:0) species also accounts for 
over 50% of PC in these animals. Three other species: palmitoyl-oleoyl (16:0/18:1), 
palmitoyl-linoleoyl (16:0/18:2) and palmitoyl-palmitoleoyl (16:0/16:1), together make 
up around 40% (Hayashi et al. 1990). While Khan et al (1995) found that 16:0/16:0
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represented 39% of all PC's in a lipid extract o f calf lung surfactant, disaturated 
species: 16:0/14:0 plus 16:0/16:0 together accounted for 54%.
The fatty acid composition o f surfactant PC may have important implications for 
surface activity, and this is discussed in later sections.
Phospholipid species - PG and PI
Approximately 60% of PG in rabbits was found by Hayashi and colleagues (1990) to 
be composed of a roughly equal mixture o f dipalmitoyl and palmitoyl-oleoyl species . 
The species pattern o f PG and PI in rat surfactant has been shown to be similar, 
containing about 26% 16:0/18:1 species and 15% 16:0/16:0 species (Rustow et al. 
1988).
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Table 1 Proportions of phospholipid classes in animal surfactant. All numbers 
given are percentages
calf (a) monkey
(b)
cat (c) dog (c) 
dog (g) 
dog (h)
rabbit
(c)
rabbit
(0
rat (c) Pig (d) frog (e) chicken
(e)
PC 84 83.2 86.3 81.3
75
74.9
83.6
79.8
87.0 67.1 76.3 79.2
PG 5 1.4 2.1 11.1
10
12.3
8.0
3.7
8.3 2.0 9.1 0
PE 3 2.1 3.2 2.0
5
3.9
3.5
3.5
0.7 +PS 7.1 6.4 5.2
PS 3
3.0
3.1 +P1 1.5 3.0
PI 4 10.3 2
2.4
3.3 4.5 8.9
S 2 1.3 3
3.8
1.7 2.7 0.8 2.9
LPC <1 0.7 0.6 0.5
(a) (Hall et al. 1994) (b) (Egberts et al. 1987) (c) (Shelley et al. 1984) (d) (Body, 1971) (e) (Hallman 
and Gluck, 1976) (f) (Keough et al. 1985) (g) (Kumar et al. 1985) (h) (Clercx et al. 1989)
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Table 2. Percentages of fatty acids in bronchoaiveoiar lavage PC
cow (a) human (b)
neonatal
(d)
human (e) 
human (h)
cat (b) 
turkey (g)
dog(b) 
dog (i)
raWDÎt (b) 
rabbit (f) 
rabbit (g)
rat (b) pig (c)
14:0 3.1 3.5
4.1 
7.4
3.2
3.8
2.3
2.6
5
2.3
2.9
4.0
3.9 5.4
14:1 1.8
14:2 0.5 2.6 (d)
16:0 64.0 73.1
58.9
74.5
72.5
65.7
86.6 65.868
71.6 79.5 
86.9
72.8 73.4
16:1 7.5 7.3
6.9
2.1
5.6
2.8 7.4
12
5.5
1.7
10.4 6.3
16:2 0.4
18:0 2.4 3.2
4.2 3.1 
3.9
3.94.0 6.76 1.61.6
1.1
2.4 3.0
18:1 17.3 8.912.7
7.0
10.0
13.9
5.6 12.87 11.9 10.8 4.8 4.7 10.4
18:2 1.6 2.0
10.1
4.2
4.8
3.0
1.5
1.8
2
5.7
3.33.1
3.7 0.8
18:3 0.3
18:4 0.4
20:4 0.5
:*s
!(a) (Yu et al. 1983) (b) (Shelley et al. 1984) (c) (Body, 1971) (d) (Motoyama et al. 1976) (e) (Post et al. 1982) (f) (Keough et al. 1985) (g) (Fujiwara et al. 1970)
(h) (Pison et al. 1989) (i) (Kumar et al. 1985)
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Table 3. Percentages of fatty acids in bronchoaiveoiar lavage PG
cow (a) human (b) 
human (c)
cat (b) dog(b) rabbit (b) rat (b)
14:0 0.8 1.4 (b)
14:1 0.6
14:2
16:0 51.2 22.2
31.4
36.0 54.5 50.5 58.9
16:1 4.3 3.0
1.1
0.8 3.3 3.2 4.0
16:2 0.4
18:0 4.7 16.7
13.9
6.3 12.6 5.3 5.8
18:1 33.0 51.3
40.4
31.0 23.4 33.5 19.2
18:2 2.9 4.0
6.0
11.2 1.6 5.0 8.7
18:3 0.5
18:4 0.3
20.4 1.0
22:5 0.3
(a) (Yu et al. 1983) (b) (Shelley et al. 1984) (c) (Post et al. 1982)
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1.2.3. THE ROLE OF SURFACTANT PHOSPHOLIPEDS IN THE 
ALVEOLUS 
Lamellar bodies
Surfactant is synthesised and packaged into lamellar bodies in type II cells which, 
together with type I cells, line the alveoli. Lamellar bodies are granular structures 
visible in the cytoplasm of type II cells in frozen sections or on electron microscopy. 
They are composed of surfactant phospholipid bilayers tightly packed around each 
other and woven into a complex array with a variety o f proteins. Once formed, these 
granules are secreted from the Type II cells by exocytosis into an aqueous hypophase 
which is thought to line the alveolus (Figure 1).
Tubular myelin
As well as lamellar bodies, electron microscopic studies (Bastacky et al. 1995) suggest 
the presence, in the hypophase, of tubular myelin, a mesh-like matrix formed from 
surfactant lipids and proteins. It has been suggested that tubular myelin provides a pool 
of surfactant for adsorption to the air-liquid interface in the alveoli (Williams, 1992) 
(Figure 1). However, tubular myelin does not appear to be essential for surfactant 
function as this lattice is not present in all animal species (Wetzstein et al. 1980). 
Furthermore, recent work has shown that in mice who lack surfactant protein A (a 
protein needed for formation of tubular myelin), tubular myelin is not present yet lung 
compliance is normal, indicating satisfactory surfactant function (Korfhagen et al.
1993).
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Figure 1. Surfactant secretion and morphology
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surface tension further still.
Reduction of surface tension and the surfactant monolayer
In 1929, Von Neergaard noted that excised lungs, when filled with fluid, required a
lower transpleural pressure for inflation than air filled lungs. From this observation he
speculated that a substance was present in the lung lining which acted to reduce
surface tension. Von Neergaard's paper, written in German, was all but forgotten until
.the 1950's, when studies o f pulmonary mechanics and foam derived from lung-tissue 
pointed to a similar conclusion (Mead et al. 1957; Pattle, 1958; Clements, 1956; 
Macklin, 1954).
Surfactant phospholipids are thought to align in a monolayer at the air-liquid interface 
in the alveolus, orientated with their hydrophobic tails towards the air phase, and their 
hydrophilic heads in the liquid phase (Figure 1). In simple terms, these phospholipids 
pack together at the interface, reducing the area of contact between air and liquid 
phases, thus reducing surface tension, and preventing alveolar collapse. As the alveolar 
volume becomes less during expiration, the phospholipid molecules pack even closer 
together, reducing the contact between air and liquid even further, and thus reducing
.<5;
Several models of the arrangement o f surfactant in the alveolus have been proposed.
i) Alveolar surfactant models - the bubble
If the alveolus is considered as a bubble connected by a tube to air, this is potentially a 
very unstable situation. If the air pressure outside the bubble is greater than the recoil 
pressure (2y/r from Laplace's Law for a sphere where y is the surface tension and r is
the radius of the bubble), the bubble will rapidly expand and eventually burst. If, on the
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other hand, the outside air pressure is less than the bubble recoil pressure, the bubble
.will empty itself, and eventually collapse. As alveoli are of different sizes, there is no
.
single outside air pressure which could balance 2y/r for all alveoli, as the radius, and 
thus the recoil pressure varies greatly between alveoli. In this situation, alveolar 
'bubbles' would tend to empty into each other and collapse or burst. Clearly since this 
is not what happens in the lung, some mechanism must be operating to prevent this 
from happening.
Clements and colleagues (1961) suggested that a monolayer of surfactant 
phospholipids lining the alveolus would reduce surface tension (y), and thus reduce 
bubble recoil. These phospholipids would keep on reducing surface tension (and thus 
recoil) as the bubble got smaller and the molecules packed more densely. This 
reduction in y would eventually exceed the reduction in radius on the denominator of 
Laplace's equation, thus achieving an equilibrium recoil pressure which is the same for 
all alveoli. This theory, however, assumes that the alveoli behave as though they are 
separate and mechanically independent units. Objections to the 'bubble' model have 
been raised on the grounds that alveoli are mechanically interdependent via connective 
tissue forces, and via a continuous inerconnecting aqueous hypophase and surfactant 
monolayer (Hills, 1988),
ii) Alveolar surfactant models - water repellancy
Hills proposed a model of the alveolus in which the alveolar aqueous hypophase is seen 
as discontinuous. Surfactant is directly adsorbed to the alveolar epithelium, in a water- 
repellent layer. Pools of water, with their convex surfaces orientated in to the alveolar 
cavity are found covered with a surfactant monolayer at the 'corners' of the alveoli.
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Hills maintained that the continuous alveolar lining was found only in the pathological
state when alveolar water increased due to, for example, increased capillary hydrostatic
'
pressure in cardiac failure (Hills, 1988).
Hi) Alveolar surfactant models - the surfactant shell
In contrast, in a third model, Bangham proposed a pulmonary surfactant system where 
a mixed monolayer of DPPC and PG when compressed repeatedly generates an 
irreversible collapse phase o f liposomes enriched with PG, leaving a monolayer 
progressively enriched in DPPC. This DPPC monolayer then provides a mechanically 
rigid 'sheir which stabilises the alveoli, and acts as a splint to stop small alveoli from 
collapsing into large ones. Bangham proposed that these patches o f solid DPPC remain 
functional throughout life, slowly disappearing, and being replenished from lamellar 
bodies (Bangham et al. 1979; Bangham, 1987).
Evidence from electron microscopy
The nature of the surfactant monolayer, and the existence of the aqueous hypophase 
have been difficult to demonstrate microscopically due to evaporation of water with 
use of a vacuum during EM visualisation, and disturbance of aqueous and phospholipid 
layers on fixation. However, Bastacky and colleagues (1995) have recently used rapid 
freezing of rat lung, followed by low temperature scanning electron microscopy, which 
preserves lung water in a frozen, hydrated state to visualise the alveolar lining layer.
Using this technique, they demonstrated a thin, continuous aqueous hypophase 
covering the entire alveolar surface. Additionally, Schurch and co-workers (1995), 
using different fixation techniques, demonstrated a continuous surfactant film lining the
■
alveoli which was thicker than a phospholipid bilayer. This indicates that the putative
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'surfactant monolayer' may actually be a surfactant 'multilayer'. The same authors 
performed in-vitro studies showing recruitment of extra surfactant from a 'surface 
associated reservoir' into the interface of an expanding bubble. This suggested that 
such an arrangement could operate in vivo as the reservoir of surplus surfactant in the 
multilayer which could be incorporated into the surface active film.
Compression, spreading and squeeze out
The ideal features of an effective pulmonary surfactant are as follows:
1. The ability to achieve high dynamic surface pressure and low surface tension when 
compressed at the air liquid interface.
2. The ability to spread rapidly from the hypophase.
3. The ability to respread immediately after compression and monolayer collapse.
4. The ability to sustain a low surface tension for sufficient time to prevent alveolar 
collapse (Clements, 1977; Vodyanoy et al. 1990).
Pure DPPC at 37°C has been described as 'a solid, like candle wax' (Widdicombe, 
1987). The phase transition temperature for DPPC is 42°C. Above this temperature, it 
assumes a more internally mobile liquid-crystalline form. The two rigid, saturated acyl 
tails of dipalmitoylphosphatidylcholine (DPPC) molecules make them ideally suited to 
packing together in an alveolar surfactant monolayer to achieve a high surface pressure 
(satisfying conditions 1 and 4 above). However, fluid unsaturated chains are much 
more suitable for rapid spreading and respreading, and rigid chains are detrimental to 
this ability.
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;Some indication of the influence of acyl chains on spreading and compression of 
surfactant monolayers comes from a study of lamellar body material isolated from 
rabbit lungs. Fetal lamellar body films were found to respread better than adult lamellar  ^ /
body material, and this was thought to be related to the finding of relatively high levels 
of unsaturated lipids in fetal rabbit lung (5 times more 16:1 at position sn-2 of PC in 
fetal compared to adult material). Also, adult lamellar body material achieved a higher 
surface pressure than fetal material, supporting the idea that saturated chains make for 
superior compressibility. Study o f the enthalpy and entropy o f collapse suggested that 
adult lamellar body films, with lower concentrations of unsaturated lipids, undergo on 
compression, a monolayer collapse with energetics similar to that of DPPC 
monolayers. In contrast, fetal lamellar body films tolerated film compression with a 
rapid, reversible loss o f molecules from the surface, providing for better re spreading 
during expansion (Vodyanoy et al. 1990).
I
Supplementation of DPPC in vitro with the more fluid lipids cholesterol or dioleoyl PC 
has also been shown to enhance respreading of DPPC after dynamic post-compression 
collapse (Notter et al. 1980).
Phase transition temperature influences compressibility and spreading of surfactant. It 
appears to be the phase transition temperatures of different PC species which mediates 
their spreading and compressibility at body temperature. Hawco and colleagues (1981) 
studied various mixtures of PC with different fatty acid tails. All could reach a 
minimum surface tension of OmN/m, as long as the temperature of the mixture was 
below the gel to liquid crystalline transition temperature of the lipids under 
observation. This was the case regardless of whether or not the PC's were saturated.
Those above their transition temperature were unable to reach a minimum surface 
tension below 15mN/m, even when highly compressed.
Clements (1977) discussed the dynamic changes which may occur in surfactant during 
the respiratory cycle. He noted that adsorption of lung surfactant to the interface in 
vitro proceeds towards an equilibrium state in which the surface tension is 24 - 28 
mN/m, and that values of surface tension less than this are achieved by compressing 
the film and packing the molecules closer together. In this state, the film is metastable, 
as material escapes fi'om the interface. Clements remarked that this escape happens 
much more slowly from films of pure DPPC at 37°C, and therefore, minimum surface 
tension returns very slowly to equilibrium with DPPC films. On the other hand, 
unsaturated lipids escape much faster, and it may be impossible to drive the surface 
tension below equilibrium. Temperature affects phospholipid escape due to differences 
in behaviour of lipids above and below their phase transition temperature. Clements 
suggested that in inflation, the film is a mixture o f lipids, and in deflation, less stable 
lipids are 'squeezed out'. So perhaps in inspiration, the film may liquefy, and when we 
breathe out, the film may become almost pure solid DPPC.
The role of PG
The second most abundant phospholipid in human surfactant, PG, also appears to play 
a role in the reduction of surface tension in the lung. This acidic phospholipid may act 
as an adjuvant in surfactant adsorption. Obladen and colleagues (1983) found that
:
inclusion of PG in a suspension of DPPC liposomes increased the rate of PC
adsorption to the air-liquid interface. King and MacBeth (1981) also found that 14%
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DPPG in 85.7% DPPC showed enhanced adsorption compared to pure DPPC. 
Interestingly, pure DPPC mixed with PG has a melting point below body temperature.
However, it appears that surfactant function in vivo does not specifically require the 
presence of PG. The pulmonary surfactant of some animals contains another acidic 
phospholipid, PI in place of PG (Table 1). Also, Hallman and co-workers (1985) 
manipulated dietary precursors of PG and PI to favour synthesis of PI in experimental 
animals whose surfactant normally contained PG. They found that surfactant function 
in these animals was not adversely affected by replacement of PG with PL
There are interesting differences in other animal species. For example, PG and PI are 
both absent in the rattlesnake (Daniels et al. 1995). Here, however, removal of 
surfactant has only a marginal effect on lung compliance. Perhaps in these animals, 
surfactant has a different role, for example acting as an anti-glue in folding and 
unfolding lung faveoli.
Temperature and reptilian studies
As stated earlier, normally, the temperature at which DPPC changes fi'om an ordered 
gel phase to a more internally mobile liquid-crystalline phase is around 42°C. Some 
interesting light can be thrown on the function of surfactant by studies of surfactant in 
amphibians, who undergo dramatic alterations in body temperature as part of life.
In a seminal paper on this subject, Lau and Keough (1980) investigated the 
composition of surfactant taken from turtles kept at different temperatures for 1 
month. In BAL surfactant from these animals, stearate and palmitate rose with
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increasing temperature, while myristate and palmitoleate fell, and the proportion of 
saturated fatty acids in PC from BAL was higher in samples from turtles at a higher 
temperature. This suggests that the turtles responded to increasing temperature by 
acquiring lipids in their surfactant with a higher transition temperature. Similarly, 
lizards which habitually maintain a high body temperature (37-40°C) possess relatively 
high levels of disaturated PC and cholesterol in their surfactant (Smits et al. 1994). In 
another species of lizard which may sustain a nocturnal temperature fall from 37 to 
10°C, 48% of fatty acids in the total lipid fraction were found to be saturated, 
compared with 64% in the rat (a homeothermic animal). The saturated 16:0 species, 
which has a relatively high phase transition temperature, predominated in both rat and 
lizard, but the percentage of this fatty acid was greater in the rat (Daniels et al. 1989). 
These studies suggest that body temperature is an important factor in determining 
surfactant fatty acid composition.
As well as altering the degree o f saturation o f their surfactant phospholipids, 
amphibians respond to acute or chronic changes in body temperature by altering the 
amount of cholesterol in their surfactant. Cholesterol inhibits van der Waals forces 
between opposed acyl chains. Below the transition temperature, cholesterol molecules 
align to disrupt acyl-acyl interactions, allowing increased movement o f the tails and 
enhancing fluidity. Toad surfactant has a relatively high cholesterol content and a low 
level of saturation of surfactant phospholipids, which helps surfactant in these animals 
to remain fluid at relatively low water temperatures (Daniels et al. 1994).
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This suggests that the proportions of different lipids and the level of saturation of 
phospholipids in the surfactant of any animal may be specifically designed to allow 
optimal function at that animal's body temperature. In humans, this is 37°C.
1.2.4 SURFACTANT LIPID FUNCTION IN THE SMALL AIRWAYS
Until recently, most considerations of surfactant physical activity have been confined to 
its role in the alveolus, where it lowers surface tension and protects against alveolar 
collapse. Evidence is increasing, however, that surfactant may also play an important 
part in maintaining the patency of small airways in the lung.
In 1991, Liu and colleagues reported that pulmonary surfactant could maintain the 
patency of a narrow glass capillary tube, preventing it from becoming blocked with 
fluid . The capillary tube can be thought o f as analagous to the small airways in the 
lung. This analogy would suggest that an intact and functioning surfactant system may 
be necessary to maintain small airway patency. Enhoming et al. (1995), using excised 
rat lungs, subsequently provided evidence to suggest that surfactant did indeed act to 
maintain the patency o f small airways in these lungs.
1.2.5. IMMUNOLOGICAL FUNCTIONS OF SURFACTANT LIPIDS
In addition to their surface active properties, surfactant lipids may possess 
immunomodulatory properties. Evidence suggests that the immunological activity of 
surfactant lipids depends on what class or species of lipid is studied. 
Phosphatidylcholine, PG and PI have been shown to inhibit T lymphocyte proliferation,
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while PE, S and cholesterol appear to stimulate the growth of lymphocyte colonies in 
response to phytohaemagglutinin (PHA) (Wilsher et a l 1988). Wilsher and colleagues 
(1988) found that the suppression of proliferation by PC, PG and PI depended on the 
relative proportions o f these phospholipids present. It is interesting to note that the 
immunosuppressive lipids PC and PG are prominent in pulmonary surfactant. It is 
tempting to speculate that this helps explain why humans do not mount an immune 
response to surfactant lipids.
Increasing concentrations of DPPC have been shown to suppress concanavalin A - 
induced proliferation of rat splenocytes. (Spleen cells were used rather than immune 
cells from the lung which may already have been influenced by surfactant) (Kremlev et 
al. 1994).
Unsaturated phosphatidylcholines have been shown to inhibit superoxide generation by 
neutrophils in vitro stimulated by 1,2-dioctanoyl-sn-glycerol, while saturated PC's had 
no effect. Individual surfactant lipid components have also been demonstrated to have 
different effects on priming o f alveolar macrophages for oxidative responses 
(Hayakawa et al. 1992).
The immunological functions o f whole surfactant may prove complex to unravel. As 
described above, different lipids have different effects on cells of the immune system. 
In addition, there is evidence that both surfactant lipids and surfactant proteins 
participate in pulmonary defence mechanisms. The immunological role of surfactant 
proteins is discussed in the next section.
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1.2.6. SURFACTANT COMPOSITION - PROTEINS
As noted earlier, proteins account for 5-10% of the composition of pulmonary 
surfactant. Four proteins have been named as surfactant proteins (SP): SPA, SPB, SPC 
and SPD. However, it is interesting to note that although SPD is designated as a 
surfactant protein, 70% of SPD is recovered in the supernatant after high speed 
centrifugation of alveolar surfactant, while SPA, SPB and SPC are recovered in the 
surfactant lipid pellet. Also, although surfactant proteins A, B and C are present in 
lamellar bodies, SPD is not (Johanssen and Curstedt, 1997).
Surfactant protein A has immunological functions, and affects the surface-activity of 
surfactant lipids. Surfactant proteins B and C, two small hydrophobic proteins, have 
functions mainly associated with modulating surface activity, while the most recently 
discovered protein, surfactant protein D appears to play a role in local immune 
defences in the lung.
Surfactant protein A
Human surfactant protein A (SPA) is a glycoprotein (White et al. 1985) with a similar 
tertiary structure (but not amino acid sequence) (Benson, 1993) to the 
immunologically active complement protein, C lq, and to a group o f carbohydrate 
binding proteins, the C-type lectins. C-type lectins are extracellular proteins which 
possess disulfide bonds and bind to carbohydrate ligands in a calcium dependent 
manner (Van Golde, 1995; Benson, 1993).
The quaternary stmcture of SPA is shown in Figure 2. Polypeptide chains of SPA form 
into trimeric units, and six of these trimers associate in vivo to form the SPA oligomer
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which has been likened in shape to a 'bunch of tulips'. As indicated in Figure 2 the 
protein has a collagenous domain and a carbohydrate recognition domain, and these 
sites appear to mediate immunological functions . Surfactant protein A has been 
identified not only in the lamellar bodies of Type II alveolar cells, where it is closely 
associated with surfactant lipids, but also in pulmonary alveolar macrophages and in 
non-cilated bronchiolar cells (Clara cells) (Walker et al. 1986). In fact, lamellar bodies 
have a significantly lower content of SPA relative to BALF indicating that secretion of 
SPA may occur separately from phospholipids (Doyle et al. 1994; Johanssen and 
Curstedt, 1997). Surfactant protein A has been shown, by immunoelectronmicroscopy, 
to reside in the comers of the tubular myelin lattice (Voorhout et al. 1991), and, in 
vitro, it is an essential factor in the formation o f this matrix (Williams et al. 1991).
Surfactant protein A facilitates the formation o f a lipid-rich, surface-active film at the
air-liquid interface. In the presence o f surfactant proteins B and C, SPA improves the
surface active properties o f a lipid surfactant extract (Chung et al. 1989), suggesting a
co-operative association between proteins and lipids in the formation o f a surfactant
film. Kuroki and Akino (1991) demonstrated calcium-dependent binding of SPA to the 
.hydrophobic region of PC, and it is possible that this binding affects the packing of PC 
molecules at the air-liquid interface (King et al. 1986).
However, a study of mice in whom the SPA gene was ablated ('SPA knockout mice'),
showed that, in these mice, surfactant tunction was reduced at low phospholipid
concentrations, but normal at higher concentrations. These mice also had normal
pulmonary compliance (Korfhagen et al. 1993). This suggests that SPA may not be 
.essential to surfactant function in health, but may be important when lung pathology
44
' 3 '
compromises the secretion o f phospholipids. One other interesting quality of SPA 
highlights a potential role for SPA in maintenance of surfactant function in disease.
That is, the protection wliich SPA offers to surfactant phospholipids from inactivation 
by plasma proteins which flood into the alveolus in some respiratory diseases 
(Cockshutt et al. 1989).
The homology between SPA and C lq  and the C-type lectins has stimulated research
-
into the interaction between SPA and pulmonary defence mechanisms. Surfactant 
protein A has been shown to enhance concanavalin A-induced proliferation of rat 
splenocytes in vitro (Kremlev et a l 1994). Additionally, Malhotra and colleagues
(1990) demonstrated that SPA binds to the C lq  receptor on phagocytic cells, and 
binding of SPA to the C lq  receptor on human monocytes has been shown to mediate 
phagocytosis of staphylococcus aureus by these cells (Geertsma et al. 1994).
Phagocytosis of staphylococcus aureus by alveolar macrophages is also enhanced by 
SPA (Van Golde, 1995; van Iwaarden et al. 1990) and SPA has been shown to bind, in
-
a calcium dependent manner to pneumocystis carinii (Zimmerman et al. 1992).
As well as the interactions with microorganisms described above, SPA has also been 
shown to interact with viruses, interactions which appear to be mediated via the 
protein's carbohydrate moiety (Van Golde, 1995; Van Iwaarden et a l 1991).
Surfactant protein A acts as an opsonin in phagocytosis of herpes simplex type 1 virus 
by alveolar macrophages (Van Iwaarden et al. 1991) and has been shown to bind to the 
influenza A virus (Malhotra et al. 1994), and to cells infected by the influenza B vims 
(Van Golde, 1995).
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In summary, then, there is evidence that surfactant protein A facilitates the formation 
of a phospholipid film at the air-liquid interface, assists in the formation of tubular 
myelin, modulates the secretion and clearance of surfactant, protects surfactant against 
inactivation by plasma proteins, acts as an opsonin and enhances the defensive 
functions o f alveolar macrophages.
Macrophage function is enhanced by SPA. There is evidence that SPA stimulates 
phagocytosis of foreign particles and micro-organisms by alveolar macrophages, 
causes secretion of reactive oxygen species fi’om these cells (reviewed by Van Golde,
1995) and increases macrophage chemotaxis (Wright and Youmans, 1993). Alveolar 
macrophages have been shown to possess specific SPA receptors (Oosting and Wright, 
1994; Pison et al. 1992).
There is evidence to suggest that SPA has a role in the regulation of phospholipid 
secretion and clearance (Hawgood, 1992). Type II pneumocytes have an SPA receptor 
on their surface (Kuroki et al. 1988) and, in vitro, SPA inhibits secretion (Rice et 
a l l  987) and stimulates uptake (Wright et al. 1987) of lipids by type II alveolar cells . 
However, SPA knockout mice have no alterations in surfactant phospholipid pool 
sizes, suggesting that SPA is not solely responsible for regulation of surfactant 
secretion (Korfhagen et al. 1993).
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Surfactant proteins B and C
Surfactant proteins B and C (SPB and SPC) are low molecular weight (around 9 and 
3.5 kD respectively), hydrophobic proteins which remain associated with surfactant 
phospholipids during organic extraction. Surfactant protein B mRNA has been found 
in type II pneumocytes and Clara cells, but not alveolar macrophages, type I cells or 
pulmonary interstitial cells. Surfactant protein C has been demonstrated in the lamellar 
bodies of type II pneumocytes (Benson, 1993).
Addition of SPB to a phospholipid mixture significantly improves the adsorption and 
surface-tension lowering properties o f that mixture and this effect is further enhanced 
by the addition of calcium (Curstedt et al. 1987; Revak et al. 1988). Surfactant protein 
B is palmitoylated, and it is thought that SPB may associate with the polar head groups 
of phospholipids by electrostatic interactions with the positively charged amino acids, 
whereas the hydrophobic portions of SPB interact with the phospholipid acyl chains to 
modulate surface properties of the monolayer (Benson, 1993; Longo et al. 1993). In 
vitro experiments have also indicated that SPB, along with phospholipids, calcium and 
SPA is necessary for formation of tubular myelin (Suzuki et al. 1989; Williams et al. 
1991).
Surfactant protein C also participates in the lowering of surface tension, enhancing the 
surface active properties and adsorption rate of a phospholipid mixture (Whitsett and 
Baatz, 1992). Like SPB, SPC is palmitoylated on cysteine residues, and SPC has been 
shown to produce rapid adsorption of a DPPC/PG suspension. Adsorption was 
enhanced by palmitoylated and by depalmitoylated SPC, although there was a trend for 
the depalmitoylated form not to enhance adsorption to as great an extent (Qanbar et al.
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1996). Palmitoylated SPC cysteine residues may intercalate with the phospholipid 
matrix of the surfactant film (Benson, 1993), increasing surfactant film stability, and 
lateral pressure within the hydrophobic region at the air-liquid interface (Horowitz et 
al. 1992). Qanbar and colleagues (1996) suggested that SPC may be involved in a 
process of selective adsorption whereby DPPC appears preferentially at the air-liquid 
interface. It has also been suggested that SPC may enhance surfactant respreading by 
preventing phospholipids from detaching from the surface layer upon area compression 
(Qanbar et al. 1996).
Surfactant proteins B and C have been shown to act in a co-operative manner to 
protect surfactant against inhibition by serum (Amirkhanian et al. 1993) and SPB has 
been found to protect a lipid surfactant extract from functional inhibition by fibrinogen 
(Seegeretal. 1992).
Surfactant protein D
Surfactant protein D is the most recently isolated lung-specific protein (Persson et al.
.1988; Kuroki et al. 1991). This protein is made up of four subunits; each of which is a 
disulphide bonded trimer. Surfactant protein D is similar to SPA, in that it posesses a 
collagen-like region and a globular head which has C-type lectin activity (Figure 2).
Surfactant protein D, like SPA, has been implicated in the immunological defence of 
the lung. It has been shown to bind to alveolar macrophages in vitro (Miyamura et al, 
1994a) and to enhance formation of reactive oxygen species in rat alveolar 
macrophages (Van Iwaarden et al. 1992). Alveolar macrophages have been shown to 
have specific SPD receptors (Miyamura et al. 1994a).
4 8
Surfactant protein D also binds to E.Coli, probably by associating with bacterial 
endotoxin (Van Golde, 1995) and has been shown to inhibit the haemagglutination 
activity o f influenza A virus, mediated by its carbohydrate binding domain (Hartshorn 
et ai. 1994).
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Figure 2. Quaternary structure of SPA and SPD
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Surfactant disposal and recycling
Spent surfactant lipids may be subject to a number of fates including recycling by type 
II cells. Studies on newborn rabbits have shown that 95% of surfactant PC is recycled 
by the alveolar epithelium (Robertson, 1985). Surfactant may also be taken up by 
pulmonary lymphatics, migrate upwards to larger airways, or be metabolised by 
phospholipases (Figure 3) in type II cells and in alveolar macrophages.
1.2.7 SURFACTANT SECRETION AND CLEARANCE 
Stimulation of surfactant secretion
- ^Various physiological and pharmacological mechanisms enliance the secretion o f ^
'
surfactant (Rooney, 1985; Morton, 1989). These include stimulation o f p 
adrenoreceptors on the surface of type II pneumocytes, cholinergic stimulation, lung
:distension and binding o f SPA to the cell surface. Glucocorticoids also have a
.stimulatory effect on secretion, possibly by their permissive action on catecholamine 
receptors. Fatty acids, specifically the long chain polyunsaturated arachidonic and 
eicosopentanoic acids promote surfactant secretion possibly by effects on membrane 
fluidity. Linoleic, oleic and palmitic acids also stimulate secretion o f surfactant, but to a 
lesser extent (Baybutt et al. 1994). Surfactant synthesis is enhanced by glucocorticoids, 
oestrogen, mechanical ventilation and vagal stimulation (Rooney, 1985; Morton,
1989).
Surfactant protein A, SPB and SPC re-enter the Type II cell whose lamellar bodies are 
.rich in phospholipids, SPB and SPC Recycling of SPD has not been demonstrated.
Clara cells do not appear to take part in recycling. There is some suggestion that 
surfactant proteins and phospholipids may be recycled separately (Rooney et al. 1994).
■ir
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Figure 3. Action of phospholipases
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1.3. SURFACTANT IN LUNG INFLAMMATION
The pulmonary surfactant system can be adversely affected by disease. One of the most 
complicated disease processes which can result in surfactant dysfunction is acute 
inflammatory lung disease. The main histological characteristics of this are the 
presence in airways, alveoli and lung parenchyma of inflammatory cells and a 
proteinaceous alveolar exudate. Two diseases in which severe acute lung inflammation 
is seen frequently are pneumonia and Acute Respiratory Distress Syndrome (ARDS). 
The main pathological features o f these two conditions are summarised in Table 4.
Table 4. Clinical features of ARDS and pneumonia
PATHOLOGICAL
FEATURES
CLINICAL
FEATURES
ARDS
Interstitial and alveolar 
oedema. Haemorrhage, cellular 
debris and proteinaceous fluid 
in the alveoli. Inflammatory 
cellular infiltrate around 
alveolar walls.
Triggered by eg. tramna, 
haemorrhagic shock, bums. 
Tachypnoea, hypoxaemia, low 
pulmonary compliance. Mortality 
around 50%.
PNEUMONIA
Inflammatory cells in the lung 
parenchyma and alveoli. 
Alveoli filled with exudate. 
May be necrosis of lung tissue 
and abscess formation.
Malaise, fever, cough, pleuritic pain, 
tachypnoea, tachycardia, cyanosis, 
hypoxia.
I
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administration of fatty acids or n-nitroso-n-methylurethane and administration of 
intratracheal endotoxin. Lung irradiation has also been studied, as it produces an 
alveolar leak of oedema fluid which is also seen in ARDS. Irradiation studies produce a 
model in which the effects of this fluid on surfactant can be studied in the absence of 
the other inflammatory events. Surfactant has been studied extensively in animal 
models in an attempt to elucidate the pathology of ARDS in humans.
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Pneumonia arises from pulmonary infection by micro-organisms. The infection may be 
restricted to one or more lobes, or may be generalised to the entire lung. Infection o f 
the lung with bacteria or viruses results in an inflammatory reaction (Table 4), the 
purpose of which is to destroy the invading pathogen.
Acute respiratory distress syndrome can arise from a panoply of primary pulmonary 
and systemic insults including pneumonia, bums, sepsis, trauma and massive blood 
transfrision. The final common pathway is a state of lung inflammation with increased 
capillary permeability, invasion of inflammatory cells and ingress into the alveoli of 
oedema fluid containing plasma proteins. i
Surfactant abnormalities have been shown to occur as the result o f pneumonia and of 
ARDS. There is evidence for surfactant dysfunction in ARDS, and alterations in the 
absolute amount of surfactant components have been seen in both conditions. There is 
also potential for surfactant damage or inhibition in pneumonia and in ARDS, as a 
consequence of the inflammatory response.
There are several animal models for inflammatory lung disease including intravenous
■ i :
Both human and animal studies of the pulmonary surfactant system in lung 
inflammation are reviewed below. The aspects of surfactant dysfunction, inhibition, 
deficiency and damage are considered.
1.3.1. SURFACTANT DYSFUNCTION 
Respiratory distress syndrome of the newborn
In 1959, Avery and Mead noted that premature infants who died with a form of 
respiratory failure - Respiratory Distress Syndrome of the newborn (RDS) - were 
surfactant deficient.
Over a decade later, administration of exogenous surfactant was shown to benefit 
rabbits bom prematurely with RDS (Enhoming and Robertson, 1972). Eventually, 
after many therapeutic trials following on from early replacement studies in human 
neonates (Morley et al. 1981; Fujiwara et al. 1980), surfactant replacement has become 
a well established therapy for newborn infants with RDS.
Acute respiratory distress syndrome
Acute Respiratory Distress Syndrome (ARDS) was first described by Ashbaugh and 
colleagues in 1967 as a syndrome of hypoxaemia, poor lung compliance and 
tachypnoea occurring in adults, in which there were clinical and radiological similarities 
to infantile RDS. Because of these similarities, Petty and Ashbaugh (1971) suggested 
that the pattern of adult respiratory failure which they had observed be called the Adult 
Respiratory Distress Syndrome (ARDS). By this time, the role of surfactant deficiency 
in RDS of the newborn was well established, and implicit in the title ‘adult RDS’, was
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the suggestion that surfactant function was abnormal in this newly-described condition.
The title ‘Acute Respiratory Distress Syndrome’ (ARDS) has since been adopted, as it ï ||
has become evident that the condition is not confined to adults.
Surfactant dysfunction in ARDS
; {In their original description of ARDS, Ashbaugh and associates (1967) described an 
increase in the minimum surface tension produced by surfactant fi’om post mortem lung 
extracts o f patients who had died from ARDS, suggesting surfactant dysfunction. I
Subsequent studies have confirmed these findings. Hallman and colleagues (Hallman et 
al. 1982; Spragg and Hallman, 1983) found that the minimum surface tension of BAL 
surfactant purified by density gradient centrifugation (to remove surfactant inhibitors) i
was far greater in patients with ARDS than in controls, suggesting an intrinsic 
surfactant abnormality independent of inhibitory substances. Gregory and co-workers
(1991) studied a crude surfactant pellet obtained by high speed centrifugation of 
bronchoaiveolar lavage fluid, and also found increased minimum surface tension in 
surfactant from patients with ARDS, compared to normal subjects. Gregory and 
colleagues also found raised minimum surface tension in surfactant from patients who 
were considered to be at risk for ARDS.
Surfactant function in animal models of lung injury
Intravenous injection o f a free fatty acid mixture containing predominantly oleic acid
has been used to produce a clinical picture in experimental animals, similar to that seen 
«in humans with ARDS. Hall et al (1990) obtained surfactant from BAL fluid of oleic- 
acid treated rabbits, by evaporation of lavage fluid to dryness under nitrogen. This 
surfactant had a reduced ability to lower surface tension compared to that from the
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lungs of healthy controls. A later study by Hall and co-workers (1994), showed that a 
crude surfactant pellet from BAL of fatty acid injured animals also had lower surface 
activity than a similar pellet obtained from controls. As surfactant in these two studies ^
'
was not subjected to lipid extraction or density gradient centrifugation which would 
remove inhibitory proteins, the importance of plasma protein inhibition on surfactant 
function cannot be accounted for.
Intra-tracheal introduction of endotoxin in animals induces a condition similar to 
ARDS with hypoxia, reduced compliance, interstitial alveolar oedema and 
haemorrhages. In guinea pigs whose lungs had been injured with endotoxin, maximum
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However, another animal model suggests that surfactant function is similar in 
surfactant obtained by high speed centrifugation, and that purified by density gradient 
centrifugation. N-nitroso-n-methylurethane (NNMU) is another compound which 
causes lung injury similar to ARDS in animal models. Liau and colleagues (1987) 
obtained surfactant by two different methods from BAL in dogs injured with NNMU, 
Both a crude surfactant pellet from centrifugation at 27,000 x g and a surfactant 
fraction purified from BAL by density gradient centrifugation were tested for surface 
activity. The surface properties of both surfactant preparations were reduced to a 
similar degree in the injured animals. This indicates that either density gradient 
centrifugation did not remove surfactant inhibitors to any greater extent than simple 
centrifugation or that inhibition was not a significant cause of surfactant inhibition. 
Surfactant taken from the lungs after recovery functioned normally in vitro, suggesting 
that the surfactant dysfunction was temporaiy.
I
I
and minimum surface tensions of a lipid extract o f BAL fluid were increased compared
i i
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to control. Surfactant inhibition by non-sedimentable protein from a 105,000 x g 
supernatant of BAL fluid from the endotoxin group was also greater than control on a 
mg/mg basis (Tahvanainen and Hallman, 1987). This study established that the surface ; 
activity of hydrophobic components o f BAL fluid was abnormal, and also that the 
inhibitory capacity of BAL proteins was increased. This would suggest an intrinsic 
surfactant abnormality. However, it is interesting to note that endotoxin was 
administered intratracheally, and it is possible that lipid soluble components of this 
bolus could have interfered with surface activity of a lipid extract of BAL.
Inhibition or intrinsic abnormality?
In the human and animal studies o f lung injury reviewed above, different methods of 
purification of surfactant were used before surface activity was studied. The evidence 
from these studies suggests that both inhibition by proteins and intrinsic surfactant 
abnormality are factors causing the surfactant dysfunction seen in lung injury. The role
ï'S i'
of inhibition is explored further in the next section.
.,iC
1.3.2. INHIBITION OF SURFACTANT FUNCTION 
Inhibition by proteins
Altered capillary permeability in acute lung inflammation and infection leads to leakage 
of proteins and other constituents of plasma into the alveolus. Granulocytes, which 
invade the lung in the inflammatory response, have been shown to cause lung oedema 
as a consequence of their releasing oxygen radicals (Shasby et al. 1982) and increased 
protein has been found in BAL from patients with ARDS (Veldhuizen et al. 1995).
ï
Kobayashi et al (1991) demonstrated in vitro and in vivo inhibition of surfactant by 
oedema fluid and it has been shown that various plasma proteins (Table 5) inhibit the 
surface activity o f surfactant in vitro. Holm and colleagues (1988) suggested that 
inhibitory proteins may compete with surfactant phospholipids for adsorption at the 
air-liquid interface. Additionally, Schurch and co-workers (1995) have suggested that 
proteins may prevent additional surface active material being recruited from the 
surface-associated reservoir to the surface active film. Addition of surfactant protein A 
has been shown to reverse the inhibitory effects of some blood proteins on lipid extract 
surfactant (Cockshutt et al. 1990).
Table 5. Substances which inactivate surfactant
I,
Albumin (Keough et al. 1988; Seeger et al. 1985)
C-reactive protein (Amirkhanian and Taeusch, 1993; Li et al. 1989)
Elastin (Seeger et al. 1985)
Erythrocyte membrane lipids (Holm and Notter, 1987)
Fibrin degradation products (Seeger et al. 1993b; O'Brodovich et al. 1990b) 
Fibrin monomer (Seeger et al. 1985)
Fibrinogen (Keough et al. 1988; Amirkhanian and Taeusch, 1993)
Globulins (Keough et al. 1988; Seeger et al. 1985)
Haemoglobin (Holm and Notter, 1987)
Lysophosphatidylcholine (Amirkhanian and Taeusch, 1993)
Meconium (Moses et al. 1991)
Oleic acid (Hall et al. 1992)
Phospholipases (Enhorning et al. 1992; Holm et a l 1991)
Platelet activating factor (Amirkhanian and Taeusch, 1993)
Polymerising fibrin (Seeger et al. 1993a)
Pulmonary oedema fluid (Kobayashi et al. 1991)
59
Inhibition in radiation injuiy
Radiation pneumonitis is associated with leakage of proteins from the microvasculature 
into the alveoli, in the absence o f other inflammatory events which occur in ARDS. It 
therefore provides some insight into the role of plasma proteins in surfactant 
dysfrinction. Gross and colleagues (1991) studied surfactant in mice which were 
irradiated, and killed when pneumonitis had developed. Surfactant which was isolated 
by centrifugation of BAL after death showed abnormal surface activity. However, 
when extraneous material was removed from the pellet by equilibrium centrifugation, 
surface activity was the same in irradiated and sham-irradiated mice.
In 4 patients with mesothelioma (a malignant tumour of the pleura), who received 
irradiation of the hemithorax, a 105,000 x g crude surfactant pellet from BAL showed 
increased maximum and minimum surface tension after irradiation. There was an 
increase in soluble protein in the supernatant o f BAL, and lyophilised supernatant 
from these patients increased the minimum surface tension of human amniotic fluid 
surfactant. This suggests that surfactant inhibition by protein does indeed contribute to 
the pathogenesis of radiation induced injury (Hallman et al. 1990).
Inhibition by lysophosphatidylcholine
Another potential source of surfactant inhibition arises from lysophosphatidylcholine 
(LPC), a phosphatidylcholine breakdown product, and increased concentrations of this 
have been found in BAL fluid from patients and animals with lung injury.
Surfactometer studies of surfactant inhibition by LPC reveal a complex picture which 
has not as yet been fully elucidated. Some in vitro experiments have shown that
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addition of LPC or phospholipases (which break down PC to LPC) to surfactant 
inhibits surface activity (Holm et al. 1991; Enhoming et al. 1992). The inhibitory effect
'of LPC on surfactant is counteracted by addition of palmitic acid and may be due to ^
'
the 'conical' molecules o f LPC dismpting the packing o f ‘cylindricaT PC molecules at
‘
• Îthe air-liquid interface (Cockshutt et a l 1991). Lysophosphatidylcholine also has been 
shown to sensitise a lipid extract of surfactant to inhibition by fibrinogen in vitro 
(Cockshutt and Possmayer, 1991).
However, against this, Lema and Enhorning (1997) showed that substitution of 
LPC/palmitic acid (simulated hydrolysis products of DPPC) for DPPC led to increased 
surface activity of the mixture containing LPC when measured in pulsating bubble and 
capillary surfactometers (dynamic in vitro models o f the alveolus and small airway 
respectively). In the presence o f albumin, activity was inhibited in the capillary 
surfactometer but not the pulsating bubble surfactometer. The authors suggested that 
lipids other than DPPC may be hydrolysed by phospholipases in vivo and that this may 
dismpt a delicate balance in the distal parts of the lung.
There is evidence to suggest that LPC is increased in ARDS and in animal models of 
this condition, possibly due to increased phospholipase activity. Veldhuizen and 
colleagues (1995) found increased levels o f LPC in cell-free BAL supernatant from 
patients with ARDS while Pison and colleagues (1987), studying sequential cell-free 
BAL fluid samples from patients with ARDS due to trauma found an increase in 
lysophposphatidylcholine on the day of trauma. However, surface activity was not 
tested in either of these studies, so the effects of this increase in LPC on surfactant
fiinction remain unknown.
6 1
Studies of BAL fluid from animal models of lung injury have revealed an increase in 
the LPC fraction (Liau et al. 1987; Tahvanainen and Hallman, 1987; Casals et al.
1989). In one of these studies, a lipid extract of BAL fluid also showed increased 
maximum and minimum surface tensions (Tahvanainen and Hallman, 1987). This 
would suggest that some abnormality in the hydrophobic fraction of surfactant was 
causing abnormal surface activity. In another, surface activity o f surfactant fractions 
obtained by density gradient centrifiigation and by high speed centrifugation was 
similarly impaired, indicating either that inhibitory proteins were eliminated to a similar 
degree by both preparation methods or that some intrinsic abnormality o f surfactant 
was present independent o f inhibition (Liau et al. 1987).
It is impossible, from these in vivo studies to establish a causal link between LPC and 
surfactant inhibition in lung inflammation, and the in vitro evidence for surfactant 
inhibition by LPC is conflicting. However, evidence presented above does give 
grounds for speculation that LPC per se or in combination with plasma proteins may 
inhibit surfactant in inflammatory lung disease. The situation in vivo is so complex that 
LPC is only likely to be one part of a larger picture of surfactant dysfrinction involving 
protective surfactant proteins, inhibitory plasma proteins, abnormalities of surfactant 
lipid composition and quantity and damage to surfactant.
1.3.3. SURFACTANT LARGE AND SMALL AGGREGATES - 
IMPLICATIONS FOR FUNCTION
Centrifugation can separate surfactant recovered from BAL into large aggregates
(LA), which are easily sedimentable, and small aggregates (SA) which resist
sedimentation during high speed centrifugation. Work on rabbit surfactant has shown
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that the phospholipid concentrations and phospholipid compositions of large and small 
aggregate fractions are similar. However a lipid extract of large aggregates was shown
• ■
to be effective in improving dynamic compliance in ventilated pre term rabbits, whereas  ^ .
a lipid extract of small aggregates did not. Small aggregates o f surfactant have also 
been shown to be less surface active in vitro than large aggregates (Yamada et al.
1990). Large aggregates from injured lungs are converted in vitro more rapidly to 
small aggregates than are large aggregates fi-om normal lungs (Gunnison and 
Finkelstein, 1997), It is thought that small aggregates may represent an effete form of 
surfactant at the end o f its 'life cycle' in the alveolus.
Surfactant large and small aggregates in ARDS
Small aggregate/large aggregate ratio has been found to be significantly higher in 
samples from ARDS patients compared to control (Lewis et al. 1997; Veldhuizen et al.
1995). This may contribute to the surfactant dysfunction seen in ARDS.
Surfactant large and small aggregates in animal models
In rabbits injured with IV fatty acid (Hall et al. 1994), the recovery of large aggregates 
of surfactant was reduced, and this was not mimicked by the addition of serum to BAL 
from healthy animals. Supplementation o f BAL from injured animals with large 
aggregates improved surface activity. The authors speculated that conversion of large 
particles to small ones may be due to serine protease activity, and such enzymes are 
known to be elevated in injured lungs. Alternatively, they suggested that phagocytosis 
of large particles by leucocytes or decreased secretion of new lamellar bodies may have 
been responsible for the decrease in large aggregates.
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1.3.4. SURFACTANT PHOSPHOLIPID DEFICIENCY OR EXCESS 
Changes occur in the amount o f phospholipids and proteins present in pulmonary 
surfactant in response to lung inflammation fi-om ARDS or pneumonia.
Acute respiratory distress syndrome
It is not clear whether the amount of surfactant phospholipids is reduced in ARDS. 
Several authors have found that the total phospholipid level in BAL fluid centrifuged 
to remove cell debris (Gunther et al. 1996; Hallman et al. 1982; Spragg and Hallman, 
1983; Pison et al. 1990) was not different from control. Jacobson et al. (1993) 
examining tracheal aspirates from patients with ARDS under polarised light for the 
presence of characteristic surfactant particles, found no difference in occurrence of 
these particles from control. Offenstadt and colleagues (1981), on the other hand, 
found an increased concentration o f phospholipids in cell free BAL supernatant from 
patients with ARDS compared to control. In contrast, Gregory and colleagues (1991) 
found decreased levels o f phospholipid in the crude surfactant pellet of BAL fluid from 
patients with ARDS and patients at risk for ARDS, compared to normal controls.
Pneumocystis carinii pneumonia
Pneumocystis carinii pneumonia (PCP), which occurs in patients with HIV infection, 
has become of particular interest as it causes a generalised pneumonia (ie. not just 
affecting one lobe of the lung), and the changes evident on chest radiographs can be 
similar to those seen in RDS of the newborn and ARDS. This would suggest that 
surfactant deficiency may be a factor contributing to the pathogenesis of PCP.
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Several researchers have studied phospholipid profiles in HIV-infected patients with 
PCP. A decreased lipid concentration in BAL fluid centrifuged to remove cells from 
patients with PCP was found by two groups (Escamilla et al. 1992; Hoffinan et al.  ^ /
Ï -1992), while Rose and colleagues (1994) found no reduction in total phospholipid in 
cell-free lavage samples fi*om patients with AIDS-related lung disease (including PCP).
However, it has not been unequivocally established that surfactant lipid concentrations 
are altered in this disease.
Nosocomial pneumonia in neonates |
Griese and colleagues (1996) found that phospholipid concentration was reduced in a 
crude surfactant pellet o f tracheal aspirates fi-om neonates with nosocomial pneumonia 
in neonates during deterioration and at the peak of infection.
Animal studies
When lung injury was produced in guinea pigs with intra-tracheal endotoxin and 
ventilation with 100% oxygen, reduced surfactant phospholipids were found in a 
surfactant pellet obtained by high speed centrifugation (Tahvanainen and Hallman, 
1987). In contrast, in fatty acid injured rabbits, normal amounts of phospholipid were 
found in cell fi*ee BAL compared to controls (Hall et al. 1994). This suggests that the 
method of injury may have important consequences for the change seen in 
phospholipid level.
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It should be noted, at this point, that the extreme insolubility o f SPC in aqueous media 
has hampered its detection in disease states, and therefore, no information is available 
on any changes in the levels o f this protein which may occur in response to pulmonary 
inflammation.
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1.3.5. DEFICIENCY OR EXCESS OF SURFACTANT PROTEINS 
Acute respiratory distress syndrome
Gregory and colleagues (1991) also found decreased levels o f SPA and SPB in the 
crude surfactant pellet from patients with ARDS, compared to normal subjects and 
decreased SPA in surfactant from patients who were considered to be at risk for 
ARDS. Gunther and colleagues (1996) demonstrated a reduction in SPA but not SPB 
in cell-free BAL supernatant from patients with ARDS.
AIDS-related pneumonia and bacterial pneumonia
Surfactant protein A levels have also been studied in pneumonia. Increased 
concentrations of SPA were found in cell-free lavage fluid from patients with AIDS- 
related pneumonia due to Pneumocystis Carinii and also to other pathogens (Phelps 
and Rose, 1991), while Baughman and colleagues (1984) found reduced levels of SPA
I
in cell-free bronchoaiveolar lavage samples from patients with non-AIDS related 
bacterial pneumonia. A recent report details a reduction in SPA (but not SPB) in BAL 
filtered and centrifuged to remove cells from patients with ARDS and/or pneumonia 
(Gunther et al. 1996).
Surfactant protein C
.Id#
1.3.6. CHANGE IN SURFACTANT COMPOSITION - PHOSPHOLIPID 
CLASSES
Infant respiratory distress syndrome
Early studies found reduced levels of PG in tracheal effluent from infants with RDS 
(Obladen, 1978; Bose et al. 1984). This stimulated research to elucidate changes in 
phospholipid composition of surfactant in ARDS.
Adult respiratory distress syndrome
Pison and colleagues found that in cell-free BAL fluid from patients with ARDS due to 
multiple trauma PG was reduced and PI increased at 6 hours after trauma, and PC was 
reduced at 24 hours after trauma. In a subgroup of these patients who had severe 
respiratory failure, reductions in PC and PG and an increase in PE and sphingomyelin 
were found throughout the course of the disease (Pison et al. 1990; Pison et al. 1987). 
Two other studies found PC and PG to be reduced and sphingomyelin to be increased 
in cell-free BAL supernatant from patients with ARDS (Veldhuizen et al. 1995; Spragg 
and Hallman, 1983). Hallman et al (1982) also found PS to be increased. Additionally, 
Gregory and colleagues (1991) found decreased levels of PC and PG in a crude 
surfactant pellet from BAL in patients with ARDS.
The most consistent findings to emerge from these studies of ARDS appears to be a 
reduction in PC and PG, and an increase in sphingomyelin.
Pneumonia
No changes were found in phospholipid composition of tracheal aspirates in 
nosocomial infection in ventilated preterm human neonates (Griese et al. 1996),
67
Animal models of lung injury
Several studies have investigated changes in phospholipid classes in animal models of 
lung injury, and the changes which occur seem to be specific to the model studied. 
However, in general as with studies o f ARDS, a pattern o f reduced PC and PG 
emerges.
In rabbits injured with IV oleic acid, surfactant purified fi-om BAL by density gradient 
centrifugation showed reduced levels o f PG and increased sphingomyelin (Casals et al.
1989). In endotoxin - injured guinea pigs, PG and PC were found to be reduced in a 
lipid extract o f cell-free BAL fluid whereas PI and sphingomyelin were increased 
(Tahvanainen and Hallman, 1987). In NNNMU injured dogs PC and DSPC were 
found to be reduced in cell-free BAL. In these animals, reduction in respiratory 
compliance showed a significant linear correlation with quantities o f PC in BAL (Ryan 
et al. 1981). In another study o f dogs similarly injured, DPPC, PG, PC and PE were all 
reduced but increased towards late recovery. PI was increased compared to controls. 
In this study, surfactant composition was studied in cell-free lavage, crude surfactant 
pellet from high speed centrifugation and in this pellet after purification by density 
gradient centrifugation. The method by which surfactant was obtained did not appear 
to affect the composition o f surfactant phospholipids measured (Liau et al. 1987). In 
contrast to studies of other animal models. Hall and colleagues (1994) found minimal 
change in phospholipid classes from cell free BAL fluid in fatty acid injured rabbits.
The evidence from animal models of lung injury therefore suggests that, although the 
pattern of phospholipid change probably depends on the method of injury employed, 
the most consistent pattern to emerge is a reduction in PC and PG.
Animal models of infection
Calves inoculated with bovine herpes virus or parainfluenza 3 virus showed reduced 
PC and increased PE in (Engen and Brown, 1991), while pigs inoculated with 
pasteurella multocida showed an increase in relative PI and a reduction in PG in BAL 
(Sachse, 1989).
1.3.7. CHANGE IN SURFACTANT COMPOSITION - FATTY ACID SPECIES 
Human disease
Two groups have studied fatty acid species in BAL fluid centrifuged to remove cells 
from patients with ARDS. Baughman and colleagues (1984) reported a reduction in 
phospholipid palmitic acid (16:0), and a greater proportion of stearic acid (18:0) and 
oleic acid (18:1) in ARDS and in pneumonia. Hallman and colleagues (1982; 1983) 
also found reduced 16:0, but in addition increased 16:1 increased 18:2 and increased 
20:4 in PC from patients with ARDS. Both these authors found reduced saturated fatty 
acids and disaturated PC in ARDS.
It is interesting to note that lung tissue PC contains less 16:0/16:0 but is enriched in the 
16:0/18:1 and 16:0/18:2 species compared to BAL PC (Hunt et al. 1991). Since 18:1 
and 18:2 species are typically found in cell membranes, this raises the possibility that 
the changes in fatty acid content noted in studies of ARDS may be due to 
contamination of BAL with cell membrane fragments from pulmonary epithelial cells 
destroyed by the disease process.
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1.4. OXIDANT DAMAGE TO SURFACTANT
1.4.1. REACTIVE OXYGEN SPECIES AND SCAVENGING IN THE 
ALVEOLUS
The lipid and protein components of surfactant are susceptible to damage from reactive 
oxygen molecules which may be released into the alveolus in lung inflammation. 
Pathways for the generation of these reactive molecules are shown in Figure 4
Oxidant injury in the lung may be limited by the presence in alveolar lining fluid of 
catalase, superoxide dismutase, reduced glutathione (Mcllroy et al. 1992, Cantin et al. 
1987; Matalon et al. 1990), vitamins C (Snyder et al. 1983) and E (Pacht et al. 1986), 
Caeruloplasmin and transferrin (Pacht and Davis, 1986) which act as 'scavengers' of 
reactive molecules.
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Animal studies
A study of bronchoaiveolar lavage from dogs injured with NNNMU found increased 
PC 16:0 in the experimental group whereas 16:1 and 18:1 were less (Ryan et al. 1981). ^
The reason for the discrepancy between findings in this model and human studies is not 
clear.
:
It appears that an alteration in fatty acids recovered from BAL occurs in acute 
inflammatory lung disease in humans. However, it is not possible to determine whether 
this is due to an alteration in surfactant phospholipids or to contamination o f BAL with 
fragments of membranes from cells damaged in the disease process.
Peroxynitrite
One particular reactive oxygen molecule that has been attracting great interest recently 
is peroxynitrite, a reactive molecule formed by combination of superoxide and nitric 
oxide, both of which are released by activated alveolar macrophages (Ischiropoulos et 
al. 1992) (Figure 4). The role of peroxynitrite in lung injury is interesting as it is 
generated by a pathway which is separate from the Haber Weiss reaction. The 
antioxidants listed above, which are found in alveolar lining fluid act by keeping the 
participants in the Haber Weiss reaction at low levels. However, peroxynitrite is 
generated by a different mechanism (Figure 4), and may therefore be acting relatively 
unchecked in the alveolus to cause lung injury.
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Figure 4, Pathways of free radical generation and molecular damage
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Peroxynitrite can participate in several oxidative pathways which have the potential to 
induce lipid peroxidation (Radi et al. 1991), DNA damage and protein damage (Figure 
4). Exposure of proteins to peroxynitrite can cause cysteine oxidation, tryptophan 
oxidation, protein fragmentation and tyrosine nitration. The product of this last 
reaction, nitrotyrosine, has been shown to be a specific marker for protein damage 
caused by peroxynitrite (Ischiropoulos and Al-Mehdi, 1995).
1.4,2. OXIDANT DAMAGE AND SURFACTANT 
Peroxynitrite and surfactant
Haddad and colleagues (1993) studied the effects o f peroxynitrite on surfactant in vitro 
and demonstrated that surfactant components could be damaged structurally and 
functionally by this molecule. The detailed findings of Haddad’s study are summarised 
below.
Surfactant proteins were degraded by exposure to peroxynitrite in vitro as evidenced 
by SDS-PAGE of SPA, SPB and SPC. Additionally, an increased content of 3-nitro- 
L-tyrosine residues was demonstrated in SPA after exposure.
The surface tension lowering properties of surfactant were also shown to be 
susceptible to damage. Calf lung surfactant extract (CLSE - an organic extract 
containing surfactant phospholipids, SPB and SPC) exposed to peroxynitrite, lost 
surface activity and an increased concentration of lipid peroxidation products was 
found in CLSE after exposure, suggesting damage to surfactant lipids. Interestingly, if 
CLSE was supplemented with SPA before contact with peroxynitrite, the damaging
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effects on surface tension were not seen, implying that SPA may have a protective 
function.
To investigate the influence of the lipid composition of surfactant on oxidative damage, 
Haddad et al studied two surfactant preparations. When Exosurf (a synthetic surfactant 
containing only the DPPC lipid species) or a mixture of surfactant lipids (containing 
various phospholipid and fatty acid species) were incubated with peroxynitrite, only the 
surface activity of the lipid mixture decreased. This suggests that unsaturated lipids are 
the site o f peroxidative injury.
This extensive in vitro study establishes that peroxynitrite has the potential to cause 
functionally significant damage to the lipid and protein components of surfactant.
O ther reactive species
There is evidence that reactive molecules other than peroxynitrite can cause damage to 
surfactant. Gilliard and colleagues (1994) exposed CLSE to ferrous chloride and 
hydrogen peroxide, and demonstrated a subsequent loss of surface active properties 
and an increase in indicators of lipid peroxidation. This indicates that activation of the 
Haber Weiss reaction can lead to surfactant damage (Figure 4). However, as discussed 
above, extensive scavenging mechanisms may offset damage by this route in vivo.
In summary, therefore, it seems that reactive species released during the inflammatory 
response in the lung have great potential to cause damage to pulmonary surfactant.
The microenvironment of the alveolus has, however a defence system in place which
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may mitigate some of this damage. The picture is still sketchy and further work will be 
required before the effects of reactive molecules on surfactant are fully understood.
L4.3. EVIDENCE FOR OXIDANT ACTIVITY IN THE LUNG IN ARDS 
Nitre tyrosine
Peroxynitrite-induced damage may well be significant in the clinical setting of 
inflammatory lung disease. Immunohistochemical studies (Haddad et al. 1994; Royall 
et al. 1995) have shown an increase in nitrotyrosine in postmortem sections of lungs 
from patients with ARDS and with pneumonia, indicating damage by peroxynitrite to 
surfactant proteins or to other proteins present in the lung.
Lipid peroxidation
Roumen and colleagues (1994) measured serum lipofuscin - a pigment formed by 
combination o f lipid peroxidation products with amino-groups on phospholipids and 
proteins. They found that in patients who had undergone major surgery or traumatic 
injury, those who subsequently developed ARDS had higher serum lipofuscin levels on 
the first day in intensive care than those who did not. They also found that serum 
lipofuscin level was inversely correlated with Pa02/Fi02 ratio (a measure of 
respiratory function) on the first day of intensive care stay. This indicated that poor 
pulmonary function was associated with a higher lipofuscin level, and by implication, 
with increased oxidant damage in the lung.
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a-l"proteinase inhibitor
Alpha-1-proteinase inhibitor, a substance which helps to mitigate lung damage in the 
inflammatory response, was found inactivated in the BAL fluid from patients with 
ARDS. It was possible to reactivate this inactivated a -l-P I by reduction, suggesting 
that it had been inactivated by oxidation (Cochrane et al. 1983).
-I
Hydrogen peroxide
As can be seen from figure 4, Hydrogen peroxide is produced in the Haber Weiss 
reaction. Hydrogen peroxide has been found to be increased in the expiratoiy gas ,
condensate from intensive care patients who developed ARDS compared to those who 
did not (Baldwin et al. 1986; Sznadjer et al. 1989). In Baldwin's study (1986), breath 
hydrogen peroxide was correlated positively with plasma lysozyme (an indicator of 
neutophil turnover) in both groups. However, interestingly, in a subgroup of 5 patients 
with pneumonia but not ARDS, breath peroxide was low, despite what the authors 
referred to as 'the probable accumulation o f activated neutrophils in their lungs'.
Sznadjer and colleagues (1989) studied intensive care patients with ARDS, patients 
with acute hypoxaemic respiratory failure (AHRF) with pulmonary infiltrates on chest 
X ray and patients with AHRF but without infiltrates. Infiltrates were due either to 
pulmonary contusion or to pneumonia. In contrast to Baldwin, Sznadjer found that 
expired hydrogen peroxide levels were similarly high in the ARDS and the AHRF with 
infiltrates' group, and significantly lower in the 'AHRF without infiltrates' group. The 
reason for this discrepancy is unclear, althogh Sznadjer and colleagues did study a 
larger number of patients than Baldwin, and used a different assay technique to 
measure hydrogen peroxide.
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;Plasma indicators of lipid peroxidation
Acute respiratory distress syndrome is ultimately a multi-systems disorder, with death 
often occurring due to failure of organs other than the lungs. Plasma lipid peroxides 
have been found to be increased in patients with ARDS (Cross et al. 1990). It is 
possible that, if lipid peroxides were studied in BAL from these patients, this increase 
would be reflected in BAL fluid, not necessarily as a result of lipid peroxidation 
occurring in the lungs, but as a result o f leakage of plasma into the alveoli.
1.4.4. LUNG ANTIOXIDANT ACTIVITY IN ARDS
Two studies have demonstrated an increase in caeruloplasmin and transferrin in BAL 
fluid from patients with ARDS compared to control (Kfrsek-Staples et al. 1992; Lykens
which they found in ARDS.
A study of patients with ARDS who had increased lipid peroxidation products in their 
plasma also revealed a deficiency of plasma vitamin E in these patients (Cross et al
1990). This suggests that, in severe lung injury, the balance of antioxidants is altered in 
plasma and alveolar lining fluid.
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et al. 1992). Lykens and colleagues suggested that increased levels of these proteins t
Iwere responsible for the greater antioxidant capacity of broncholaveolar lavage fluid y
1.4.5. THE EFFECTS OF HYFEROXIA ON SURFACTANT
The clinical and histological changes o f ARDS are very similar to those seen in 
hyperoxic lung injury (Dedhia and Banks, 1994), possibly due to the common factor of 
oxidant damage to lung tissues. Hyperoxia has been shown to increase oxygen radical
production by mitochondria in rat lungs (Freeman and Crapo, 1981) and there is 
evidence to suggest that hyperoxia-exposed lung epithelial cells are more susceptible to 
damage by products secreted from neutrophils in vitro (Suttorp and Simon, 1982).
Also, hyperoxia can impair the bactericidal ability of pulmonary macrophages (Suttorp 
and Simon, 1981). It is difficult to disentangle the effects of hyperoxia and the effects 
of lung inflammation in vivo, as patients and animals with severe lung inflammation 
invariably need to be ventilated with high concentrations of oxygen for survival.
Several animal studies have been performed to investigate the effect of hyperoxia on 
pulmonary surfactant. In rats exposed to hyperoxia, total phospholipids (Balaan et al. 
1995; Valimaki et al. 1975), total proteins (Balaan et al. 1995) and unsaturated fatty 
acids in PC and PG (Valimaki et al. 1975) were found to be incresed in lung washings. 
Balaan and colleagues (1995) exposed rats to 100% oxygen, and found that maximum 
and minimum surface tension of surfactant from these animals was increased. In 
contrast, rabbits (Holm et al. 1985) and mice (Gross and Smith, 1981) exposed to 
hyperoxia developed reduced alveolar phospholipid levels.
Rabbits exposed to 100% oxygen showed increased alveolar permeability (measured 
by detection of labelled cyanocobalamin) and reduced surface activity o f cell free 
lavage concentrated to ImM phospholipid. When these measurements were repeated in 
the recovery phase at 200 hours after exposure, lavage protein and surface activity had 
returned to the same as that in controls, while phospholipids were double compared to 
control (Holm et al. 1985). Increased alveolar permeability was offset by 
administration of calf lung surfactant extract to oxygen-exposed rabbits (Engstrom et 
al. 1989).
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Primates ventilated for 7 days with high inspired oxygen concentrations developed an 
inverse ratio of PC to PI in a 'high speed' pellet of surfactant purified by dialysis (King 
et al. 1989). However, exposure of rats to 95% oxygen resulted in no change in 
proportions of phospholipid classes in cell free lung washings after 60 hours (Valimaki 
et al. 1975).
Therefore, it seems that the picture found in hyperoxic lung damage is quite similar to 
that in ARDS, with an alveolar protein leak, alterations in surfactant phospholipid 
composition and quantity (with both increases and decreases found), and functional 
abnormality o f surfactant.
1.5. SURFACTANT REPLACEMENT IN ARDS
If surfactant is dysfunctional in acute lung injury, then surfactant replacement therapy 
may have an important role. However, the complexity of the impact which ARDS has 
on the pulmonary surfactant system, and the role of factors other than surfactant 
deficiency has been emphasised by initial attempts to use surfactant replacement 
therapy in ARDS. A multi-centre trial was conducted recently on the effects of 
aero soli sed synthetic surfactant in sepsis-induced ARDS. No improvement was found 
in 30 day survival (Anzueto et al. 1996). However, more recently, administration o f a 
bovine surfactant (containing SPB and SPC) was shown, in a pilot study, to reduce 
mortality substantially in ARDS (Gregory et al. 1997).
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In a paediatric population with ARDS, Exosurf treatment did not improve survival, but 
with Exosurf, dynamic compliance improved and there was a tendency for gas 
exchange to stabilize earlier (Perez-Benavides et al. 1995).
1.6. SUMMARY
From the review of studies above, it can be seen that the factors possibly leading to
surfactant dysfunction in acute inflammatory lung disease are complex and far from
understood. These may be summarised as:
1. It is a matter of some controversy as to whether or not there is a deficiency of 
surfactant phospholipids in ARDS.
2. There is evidence for intrinsic alterations in surfactant composition, specifically 
a reduction in PC and PG and an increase in sphingomyelin. Whether these 
affect surfactant function is not clear.
3. Fatty acid species seen in BAL fluid from patients with ARDS are different 
from control. However, this must be interpreted with caution in the light of 
possible contamination of BAL with membrane fragments.
4. It is likely that surfactant in the inflamed lung is inhibited by plasma proteins 
(and possibly by LPC which can exacerbate this inhibition). Yet this has to be 
considered in the light of the balance between phospholipids and surfactant 
proteins which protect surfactant from inhibition.
5. An imbalance between small and large aggregates of surfactant may lead to 
surfactant dysfunction in vivo.
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6. Surfactant may be injured by high levels of oxygen needed in therapy, or by
oxidants gemerated in the inflammatory response. However, this damage may 
be offset by antioxidants in the alveolar lining.
1,7. SURFACTANT IN SEVERE RSV INFECTION
1.7.1. SURFACTANT DYSFUNCTION
The radiological and clinical features o f severe RSV infection would suggest that 
surfactant function may be reduced in this condition. The appearances seen on chest 
radiographs from ventilated infants with RSV can be similar to those seen in ARDS 
and in infantile RDS, where surfactant function is known to be poor. As in ARDS, 
ventilated children with RSV often require positive end expiratory pressure and high 
peak airway pressures to maintain oxygenation. These ventilatory requirements are 
indicative of a tendency to alveolar collapse and increased small airways resistance or 
decreased lung compliance - all of which could result from surfactant dysfunction.
Severe RSV infection, like ARDS and pneumonia, is a form of inflammatory lung 
disease, and there are important pathological similarities between these three 
conditions. All are characterised by an infiltrate o f inflammatory cells, an alveolar 
exudate and the presence of cell debris in the alveoli. As in ARDS and pneumonia, 
there is the potential for surfactant dysfunction in severe RSV infection. Potential 
causes of this dysfunction are deficiency or abnormal composition of surfactant, 
damage to surfactant or inhibition of surface activity. These factors are summarised in 
Figure 5 and reviewed below.
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1.7.2. POTENTIAL DEFICIENCY OR ABNORMAL COMPOSITION OF 
SURFACTANT
Alterations in the absolute and relative amounts of surfactant phospholipids and ^
I
proteins have been found in BAL fluid from patients with ARDS and with pneumonia. jI
It is possible that, given the parallels between RSV and these inflammatory lung 'I
diseases, a similar pattern of surfactant abnormality may be seen in severe RSV |
infection.
Molecular participants in the inflammatory response may affect the amount of 
surfactant present in the alveolus during RSV infection. Recent in vitro work by 
Haddad and colleagues (1996) suggests that nitric oxide and peroxynitrite (which are 
produced and secreted locally in the inflammatory response) may decrease synthesis of 
surfactant. Since RSV is associated with an inflammatory infiltrate, this is, then, 
potentially a mechanism for surfactant damage.
Other mechanisms, specific to infection with RSV, could also reduce the amount 
surfactant phospholipids and proteins present in the alveolus. For example, viral 
invasion of type II pneumocytes may perturb surfactant synthesis. Also involvement of 
surfactant proteins A and D in the local immune response to micro-organisms may lead 
to alterations in the alveolar concentration of these proteins in viral infections such as 
RSV
In summary, it is possible to hypothesise that altered amounts of phospholipids and 
proteins as well as changes in phospholipid or fatty acid proportions may occur in RSV 
infection and could cause impairment of surfactant surface activity and immune
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function. Changes in relative proportions of surfactant phospholipids or fatty acid 
species would have a theoretical potential to affect surface activity, as fatty acid or 
phospholipid composition o f surfactant may be important in the packing of lipids at the 
air-liquid interface (section 1.2.3.).
1.7.3. POTENTIAL DAMAGE TO SURFACTANT
An infiltrate of inflammatory cells - probably mainly neutrophils - occurs in RSV 
infection. These cells release reactive molecules which may damage surfactant per se, 
or, in the case of nitric oxide and superoxide, unite to form peroxynitrite which has 
been proven to damage surfactant in vitro.
1.7.4. THE EFFECT OF HYPEROXIA
Ventilation with high concentrations of inspired oxygen has been shown to alter 
surfactant composition and to cause surfactant dysfunction in experimental animals 
(section 1.4.5.). If this also occurs in humans, the high concentrations o f inspired 
oxygen needed to maintain tissue oxygenation in severe RSV infection could lead to 
similar changes.
1.7.5. POTENTIAL SURFACTANT INHIBITION
Leakage of proteinaceous fluid from the pulmonary capillaries is common in 
inflammatory lung diseases, and there is evidence that such leakage is present in RSV 
infection. A fibrinous exudate fills a proportion of the alveoli in the lungs of patients
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who have died from severe RSV infection, and oedema fluid permeates the lung 
parenchyma and alveoli. Oedema fluid, containing plasma proteins, especially 
fibrinogen and fibrin degradation products is well known to cause inhibition of 
pulmonary surfactant in vitro. It is highly likely that this mechanism operates in the 
lungs o f patients with RSV.
1.7.6. RSV AND SURFACTANT - CURRENT EVIDENCE 
Until now, little investigation o f the state o f the pulmonary surfactant system in RSV 
infection has been carried out. Recent studies o f tracheal aspirate samples from 
patients ventilated for severe viral bronchiolitis and pneumonitis have found reduced 
levels of SPA (Dargaville et al. 1996; Le Vine et al. 1996). In addition to studying 
tracheal aspirates, Dargaville (1995) obtained BAL samples from some patients. 
However, when SPA was measured in these BAL samples there was no significant 
difference from the control group.
Dargaville's finding (1995) of a discrepancy between levels of SPA in BAL and 
tracheal aspirate is interesting. Bronchoalveolar lavage theoretically samples a lower 
part of the respiratory tract than aspiration of tracheal secretions. As RSV is a disease 
whose inflammatory manifestations are seen relatively distally in the bronchial tree, and 
as surfactant functions at a similar distal level in the lung, BAL would possibly give a 
better picture of the pulmonary surfactant system in RSV infection.
Surfactant protein B levels were not found to be different from controls in a study of 
ventilated children with viral pneumonitis (LeVine et al. 1996).
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Dargaville and colleagues (1996) also found reduced levels of surfactant DPPC in 
tracheal aspirates, and reduced surface activity of the surfactant pellet recovered from 
patients with viral bronchiolitis. A recent preliminary study by Skelton and colleagues 
(1994) demonstrated inhibition of surfactant and a reduced PG fraction in tracheal 
aspirates from patients with viral bronchiolitis.
Therefore, it would appear that qualitative and quantitative abnormalities of surfactant 
phospholipid and a reduction in SPA, with reduced surfactant function are present in 
severe RSV infection.
Preliminary evidence from surfactant replacement studies
If surfactant is dysfunctional, then replacement therapy might be helpful. Recently two 
groups have published case reports o f clinical improvement following administration of 
exogenous natural surfactant to children with severe viral pneumonia (Vos et al. 1996; 
Putz et al. 1996).
1.7.7. SUMMARY
The pathological features which may lead to abnormalities of the pulmonary surfactant 
system in severe RSV infection are summarised in Figure 5. These provide theoretical 
grounds on which to base a hypothesis that surfactant is dysfunctional, due to 
deficiency, abnormal composition, damage or inhibition in respiratory failure due to 
RSV infection. Recent studies have shown evidence for a reduction in surfactant 
function and amount in this condition. However, the complex range of potential causes
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of surfactant abnormality suggests that a comprehensive study of all aspects of 
surfactant composition and function in RSV infection is warranted.
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Figure 5. Potential mechanisms causing surfactant abnormality in severe RSV infection
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2. HYPOTHESIS AND AIMS
2.1. HYPOTHEISIS
Pulmonary surfactant is dysfunctional in respiratory failure due to Respiratory 
Syncytial Virus infection, due to deficiency, abnormality in composition, damage or 
inhibition.
2.2. AIMS
The aims of this study were to determine whether pulmonary surfactant is 
dysfunctional, deficient, abnormal in composition, damaged or inhibited in severe RSV 
infection. The study to be described investigated pulmonary surfactant in a group of 
ventilated children with severe RSV infection versus controls. In the RSV group, the 
profile of surfactant change throughout the disease process, and the relationship of 
surfactant components in BAL fluid to alveolar arterial oxygen ratio (as a measure of 
disease severity) was also investigated.
The specific aims were:
1. To assess surfactant function by performing functional tests on whole BAL fluid and 
a lipid extract of BAL fluid at a known concentration of phospholipid.
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2. To ascertain whether surfactant is deficient or abnormal in composition in severe
-
RSV infection by analysis o f the phospholipid and protein components o f pulmonary 
surfactant.  ^ /
3. To search for evidence o f damage to pulmonary surfactant in severe RSV infection 
by quantifying markers o f free radical damage and surfactant breakdown
4. To assess surfactant inhibition and surfactant inhibitors in severe RSV infection by;
a) quantifying proteins in BAL fluid
b) evaluating the inhibitory potential of proteins in BAL fluid
3. PATIENTS AND CLINICAL DATA
3.1. PATIENTS
3.1.1. STUDY GROUPS
The children studied were all intubated and artificially ventilated. Two groups were 
studied:
1. The study group was composed of children who were mechanically ventilated in the 
intensive care unit with a diagnosis o f respiratory failure due to RSV infection. 
Diagnosis of RSV infection was made by immunofluorescence of nasopharyngeal 
secretions. Patients were either diagnosed as 'RSV positive' on admission to the 
intensive care unit, or diagnosis was made on clinical suspicion, and subsequently 
confirmed by immunoflourescence of nasopharyngeal secretions. All ventilated infants 
with RSV were patients in the medical intensive care unit at the Royal Hospital for 
Sick Children, Glasgow.
2. The control group were children undergoing mechanical ventilation for surgical 
procedures. These patients did not have any clinical or radiological evidence of 
primary lung parenchymal disease. They came from two sources. The first group (n=8) 
were being ventilated in the surgical intensive care unit at the Royal Hospital for Sick 
Children, Glasgow to allow adequate analgesia following surgical procedures. The 
second group (n = 8) were intubated for routine surgical procedures, and were studied
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after induction o f anaesthesia and before surgery (Table 6). The median age in the 
study group was 3.1 months (range 0.3 - 42.1), while that in the surgical group was 
0.4 months (range 0.0 - 42.0). The age distribution in each group is shown in Figure 6.
Table 6. Children in the RSV and control groups.
Group number gender
(m :0
median age 
(months)
(range)
ventilated to facilitate analgesia after 
surgery*
8 6:2 0.1
(0.0-0.5)
ventilated for routine procedures** 8 3:5 6.3
(0.0-42.0)
ventilated for severe RSV infection 18 11:7 3.1
(0.3-42.1)
* Infants ventilated after operative procedures (eg. gastroschisis repair, repair of 
oesophageal atresia/tracheosophageal fistula, inguinal hernia repair) in the surgical 
intensive care unit at the Royal Hospital for Sick Children, Glasgow.
**Children intubated for routine procedures (eg. dental extraction, CT scan, inguinal 
hernia repair) and studied after induction of anaesthesia and before surgery
90
30 'I 20 -&I
10  -
surgical control 
group (RSV-ve) RSVgroup
Figure 6. Age at sampling of patients with RSV infection and patients undergoing 
surgery. It can be seen that the distribution of ages is similar in the two groups.
3.1.2. ETHICAL APPROVAL AND INFORMED CONSENT
Approval for study of the patient groups detailed in section 3.1.1. was given by the 
Ethical Committee of the Royal Hospital for Sick Children, Glasgow. The procedure 
o f sample collection and the purpose o f the study was explained to parents or 
guardians before their child's participation, and witnessed written consent obtained. 
One copy o f the consent and information form (Appendix 1) was given to parents or 
guardians, and one copy was retained alongside data collected in the study.
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3.2. COLLECTION AND STORAGE OF CLINICAL 
DATA
3.2.1. RECORDING OF PATIENT DATA
Clinical data on patients studied were collected daily at the time of sampling using 
standard form (Appendix 2). The parameters recorded included diagnosis, arterial 
alveolar oxygen ratio, drug therapy and details of any significant clinical incidents 
occurring in the preceeding 24 hours.
3.2.2. ARTERIAL ALVEOLAR OXYGEN RATIO AS A MEASURE OF 
DISEASE SEVERITY
The arterial alveolar oxygen ratio provides an accurate and relatively non-invasive 
measure of pulmonary function. It utilises measurements o f arterial oxygen tension and 
a calculated measure o f “ideal alveolar gas” (Appendix 3).
The form of the equation which is commonly used clinically for calculation of ideal 
alveolar oxygen content is ;
PaOi = Fî02{Pb — Phzo) — PAC0i{FiO2 + —
(alveolar Pco^ is assumed to be equal to arterial Pç^Q^in practice)
The arterial alveolar oxygen tension ratio has been demonstrated to be a reasonably 
stable index of pulmonary function in the presence of different inspired oxygen 
concentrations (Gilbert and Keighley, 1974). It has been evaluated theoretically and
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index o f disease severity for use in this study.
.
,:,;Cclinically in adult intensive care patients by Zetterstrom (1988), and was found to 
reflect shunt fraction (the proportion of blood which passes through the lungs but is 
not oxygenated) more accurately at different levels of inspired oxygen concentration
.
than other methods in common use (eg. arterial oxygen tension, arterial oxygen 
saturation, and arterial alveolar oxygen difference).
Severe infection with RSV is associated with bronchial and bronchiolar plugging, and 
areas of atelectasis. These conditions, which resolve slowly with recovery would be 
expected to produce an increase in shunt fraction, and hence a decrease in arterial 
alveolar oxygen ratio. For this reason, arterial alveolar oxygen ratio was chosen as an
i
IThe equation above was used to calculate ideal alveolar partial pressure of oxygen. 
Inspired oxygen concentration {Fio%) was measured with a paramagnetic oxygen 
analyser. Barometric pressure {Pb) was measured with a mercury barometer. Partial 
pressure of water vapour Pah 20 was assumed as 47mmHg. Alveolar carbon dioxide 
tension {Pacoi) was assumed to be equal to arterial FCO2 (Riley and Cournand, 1949), 
and this was measured with a CO2 electrode in a standard blood gas analyser. The 
respiratory quotient, R, was assumed to be 0.8. Arterial FO2 was measured with an 
oxygen electrode in a blood gas analyser. In all intensive care patients, an arterial line 
was already in situ for blood sampling and invasive blood pressure recording and 
arterial blood samples were taken from this line.
The alveolar oxygen tension was calculated, and arterial PO2 was divided by this value
to give the arterial/alveolar oxygen ratio.
j '
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4. MATERIALS
4,1. CHEMICALS
All chemicals used in this work were of analytical grade and were purchased from 
BDH Limited or Sigma Chemical Company.
4.2. BUFFERS AND OTHER REAGENTS
All water used in preparation o f buffers and other reagents was deionised (Elgastat 
Spectrum de-ioniser) unless otherwise stated. The formulation of buffers used in this 
work is detailed in Appendix 4.
4.3. GLASSWARE AND PLASTICWARE
All glassware was washed with a lipid-ffee detergent, rinsed in acetic acid, and then 
rinsed twice with de-ionised water. Tmmulon 4 ’ (Dynatech Ltd, Billinghurst, Kent) 
microtitre plates were used in this study .
4.4. PIPETTES
The same set of pipettes was used within each assay. Pipettes were calibrated at 6 
monthly intervals.
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5. METHODS
5.1. COLLECTION AND STORAGE OF BAL SAMPLES
5.1.1. NON BRONCHOSCOPIC BRONCHOALVEOLAR LAVAGE 
Background
Bronchoalveolar lavage (BAL) is usually performed in adults and older children via a 
flexible fibreoptic bronchoscope inserted through a tracheal tube or laryngeal mask - or 
directly through the vocal cords. The flexible bronchoscope is advanced through the 
bronchial tree, and wedged in a known segmental bronchus, where saline is instilled 
through the bronchoscope. The instilled fluid, mixed with the contents of airway fluid 
distal to the wedged end of the instrument, is then aspirated through a suction channel. 
The smallest available flexible fibreoptic bronchoscope with a suction channel has an 
external diameter of 3.5mm (Wood, 1993). This bronchoscope can only be passed 
through a tracheal tube connector of 4.5mm or greater internal diameter. This makes 
bronchoscopic lavage impossible in small, ventilated infants where tracheal tube 
internal diameter is less than 4.5mm.
As an alternative, non-bronchoscopic BAL involves inserting a blindly directed suction 
catheter into the bronchial tree, wedging this catheter and then instilling and aspirating 
a volume of saline solution. The use o f this technique in intubated infants with small 
artificial airways has been described in the past decade (Aipert et al. 1992), as a safe 
and effective method of obtaining alveolar lining material. More recently, a simplified
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technique has been described (Kombourlis and Kurland, 1993). Cytological 
examination of lavage samples by these workers revealed the presence of alveolar 
macrophages, indicating that alveolar lining material had been obtained by the non- 
bronchoscopic method.
!■
Pulmonary surfactant should be largely confined to the most distal parts of the 
bronchial tree, where it is produced and recirculated. This makes it likely that this 
method of lavage will yield a more representative sample o f alveolar fluid than, for 
example, tracheal aspiration (the method usually employed to study surfactant in small 
children). This is supported by some evidence that the phospholipid composition of 
fluid collected by fibreoptic bronchoalveolar lavage is different from the composition
:of that obtained from tracheal aspirates and washings (Widdicombe, 1987).
Method
A 35cm long 2mm external diameter catheter (in children under 18 months), or a 75cm 
long 2.7mm external diameter catheter (in children over 18 months) (Combicath, 
Panmedical Ltd, Paisley, Scotland) was used for this procedure (Figure 7). Patients 
were pre-oxygenated for 5 minutes prior to the procedure by increasing the inspired 
oxygen concentration delivered via the ventilator mixer to 100%. The ventilator tubing 
was then disconnected from the patient's tracheal tube connector, and the catheter 
advanced through the tracheal tube until it was felt to 'wedge'. The catheter was then 
withdrawn approximately 2mm. A 3ml (in children under 3kg), 5ml (in children 3-13 
kg) or a 7ml (in children over 13kg) aliquot of sterile 0.9% saline solution warmed to 
body temperature was instilled, and then immediately aspirated. These volumes were 
felt to be more appropriate than weight adjusted volumes which would have led to
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lavage with excessive quantities of saline in older children. Saline was instilled from 
and aspirated into a 10ml syringe, and aseptic technique was observed at all times. 
When the 35cm catheter was used, each aliquot of saline was 'chased' by approximately 
0.5ml of air to flush out the catheter dead space. With the 75cm catheter, an aliquot of 
approximately 1ml of air followed the saline. After lavage, the patient was briefly 
reconnected to the ventilator (with the mixer still set at 100%), and the lavage 
procedure subsequently repeated until a total of three aliquots had been collected.
After the collection of these aliquots, tracheal suction was performed to collect any 
residual fluid or secretions. The duration o f the entire collection procedure was 
approximately five minutes. The inspired oxygen concentration was then gradually 
weaned down to its original value over five minutes following the procedure. Sample 
collection in the children studied was performed at 24 hour intervals from intubation 
until extubation. Samples were always taken at least one hour after physiotherapy or 
tracheal suctioning by nursing staff.
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Figure 7. System used for sampling BAL fluid
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5.1.3. CENTRIFUGATION PRO TO CO L AND STORAGE OF SAMPLES 
Samples were centriâiged at 250 x g for 5 minutes to precipitate cellular debris. The 
supernatants were then decanted, aliquoted and, within 30 minutes of collection, 
stored at -70°C until analysis.
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5.1.2. PATIENT MONITORING ■ ,
Throughout the pre-oxygenation period, during the lavage and suctioning, and
subsequently, while the inspired oxygen concentration was being weaned back to its
original value, the child's clinical condition, arterial oxygen saturation,
electrocardiogram, pulse rate, ventilator pressures and invasive blood pressure were
monitored by the experimenter and intensive care nursing staff. Chest auscultation was
performed on the patient before and after sampling. Auscultation allowed assessment
of air entry to both lungs before and after the procedure. Any change in air entry could
indicate either dislodgement o f a mucus plug or inadvertent endobronchial intubation.
Both of these are theoretical complications of BAL which can be remedied by further 1
::suction (to remove the mucus plug) or by repositioning of the tracheal tube. Neither
. . . .  of these complications occurred during this study.
I
?
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5.2, ASSESSMENT OF SURFACTANT FUNCTION
5.2.1. THE SHAKE AND CLICK  TESTS 
Background
The shake test (Clements et al. 1972) and the click test are quick, in vitro tests of 
surface activity performed on a whole sample of lavage fluid (Skelton and Jeffrey,
1994; Todd and John, 1983).
The shake test is performed by shaking BAL fluid with ethanol in a test tube and 
observing the formation of bubbles. The ethanol, at a concentration o f 47.5% excludes 
proteins, bile salts or salts o f free fatty acids which may otherwise cause a foam. At 
this fractional concentration o f ethanol, only double chain phospholipids from BAL 
surfactant should compete effectively for the surface film (Clements et al. 1972).
In the click test, bubbles formed in the shake test are suspended under a cover slip in 
air free water (obtained by boiling deionised water) in the cavity o f a glass slide, and 
examined under a microscope. If active surfactant is present, ‘clicking’ is seen as 
repeated shrinking and expanding of the bubbles. The ‘clicking’ is thought to be 
caused by repeated diffusion of air out o f the bubbles into the air-free water. This 
diffusion makes the bubbles flatter against the cover slip. The surface film of active 
surfactant then suddenly reforms in the original spherical shape, making the bubble 
appear to contract, and the cycle begins again. If active surfactant is not present, this 
does not happen, and the bubbles gradually shrink and disappear without clicking as air 
diffuses into the water.
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Skelton and Jeffrey (1994) found that the positive predictive value of both the shake 
test and the click test for diagnosis of Respiratory Distress Syndrome (where 
surfactant function is poor) in neonates was 100%. The negative predictive value of 
the click test was 93% and that of the shake test was 80%.
M ethod
Two hundred microlitres o f lavage fluid were mixed with an equal volume of 95% 
ethanol in a 12 x 75mm glass test tube and the mixture was vortex mixed for 15 
seconds. In accordance with Skelton's description (1994), the shake test was 
considered 'positive' if a rim o f bubbles surrounded more than % of the tube 
circumference after vortex mixing.
The bubbles were then removed with a pipette and placed on a cover slip. The cover 
slip was inverted onto the cavity of a slide containing air-free water and the slide was 
observed under lOx magnification. In accordance with Skelton's description (1994), 
the click test was considered 'positive' if bubbles were seen ‘clicking’, as described 
above.
The click and shake tests are useful because they provide an integrated assessment of 
whole BAL fluid and provide an overall test of surfactant function. They give no 
indication of the reason for surfactant dysfunction. Any dysfunction found by this 
method could be due to deficiency o f surfactant lipids or proteins, altered composition 
o f the lipid fraction, damage to surfactant or inhibition of surface activity.
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5.2.2. THE PULSATING BUBBLE SURFACTOMETER 
Background and principle of operation
The Wilheimy balance was extensively used in early studies of the physical properties 
of pulmonary surfactant. In this balance, surface tension o f a layer of surfactant on the 
surface of liquid in a trough is measured. Enhoming (1977) pointed to several 
disadvantages of this method - that is the comparatively large sample volume needed, 
the difficulty in cleaning the instrument, and the length o f time needed to make the 
measurement o f surface tension. Additionally, he noted that the surface area of the 
surfactant film in the Wilheimy balance was flat, unlike the curved surface in the 
alveoli, and also that the frequency of compression and expansion was much slower 
than that of breathing.
The pulsating bubble technique was first conceived in an attempt to produce a realistic 
alveolar model (Adams and Enhoming, 1966). This surfactometer employs a 25pi 
sample chamber in which an air bubble is formed. The small sample chamber is filled 
with the fluid to be studied and then inverted (Figure 9). A bubble o f air foims in the 
liquid at the end o f the air inlet. The bottom of the sample chamber is then seated into 
the surfactometer to connect to a metal tube which passes through a container of water 
at 37°C. The sample chamber and attached metal tube are pushed down until the 
chamber is immersed in water. The end o f the air inlet remains above the surface o f the 
water, thus sustaining the bubble. The water container is fixed to the stage of a 
microscope and has a transparent side which allows viewing of the sample chamber 
while it is immersed. The bubble is aligned so that its edges abut onto vertical hairlines 
on the eyepiece o f the microscope, which are a known distance apart. The sinusoidal
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pulsator unit - an arrangement of pistons ~ then moves a specified volume of liquid out 
of the sample chamber, and back in again, causing the bubble to alternate between a 
maximum and a minimum radius (r). A pressure transducer measures the pressure drop 
(AP) across the bubble (Figure 10).
According to the Young Laplace law, AP = 2y/r (for a sphere), where y is the surface 
tension. As the radius (r) and the pressure drop (AP) are known, surface tension at 
maximum and minimum radius can be calculated (Enhoming, 1977). The bubble is not, 
in fact, spherical in solutions containing aliphatic substances. However, Hall and 
colleagues (1993) have shown that use o f the spherical case of the Young Laplace 
equation results in a minimal absolute error in practice. The same authors 
demonstrated that viscosity effects were not a source of error at minimum and 
maximum bubble radii. This is because the error due to viscosity effects can be shown 
to be - 2k  • 1/r • dr/dt where k  is a term describing viscosity and r is the radius of the 
bubble. At maximum and minimum radii, the term dr/dt, the derivative of the radius 
with respect to time becomes equal to zero, and so does the eiTor.
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Figure 9. Filling the surfactometer sample chamber
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Figure 10. Pulsating bubble surfactom eter - mechanism o f  action
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Method - Surfactometer studies of a lipid extract of BAL fluid
In preparation for analysis in the surfactometer, BAL samples were centrifuged at 
40,000g for one hour (Sorvall Superspeed centrifuge) to obtain a surfactant pellet.
The 40,000g surfactant pellet was subjected to a chloroform:methanol extraction (as 
described in section 5.4.1.) in order to remove potential interfering proteins which may 
have been pelleted along with surfactant. The dried lipid was then immediately 
resuspended in suspension buffer to a concentration of ImM (750 pg) phospholipid, 
taking account of centrifugation losses.
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Sample chamber preparation
Measurements of surface tension in the pulsating bubble surfactometer are very 
sensitive to artefacts due to sample chamber contamination. A cleaning procedure was 
therefore adopted before sample chamber use (personal communication B. Robertson, 
Stockholm 1995).
Each sample chamber was rinsed ‘in situ’ for 5 minutes while connected to the 
surfactometer, using distilled de-aerated water. The sample chambers were stored in 
5% Extran M A03 (Merck Ltd, Darmstadt, Germany), and then transferred to a fresh 
solution of 5% Extran M A03, and vortex mixed manually for 5 minutes. After rinsing 
for five minutes in tap water, the chambers were sonicated for 1 hour in fresh 5% 
Extran M A 03. They were then rinsed in running tap water for 5 hours, and sonicated 
in distilled water for 30 minutes. Finally, the chambers were air dried.
.■
The organic extraction and adjustment of concentration allowed the effects of any 
damage to surfactant lipids or hydrophobic proteins to be assessed in the surfactometer 
independently of variations in phospholipid concentration or interfering proteins.
The sample was transferred to a clean surfactometer sample chamber via a disposable 
insulin syringe and the bubble cycled at a temperature of 37° C, and a rate o f 20 cycles 
per minute. Recordings of maximum and minimum surface tension were made for 10 
minutes.
5.3. QUANTIFICATION OF SURFACTANT PROTEINS
The measurements made of surfactant components on each BAL sample are 
summarised in Figure 8.
5.3.1. SURFACTANT PROTEIN A 
Background
The enzyme linked immunosorbant assay (ELISA) used to quantify surfactant protein 
A is an antigen capture assay (McMahan et al. 1987). In this technique, microtitre plate 
wells are coated with an antibody to SPA. Samples or standards containing SPA are 
added and the SPA binds to the antibody on the plate. A second antibody to SPA is 
then added, followed by a horseradish peroxidase conjugate which binds to the second 
antibody. The conjugate is then reacted with a substrate to give a colorimetric end 
point. This assay was developed and validated in the Childrens Hospital Medical
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Centre, Cincinnati, Ohio, and has been used in studies of surfactant from BAL fluid 
(Le Vi ne et al. Î996; Gregory et al. 1991). Standards and antibodies used in this assay 
were a gift from Professor J. Whit sett (Children’s Hospital Medical Centre,
Cincinnati).
Method
A microtitre plate (96 wells) was coated with lOOpl per well of a 1:200 dilution of 
goat anti-human SPA antibody in 0.1 M sodium bicarbonate. The plate was allowed to 
stand overnight at 4°C
The plate was then washed three times with SPA/SPB wash buffer and dried 
thoroughly. Human albumin 2.5% and goat serum 2.5% were added to 82b buffer to 
make a blocking buffer. One hundred microlitres per well of this blocking buffer were 
added to the plate, and the plate was allowed to stand for 15 minutes at room 
temperature. The blocking buffer was removed, and the wells blotted dry.
Standard concentrations of SPA (100, 75, 50, 25, 10 and 5 ng/ml) were prepared in 
PBS-NP40. The samples of lavage fluid to be tested were diluted to 1:50, 1:200, 1:800 
and 1:3200 with PBS NP-40. Samples, standards and a blank (PBS-NP40) were added 
in duplicate at lOOpl per well, and the plate incubated for 2 hours at 37°C. The 
contents of each well were discarded and the plate washed three times with wash 
buffer and blotted dry.
One hundred microlitres of polyclonal rabbit anti human SPA diluted 1:400 in 82b with 
human albumin 2.5% and goat serum 2.5% were added to each well. The plate was
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incubated for one hour at 37°C. After incubation, the contents of each well were 
discarded, and the wells washed three times with wash buffer and blotted dry.
One hundred microlitres of goat anti-rabbit horseradish peroxidase conjugate diluted 
1:1000 with SPA/SPB dilution buffer with human albumin 2.5% and goat serum 2.5% 
were added to each well. The plate was then incubated at 37°C for one hour. The 
contents of each well were discarded, and the plate washed three times with wash 
buffer and blotted dry.
Substrate solution was prepared by adding 5ml of lOx stock concentrate substrate 
buffer to 35ml water, and then adding this dilution to 5ml of water containing 50 pi of 
30% hydrogen peroxide, and 5 ml o f water containing 200mg of ortho- 
phenylenediamine.
One hundred microlitres o f substrate solution was added to each well, and colour 
development was observed. Colour development was stopped with 100pi per well of 
9M sulphuric acid and absorbance read at 490 nanometres on a Dynatech MR5000 
plate reader. The absorbance was read versus the concentrations of standards, a 
standard curve constructed, and the concentrations of unknowns read from this curve.
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5.3.2. SURFACTANT PROTEIN B 
Background
The ELISA for surfactant protein B, unlike that for surfactant protein A only utilises
Ione surfactant protein specific antibody (Pryhuber et al. 1991). The assay was j
Ideveloped and validated in the Children’s Hospital Medical Centre, Cincinnati, and has !
been used extensively in a clinical context for assessment of tracheal aspirate samples
from neonates suspected of congenital SPB deficiency. Standards and antibodies used
in this assay were a gift from Professor J. Whitsett (Children’s Hospital Medical
Centre, Cincinnati).
M ethod
A ninety six well microtitre plate was coated with lOOpl per well of 0. IM sodium 
bicarbonate. The plate was then allowed to stand overnight at 4°C. The plate was 
washed with wash buffer three times and blotted dry. t
One hundred microlitres of 82b with 5% human albumin were added to each well, and 
the plate was allowed to stand for 15 minutes at room temperature. The 82b/albumin 
was removed, and the plate blotted dry.
Surfactant protein B standards were made diluted in PBS-NP40. The concentrations of 
the standards were 100, 75, 50, 25, 10 and 5 ng per ml. Samples were diluted 1:2 and 
1:8 with PBS-NP40. One hundred microlitres of standard, sample or blank (PBS- 
NP40) were added to each well in duplicate, and the plate was incubated for 2 hours at 
37°C. The contents o f each well were discarded and the plate washed three times with 
wash buffer and blotted dry.
I l l
Polyclonal rabbit anti-human SPB antibody diluted 1:1000 in 82b with 5% human 
albumin was added at lOOpl per well. The plate was incubated for 1 hour at 37°C. The 
contents of each well were discarded and the plate washed three times with wash 
buffer and blotted dry.
A horseradish peroxidase conjugate o f goat anti-rabbit IgG diluted 1:1000 with 
dilution buffer with 5% human albumin was added to each well at lOOpl per well. The 
plate was incubated for 1 hour at 37°C. The contents of each well were discarded and 
the plate washed three times with wash buffer and blotted dry.
One hundred microlitres o f substrate solution (prepared as described for SPA ELISA) 
were added to each well, and colour development observed. Development was stopped 
with 100 pi per well o f 9M sulphuric acid and absorbance read at 490 nanometres on a 
Dynatech MR5000 plate reader. The absorbance was read versus the concentrations of 
standards, a standard curve constructed, and the concentrations of unknowns read 
from this curve.
5.3.3. SURFACTANT PROTEIN D 
Background
The principle of the ELISA for surfactant protein D is similar to that for surfactant 
protein A. That is, it is an antigen capture assay. This assay was developed and 
validated (Miyamura et al. 1994b) in the MRC Immunochemistry Unit Oxford, and
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standards and antibodies used were a gift from Professor K. Reid (MRC 
Immunochemistry Unit, Oxford).
Method
Rabbit anti-human SPD IgG was made up at 5pg/mi in coating buffer. One hundred 
microlitres per well of this dilution were added to each well of a 96-well microtitre 
plate. The plate was left to stand overnight at 4°C.
The wells were washed three times with wash buffer, and then to each well was added 
100 pi o f wash buffer with 3% bovine serum albumin (to block unoccupied binding 
sites). The plate was then left to stand at room temperature for 2 hours.
Meanwhile, standard solutions o f SPD (2000, 1000, 500, 125, 62.5, 31.3 and 15.7ng 
per ml) were prepared diluted in wash buffer.
The blocker was discarded, and the plate washed three times with wash buffer and 
blotted dry. Standards, samples and blank were added in duplicate at lOOpl per well. 
The plate was incubated at room temperature overnight.
At the end of this period, the plate was washed three times, and complete dryness 
ensured. Biotinylated anti-SPD IgG, diluted 1:1000 in wash buffer was then added at 
lOOpl per well and the plate incubated for 3 hours at room temperature.
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The plate was washed three times with wash buffer, and dryness ensured. Extravidin- 
alkaline phosphatase conjugate diluted 1; 1000 with wash buffer was added at lOOpl 
per well and incubated for 1 hour at room temperature.
IThe conjugate was discarded, and the plate washed three times and blotted dry. Fifty j
I
microlitres per well of developing buffer with 1 mg/ml paranitrophenolphosphate was !
i
added. The plate was incubated in the dark for 30 minutes, and optical density read at '
405 nanometres in a Dynatech MR 5000 plate reader. The absorbance was read versus 
the concentrations o f standards, a standard curve constructed, and the concentrations 
of unknowns read from this curve.
5.4. PHOSPHOLIPID ANALYSIS
5.4.1. L IP ro  EXTRACTION 
Background
Organic extraction is a preliminary to analyses of lipids in biological tissues. Two 
methods of lipid extraction were used in this study: a chloroform methanol extraction 
and a propan-l-ol hexane extraction. The former method produces a 95-99% recovery 
of total lipids from tissue samples (Christie, 1982a). The latter was adopted in this 
study for relatively selective extraction of phospholipids, and has been shown to 
extract 86.8% of DPPC, 3.8% of tripalmitin and 16.4% of palmitic acid into the 
propan-2-ol layer (Ip et al. 1977).
114
Choloroform-methanol extraction
After thawing, an aliquot of lavage fluid samples was placed in a test tube. An equal 
volume of methanol and a twice equal volume of chloroform were added, so that 
sample, methanol and chloroform were present in the ratio of 1:1:2 (v:v:v) (Bligh and 
Dyer, 1959).
The chloroform, methanol and water were first mixed vigorously by hand for 30 
seconds, and then vortex mixed for the same time. After centrifugation at 1000 x g for 
5 minutes, the upper aqueous layer was discarded, and the lower chloroform lipid- 
containing layer aspirated and transfened to a glass boiling tube, placed in a heating 
block, and evaporated to dryness under a stream of nitrogen at 45°C. The dried lipid 
was then taken up into 200pl of chloroform, and stored at -70°C until analysis.
Propan-2-ol - hexane extraction
A modification o f the method o f Ip and colleagues (1977) was used to extract 
phospholipids from BAL fluid. Five hundred microlitres o f BAL fluid was placed in a 
test tube. To this was added 1ml of n-hexane, 1.75 ml of propan-2-ol and SOOpl of 
40mM sulphuric acid. The mixture was shaken vigorously for 30 seconds and then 
vortex mixed for 30 seconds. After centrifugation for 5 minutes at lOOOg, the lower 
propan-2-ol layer was decanted and retained for analysis.
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5.4.2. SEPARATION OF PHOSPHOLIPIDS BY THIN LAYER 
CHROMATOGRAPHY
Background
Thin layer chromatography was used in this study to separate the phospholipid classes 
PC, PG, PE, PS, PI, S and LPC. In this technique, samples are applied close to the 
edge of a glass plate coated with a thin layer of silica gel. The plate is immersed in a 
tank containing a mixture of solvents, and the samples are fractionated according to 
the different adsorption and solubility characteristics of their component lipids. The 
plate can then be sprayed with an agent which renders the lipids visible. The lipids thus 
seen can then be either quantified on the plate by scanning densitometry or scraped off 
and quantified by other means.
Method
Silica gel thin layer chromatography plates (10 x 10 cm LHPK silica gel 60Â) were 
obtained from Whatman Inc, Clifton New Jersey. The plates were first washed to frill 
length in n-hexane: diethyl ether 1:1 (v:v). The plates were then activated by heating at 
110°C for 1 hour. The mobile phase was prepared by mixing methyl acetate, propan-2- 
ol, chloroform, methanol and 0.25% potassium chloride in a ratio of 10:10:10:4:3.6 
(v:v:v:v:v) respectively (Olsen and Henderson, 1989). The solvent mixture was 
allowed to equilibrate with air in a sealed, unlined tank for 10 minutes.
Surfactant lipids were extracted from lavage fluid as described in section 5.4.1. 
(chloroform and methanol extraction). The 200pl of chloroform used to re-dissolve the 
dried lipid was evaporated to dryness under a stream of nitrogen at 45°C. The product 
was then dissolved in lOpl o f chloroform.
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In selected samples, glycolipids were visualised by spraying the plates with a 0.5% 
solution of a-naphthol in a 1:1 mixture of methanol:water (Siakotos and Rouser, 
1965). After spraying, the plates were allowed to dry in air and then was heated at 
120°C. Glycolipids appeared as purple spots, and other lipids as yellow / white spots 
(Figure 12). Glycolipid detection was qualitative only.
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The lOpl sample was applied to the preadsorbent layer of the plate. A standard 
solution of LPC, S, PC, PS, PI, PG and PE was also applied to each plate in a separate 
lane. The plates were then developed in the mobile phase to within 0.5cm of the top of 
the layer. The plates were allowed to dry in air, and then dried in an oven at 110°C for 
30 minutes.
To allow visualisation of the phospholipid spots on the chromatography plate, the plate 
was sprayed until damp with 3% (w:v) cupric acetate in 8% (v:v) orthophosphoric
acid. The plate was then charred in a pre-heated oven at 160°C for 20 minutes (Figure 
11).
Plates were scanned at 340nm using a Shimadzu CS-9001 PC dual wavelength TLC 
scanner (Dyson Instruments, Houghton le Spring, UK) linked to a Shimadzu data 
recorder. Results were obtained by integration of peak areas and calculation of peak 
area percent for each phospholipid class (Olsen and Henderson, 1989).
Lane 1 Lane 2
Figure 11. HPTLC of BAL phospholipids. Typical samples from the surgical 
control group (Lane 1) and the RSV group (Lane 2) are shown. A double 
glycolipid band is clearly shown at the top o f  Lane 2.
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Figure 12. Visualisation of glycolipids on HPTLC. Typical runs for 
samples from children with RSV infection (Lane 1) and surgical 
patients (Lane 2) are shown. Glycolipids appear as purple spots; other 
lipids as yellow/white spots.
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5.4.3. FATTY ACID COMPONENTS OF PHOSPHOLIPIDS 
Background
In this study, fatty acids of phospholipids were derivatised to fatty acid methyl esters. ;
The resulting esters were separated by gas chromatography and identified by mass 
spectrometry.
Method
The propan-2-ol layer from a propan-2-ol hexane extract of BAL fluid was decanted 
into a 5ml capacity toughened glass 'Reactivial' with a teflon seal.
Five hundred microlitres of 0.5 molar methanolic sodium hydroxide were added, and 
the mixture was heated at 130°C for three minutes on an aluminium heating block. The 
mixture was allowed to cool, and then 750pl of 14% boron trifluoride in methanol 
(w:v) was added. This mixture was heated for 5 minutes, again at 130°C and allowed 
to cool.
Two millilitres of saturated sodium chloride solution were added, and the lipids 
extracted with an equal volume of petroleum ether. The petroleum ether layer was 
decanted and evaporated to dryness at 45°C under a stream of nitrogen. The resultant 
dried lipid was re-dissolved in 50 microlitres of n-hexane. The relative proportions of
4
fatty acid methyl esters were assessed by gas chromatography-mass spectrometry 
(Hewlett Packard Series II 5890 gas chromatograph with SGE BP X 70 high 
resolution polar capillary column and 5972 series mass selective detector with 
automatic peak integration).
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5.4.4. QUANTIFICATION OF TOTAL PHOSPHOLIPID 
Method
Lavage fluid phospholipids were extracted, derivatised and analysed as described in 
section 5.4.3. with the addition o f Ipg of heptadecanoic acid (as an internal standard) 
immediately before the derivatisation stage. The ratio of total fatty acid methyl ester 
peak areas (derived from the sample) to heptadecanoic acid peak area was calculated. 
The conversion factor 1.371 (Christie et al. 1970) derived from the ratio of the 
molecular weight of heptadecanoic acid methyl ester to diheptadecanoyl 
phosphatidylcholine was then used to calculate an approximation to the amount of 
total phospholipid present in the sample in pg/ml.
5.5. ASSESSMENT OF SURFACTANT DAMAGE
Figure 8.
5.5.1. MALONDIALDEHYDE 
Background
The malondialdehyde (MDA) assays were kindly performed in Dr John Paterson’s 
laboratory at the Crichton Royal Hospital, Dumfries. Malondialdehyde was detected in 
lavage fluid by formation of a thioarbituric acid ad duct of MDA and detection o f the 
adduct by high performance liquid chi’omatography (HPLC) (Young and Trimble, 
1991).
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The measurements made of surfactant damage on each BAL sample are summarised in
Method
Formation of the thlobarbiturlc acid adduct
Ten microlitres of BAL fluid were mixed with 250pl of 0.44M phosphoric acid, 450|o,l 
of HPLC grade water, and 250pl of 4.6 IM  thiobarbituric acid. This mixture was 
incubated in sealed glass tubes at 100°C for 60 minutes. It was then cooled in ice to 
4°C for 15 minutes.
HPLC
Two hundred microlitres of this mixture were added to 360pl of HPLC grade 
methanol and 40pl of IM sodium hydroxide. This neutralised the sample and 
precipitated proteins. The sample was centrifuged at 1000 x g for 7 minutes, and the 
supernatant pipetted into an injection vial.
Standards
Thiobarbituric acid adducts of MDA standards (prepared from 1,1,3,3- 
tetramethoxypropane in distilled water) were treated in exactly the same way as 
samples.
Fifty microlitres of supernatant were injected into the HPLC column (phenosphere 5 
ODS 3 column: 150 x 4.60mm). The thiobarbituric acid adduct of MDA was detected 
by spectrofluorimetry with an excitation wavelength of 529nm and an emission 
wavelength of 541nm. The column was flushed with 50% methanol between runs. The 
mobile phase contained 50% methanol 50% phosphate buffer, and a flow rate of
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0.5ml/min was used. Malondialdehyde concentrations were determined by integration 
of peak area and comparison to a standard curve. Standards used were 1.2mM, 
4.8pM, 2.4pM, 1.2|xM, and 0.6pM.
5.5.2, NITROTYROSINE 
Background
Nitrotyrosine in lavage fluid was quantitated using a competitive ELISA kit supplied 
by TCS Biologicals Ltd. (Khan et al. 1995) in the laboratory o f Dr Mike Jacobs, Royal 
Free Hospital, London.
Method
The plates for this assay are supplied already coated with a predetermined amount of 
nitrated protein. Samples and standards are then added to the plates. An anti- 
nitrotyrosine antibody is added, and any nitrotyrosine present in the samples and 
standards competes with that attached to the plates for binding to the antibody. The 
less nitrotyrosine present in the sample or standard, the more binds to the plate. This 
antibody binding to the immobilised antigen on the plate is then detected quantitatively 
to construct a standard curve.
Nitrated BSA standards (ten serial 1:2 dilutions starting from lOOpg/ml), samples 
(diluted 1:1 v:v) in Dilution Buffer (PB S/Tween/ovalbumin) and a blank (Dilution 
Buffer) were added in triplicate to the plate. Rabbit anti-nitrotyrosine polyclonal 
antibody was then added at lOOpl per well and the plate incubated for 2 hours at 37°C.
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The plates were washed twice with Wash buffer (PBS-Tween provided in the kit) and 
blotted dry. Donkey anti-rabbit IgG HRP-conjugated antibody was added at lOOpl per 
well, and the plate incubated for 1 hour at 37°C.
Substrate solution was prepared by dissolving a 1 mg tablet o f tetramethylene 
benzidine in 1 ml of dimethysulphoxide, making up to 10ml with the Phosphate-citrate 
buffer supplied and adding 4pl of 30% hydrogen peroxide.
The plates were washed twice with wash buffer and blotted dry. Substrate solution was 
added at lOOpl per well and the blue colour allowed to develop for 30 minutes at room 
temperature. Fifty microlitres o f 2M sulphuric acid were added to each well to stop the 
reaction, and the absorbance read at 450nm in a microplate reader.
A standard curve was constructed, and values for the samples calculated from this 
curve.
5.5.3. THIN LAYER CHROMATOGRAPHY
The HPTLC plates which had been run and developed as described in section 5.4.2. 
were inspected to determine qualitatively whether any phospholipids other than PC, S, 
PS, PI, PG and PE were present. Specifically, the presence or absence of 
lysophosphatidylcholine was sought.
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5.6. ASSESSMENT OF SURFACTANT INHIBITION 
AND MEASUREMENT OF POTENTIAL INHIBITORS
The measurements made to assess whether surfactant inhibition was present or not are 
summarised in Figure 8.
5.6.1. TOTAL PROTEIN 
Background
The total protein content of lavage fluid was estimated by the Lowry method (1951). 
There are two steps to this method. The first is the reaction of protein and copper in 
alkali. The second is the reduction of the Folin (phosphomolybdic-phosphotungstic) 
reagent by the copper treated protein. The blue colour produced by this second step 
can be detected in a spectrophotometer at 750nm.
Method
Protein standards were prepared to give concentrations of 0.125, 0.25, 0.5, 1, 2 and 4 
mg/ml.
Tubes containing lOpl water (blank), lOpl of each standard, and lOpl of sample were 
set up in duplicate. Lowry’s reagent A (1ml) was added to each tube, mixed 
immediately and allowed to stand at room temperature for 10 minutes. Folin- 
Ciocalteau reagent (100pi) was then added, mixed immediately and allowed to stand at
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room temperature for 30 minutes. Optical density was then read at 750nm, and the 
protein concentrations derived from a standard curve.
5.6.2. QUANTIFICATION OF ALBUMIN 
Background
This assay was performed in the Biochemistry Department at the Royal Hospital for 
Sick Children with the help o f Mr John Black. This assay, which utilises reagents from 
a Roche kit in an automated analyser is in routine clinical use for quantification of 
urinary albumin in Yorkhill Hospital.
%
-.s.;
Method
Bronchoalveolar lavage fluid was diluted in 154mM sodium chloride solution with 
0,5% Tween 20. Albumin standards (192, 96, 48, 24, 12 and 6 pg/ml) and blank were 
also made in the saline/Tween solution. Anti-serum to albumin (Roche 07 2996 5) was f
added to samples and standards and the precipitin formed was measured 
turbidimetrically at 340nm in a Cobas Far a II analyser. The concentration of albumin in 
samples was then read from a standard curve (Gerbaut, 1987).
5.6.3. QUANTIFICATION OF C-REACTIVE PROTEIN 
Background
This assay was performed in the Biochemistry Department at the Royal Hospital for 
Sick Children with the help o f Mr John Black. The assay for C-reactive protein (CRP) 
is, like that for albumin, an immunoturbidimetric technique. This technique utilises a
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CRP assay kit (Roche) and is in routine clinical use for quantification of plasma CRP in 
Yorkhill Hospital.
Method
Bronchoalveolar lavage fluid was assessed undiluted. C-reactive protein standards 
(Roche 07 1604 9) (40, 20, 10, 5 and 2.5 pg/ml) and blank were made up in 154mM 
sodium chloride solution. Antiserum to CRP (Roche 07 2184 0) and "Accelerator 1 
solution’ (Roche 07 2186 7) was added to samples and standards and the precipitin 
formed was determined turbidimetrically at 340nm in a Cobas Fara II analyser. The 
concentration of CRP in samples was then read from a standard curve (Fink et al. 
1989).
5.6.4. QUANTIFICATION OF FIBRIN DEGRADATION PRODUCTS 
Background
The assay for FDP was performed by Dr Ann Rumley in the Department of Medicine, 
Glasgow Royal Infirmary. An ELISA kit was used to detect the presence of cross 
linked fibrin degradation products containing D-dimer in BAL fluid (Dimertest Gold 
E l A kit, Agen Biomedical Ltd, Queensland, Australia) (Hart et al. 1994).
Method
Plate wells were supplied already coated with monoclonal anti D-dimer antibody DD- 
3B6 in PBS with lg/1 sodium azide as preservative.
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One hundred microlitres o f PBS with Tween 20 (0.05%) were added to each well. To 
this was added 25pi of sample, standard (2,000 to 32 ng/ml in doubling dilutions made 
up in PBS/Tween) or blank (PBS/Tween). The contents of the wells were mixed gently 
and incubated on a plate mixer at room temperature for 15 minutes.
The wells were washed three times with PBS/Tween and then dried. Fifty microlitres 
of mouse monoclonal anti-FDP peroxidase conjugate were added to each well, mixed 
gently and incubated on a plate mixer for 15 minutes at room temperature. The wells 
were then washed three times as before.
The peroxidase substrate supplied (2,2’Azino-bis (3-Ethylbenzthiazoline Sulfonic 
Acid)) was activated by the addition of 0.3% v/v hydrogen peroxide. This was added 
at lOOpI/well to each well, and incubated on a plate mixer for 15 minutes at room 
temperature.
Fifty microlitres of stopping reagent were added to each well and mixed.
Absorbance was read at 405nm, and unknowns read from a standard curve.
5.6,5. SURFACTOMETER STUDIES OF SURFACTANT INHIBITORS IN 
BAL FLUID.
The concentration of protein in the BAL fluid supernatant after centrifugation at 
40,000 X g for 1 hour was assessed by the Lowry method, as detailed above. An 
aliquot of this supernatant was lyophilised and then re-suspended to 1 mg/ml protein in 
suspension buffer. Survanta, a commercially available animal surfactant (2.5mg/ml)
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was added to this, and the mixture assessed in the pulsating bubble surfactometer for 
10 minutes as described above. It should be noted that Survanta contains the small 
hydrophobic proteins, SPB and SPC. The inhibitory effect of supernatant proteins on 
lipid-only surfactant (eg. Exosurf) was not studied.
5.7. STATISTICS
Minitab version 10.5 was used to perform all statistical tests.
Determination of normality
Data distributions were inspected in each group, for each BAL constituent measured. 
Measures of kurtosis and skewness were calculated, and the Kolmogorov-Smimov 
goodness-of-fit test performed (Conover, 1971). From this information, it was decided 
whether or not the population was normally distributed.
Continuous data
Continuous data in this study were not found to be normally distributed, by the 
procedure described above. Because o f this, non-parametric methods, principally the 
Mann Whitney U Test, were used. Ninety five percent confidence intervals for the 
median were also calculated, and these were quoted in conjunction with the median 
and range.
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Categorised variables
Results comprising categorised variables were analysed using the Chi-Square Test.
Assessment of changes occurring throughout the disease progress in patients 
with RSV infection
In the 10 children with severe RSV infection who were ventilated for more than 3 
days, results from each assay were plotted chronologically on the same diagram as 
arterial alveolar oxygen ratio. The plots were then inspected, and from this, any 
relationship between the BAL constituents and disease severity (as assessed by arterial 
alveolar (a/A) oxygen ratio) or duration of ventilation could be seen. Since initial 
inspection suggested no relationship between any measured variable and severity 
measured by a/A ratio, no formal statistical tests were performed.
Also, in children with RSV infection who had been ventilated for more than two days, 
the values of BAL constituents measured on the first and last days o f ventilation were 
compared using the Mann Whitney U test.
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6. METHODS DEVELOPMENT
6.1. PULMONARY FUNCTION TESTS
Initially, when this study was designed, it was intended to perform pulmonary function 
tests throughout the course of ventilation in patients with RSV infection, in order to 
monitor the disease process. The tests were to be carried out using a Sensormedics 
2600 infant lung fonction cart which had been purchased by the Yorkhill Sick 
Childrens Fund before the project was concieved. The tests to be used were deflation 
flow volume, single breath compliance and resistance and functional residual capacity 
by nitrogen washout. Each of these investigations raised its own problems, as did the 
whole testing procedure, and these are summarised below.
6.1.1. DEFLATION FLOW VOLUME
Forced deflation was first described in 1977 by Motoyama and colleagues as a means 
to produce flow limitation in the small airways of ventilated infants, and thus assess 
small airway function by inspection of flow volume loops. The technique involves 
applying a negative pressure of dOcmHsO to the infant's lungs, by means o f a suction 
device and valve. A flow volume loop is generated as gas leaves the lungs via a 
pneumotachograph attached to the valve.
It was hoped to be able to study the function of the small aiiways in RSV infection in 
relation to surfactant measurements, as surfactant may play an important role in
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maintaining the patency o f these airways (Yager et al. 1989; Enhorning et ai. 1995; Liu 
et al. 1991).
After preliminary evaluation in the intensive care unit, it was felt that the technique 
carried too much of a hazard to the patient, as there was a risk of potential 
dislodgement o f a mucus plug into a major airway when the negative pressure was 
applied. It was therefore not used on grounds of patient safety.
6.1.2. COMPLIANCE AND RESISTANCE
The Sensormedics 2600 infant lung function cart permits compliance and resistance of 
the respiratory system to be measured by the single breath occlusion method (LeSouef 
et al. 1984). In this technique, the infant's airway is occluded by a sliding valve at end 
inspiration, and mouth pressure is measured at this point. The valve then shifts, and the 
infant expires passively through a pneumotachograph, and a flow-volume curve is thus 
produced. In infants with healthy lungs, this curve is usually linear, allowing derivation 
o f respiratory system compliance and resistance from the curve and the mouth pressure 
measurement as follows:
respiratory system compliance = tidal volume/mouth pressure at end inspiration 
respiratory system resistance = mouth pressure/flow at beginning of expiration 
The tidal volume and flow at the beginning o f inspiration are derived from 
extrapolation o f a linear flow volume loop to intersection with the flow and volume 
axes.
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Pulmonary surfactant deficiency would be likely to produce changes in respiratory 
system compliance and resistance. Therefore, it was intended to measure these 
parameters in conjunction with assessment of surfactant levels. Unfortunately, in 
ventilated infants in the intensive care unit with RSV infection, the relationship 
between flow and volume was found not to be linear. This was probably due to the 
presence of alveoli with widely differing time constants in the diseased lung. 
Additionally, the clinical condition o f some infants with RSV infection who were 
preliminarily studied was too unstable for them to tolerate the procedure without 
significant desaturation. The technique was therefore abandoned.
6.1.3. FUNCTIONAL RESIDUAL CAPACITY BY NITROGEN WASHOUT 
The 2600 pulmonary function cart allows measurement of functional residual capacity 
by nitrogen washout (Sivan et al. 1990). It was intended to measure functional residual 
capacity, as an indication of the volume of gas contained in open alveoli at end 
expiration. If this could be assessed in combination with surfactant measurements in 
infants with severe infection, it was hoped that alveolar patency could be compared 
with surfactant function.
The measurement of functional residual capacity was first validated with an air-filled 
syringe. Measurement of syringe voulme was frequently not reproducible with, for 
example, a coefficient of variation of 65.7% when measuring 40ml of air in a syringe. 
Dr Janet Stocks's team in Great Ormond Street, who were also validating the system 
had similar problems. The system was checked for leaks, breathing circuits were
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replaced, and software and mechanical adjustments were made by the manufacturers.
These adjustments improved the problem temporarily.
The technique of measuring functional residual capacity depended upon switching the 
infant into the 'washout circuit' at end expiration. This was easy enough when a syringe 
full of gas was being studied, however, it was obvious that end expiration would be 
difficult for the investigator to detect in an intensive care setting. New software which 
allowed detection of end expiration and automatic switching was installed in 
preparation for testing of the system in the intensive care unit. This produced widely
...
varying values o f functional residual capacity when a syringe was tested. At this point, 
further concerns about accidental extubation o f the patient during testing were 
becoming obvious.
The factors predisposing to accidental extubation were as follows
1. Unexpected movement o f the infant's head may occur at any time in an incompletely 
paralysed infant.
2. The valve and attached lung function testing system which were fitted on the end of 
the tracheal tube during measurements were heavy and cumbersome.
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6.1.4. RISK OF ACCIDENTAL EXTUBATION
One of the major concerns when using the 2600, was that accidental extubation of the 
infant might occur during testing. As the babies being tested were sick, and often 
deeply sedated and paralysed to allow mechanical ventilation, accidental removal o f the 
tracheal tube through which they were being ventilated would be life threatening.
3. The tracheal tube was relatively slender, but not pliable enough to prevent 
dislodgement if subjected to excessive 'see-saw' movement.
4. The tube could not be kept reliably fixed with respect to the infant's head during  ^
testing.
5. Smooth disconnection of the valve assembly from the tube connector after testing 
was impossible, as the joint was o f a 'friction fit' type, and the presence of water 
vapour and droplets in the joint exacerbated the problem of'suction'. Often a great deal 
of force was required to disconnect the valve assembly from the tracheal tube.
6. The tester who held the valve had to remain motionless for a considerable period of 
time.
7. In FRC measurements, not only did the valve have to be held steady, but the infant 
also had to be ventilated manually, pressure kept upon the trachea to avoid air leaks, 
and test results assessed on screen simultaneously. This meant that it was difficult for 
one operator to give undivided attention to holding the valve.
In addition to these problems, there was no guarantee of a trained intubator nearby and 
available. Also recognition of extubation within the pharynx would be late if the tube 
was dislodged, as the usual cue o f decreased ventilator pressure would not be present 
when testing was being performed.
Solutions to the problem of accidental extubation were sought. Improved fixation of 
the tube to the baby's face with a foam 'butress' around the tube under the infant's nose 
for added stability was tried. However, it was not possible to achieve a satisfactory 
level of stability with this arrangement. It was not possible to design a connection 
which removed the 'suction' when trying to disconnect the tube from the valve, while ^
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still maintaining a gas-tight seal. A commercially-available 'friction-arm' was employed 
to hold the valve and tubing, however, this rendered the situation even more unsafe in 
the event of unexpected movements of the patient's head. A foam cushion was used to 
try to restrict the baby's head movements during testing, however this did not work. 
Introduction of a flexible link into the system, which would absorb movement was 
considered. However, this produced insurmountable difficulties in terms of maintaining 
a gas tight seal and in ease o f disinfection.
Eventually, it was decided by the author that, as the problem of accidiental extubation 
could not be overcome, lung function testing could not be continued.
6.1.5. M ECHANICAL PROBLEM S
During the year in which the 2600 was being validated, repeated mechanical problems 
occurred. These are listed below.
1. A leak developed at the mouth pressure port o f the occlusion valve used in 
compliance and resistance measurements. This necessitated return o f the part to the 
manufacturer on two occasions.
2. The pneumotachograph became impossible to calibrate on two occasions due to a 
substantial positive or negative drift. This was found to be due to vibration of a circuit 
board and leaking pressure transducers. After several visits from engineers from 
England and Holland, and return of the machine to the manufacturers, these problems 
were eventually solved.
3. Functional residual capacity measurements were inaccurate. This was attributed to a 
residual vacuum drawing oil up a tube when the machine was switched ofT. When the
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The measurement of pulmonary function was initially proposed in order to correlate 
the pathophysiological changes occurring in the lungs with changes in surfactant 
function. Unfortunately, the equipment available to perform pulmonary function tests 
was unsuitable for this purpose in tenus of safety, appropriateness and reliability. Lung 
function testing was therefore abandoned.
machine was switched on again, the oil was distributed thi oughout the mixing 
chamber, coating the nitrogen analyser, and rendering it inaccurate. A vacuum release 
was fitted, and this improved the readings obtained. /
4. It became impossible to perform compliance and resistance measurements, as a 
persistent 'negative pressure' message appeared on the screen whenever a test was 
attempted. However, by this time, enough data had been collected to establish that this 
measurement was not physiologically appropriate in infants with severe RSV infection.
5. Intermittently, the footswitch which controlled valve operation did not work until 
the machine had been switched on for at least 15 minutes. This was very inconvenient, 
as the lung function cart was very cumbersome, and impeded the routine nursing care 
o f patients in the intensive care unit due to its blocking of one side of the bedspace.
6. The computer would 'hang' when it was attempted to print the on-screen 
measurements. The manufacturers were not able to solve this problem.
7. Not infrequently, the computer would not 'boot up', and after switching on, would 
generate increasing powers o f 2 which were displayed on the screen. The 
manufacturers could not explain this.
6.1.6. SUMMARY
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6.2. THE CLICK AND SHAKE TESTS
A positive control (Survanta 2.5mg/ml) known to contain active surfactant, and a 
negative control (water) were assessed along with each batch o f samples. On each 
occasion tested, Survanta reliably produced clicking and a positive shake test, whereas 
no clicking and a negative shake test were produced by water.
6.3. SURFACTANT PROTEIN A
This assay reliably produced standard curves with a r-squared value greater than 0.965. 
Intra assay coefficient of variation was 8.4% (5 measurements on equal aliquots of 
same BAL sample), and inter assay coefficient o f variation was 11.5% (5 
measurements on equal aliquots o f same BAL sample).
6.4. SURFACTANT PROTEIN B
This assay reliably produced standard curves with an r-squared value greater than
0.965.
Intra assay coefficient o f variation was 6.9% (5 measurements on equal aliquots of 
same BAL sample), and inter assay coefficient of variation was 7.3% (5 measurements 
on equal aliquots of same BAL sample).
6.5. SURFACTANT PROTEIN D
Initially, when the assay was performed in Oxford (by the author with the guidance of 
Dr J. Y. Wang), in accordance with the protocol being used at that time, an antibody
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concentration of Ipg/ml was used to coat assay plates. The changes in optical density 
obtained with this protocol were low, and development times were excessively long 
(over 3 hours). After discussion with Dr Wang, the coating antibody concentration was 
increased to 5pg/ml. This produced greater changes in optical density, in a shorter 
development time.
In preparation for assay of the BAL samples in Glasgow, new chemicals were 
purchased and antibodies and standards were obtained fiom Oxford. When the assay 
was then attempted, it was impossible to produce a linear standard curve. Over a 
period of 5 months, chemicals were changed, new antibodies were obtained, and minor 
alterations were made to the assay protocol in consultation with Dr Wang. It was 
finally discovered that the standard sent had been mistakenly labelled as purified human 
SPD, when, in fact, it was recombinant SPD, which had been shown in Oxford to 
aggregate readily, and to be an unsatisfactory standard for generation o f standard 
curves. In the week before he returned permanently to Taiwan, Dr Wang kindly 
purified some human SPD fom BAL taken from a patient with alveolar proteinosis, and 
this was used satisfactorily in generation o f standard curves. The standard cuiwes 
produced reliably had an r-squared value o f greater that 0.965.
6.6. PROPAN 2 OL - HEXANE EXTRACTION
A modification o f the method o f Ip and colleagues (1977) was used to extract 
phospholipids from BAL fluid. This method has been shown to extract from a mixture 
containing an equal mixture of standards 86.8% of DPPC, 16.4% of palmitic acid and 
3.8% of tripalmitin into the propan-2-ol layer (Ip et al. 1977). A sample of BAL was
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extracted according to this method, and also with the chloroform methanol method, 
and the phospholipid fraction separated from other fractions in the extract by thin layer 
chromatography (using hexane:ether:acetic acid (60:40:1) as a solvent system - ^
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(Carroll, 1976)) and visualised under UV light with dichlorofluorescein. The sample 
extracted by this method appeared to contain contain no detectable amounts of lipids 
other than phospholipids. Although, according to Ip, the method does not produce a 
completely selective extraction o f phospholipids, the amounts o f triglycerides and free 
fatty acids present in BAL samples was probably small enough for them not to be 
present in amounts which could be visualised by this method.
6.7. SEPARATION AND QUANTIFICATION OF 
PHOSPHOLIPID CLASSES
Various methods have been used to separate and quantify relative proportions of 
surfactant phospholipid classes present in bronchoalveolar lavage fluid in human and 
animal studies o f BAL fluid and amniotic fluid. Thin layer chromatography is a method 
widely used to separate phospholipid classes (Gunther et al. 1996; Escamilla et al.
1992; Gregory et al. 1991; Daniels et al. 1996; Griese et al. 1996; Guthmann et al. 
1995). Once separated, the relative proportion of each phospholipid class can then be 
quantified by spectrophotometric methods or by scanning densitometry. Other methods 
which have been used to quantify phospholipid classes in studies of lung or amniotic 
fluid include high performance liquid chromatography (Ratjen et al. 1996; Pison et al. 
1987) and enzymatic assay (Farquharson et al. 1988).
6.7.1. THIN LAYER CHROMATOGRAPHY (TEC)
Initially, several TLC solvent systems were assessed using a mixture of phospholipid 
standards containing PC, PG, PS, PI, PE and sphingomyelin, and also using lipid 
extracts of tracheal aspirate and BAL fluid.
One dimensional and two dimensional TLC methods were used, and lipid extracts were 
spotted on 20 x 20 silica gel G, H and Whatman LK5 TLC plates. Separation of 
phospholipids by the following solvent systems in one dimension, or by combinations 
of these solvent systems in two dimensions was assessed. These included:
1. chlorofoiTn (60) methanol (20) ammonia (4) (Svennerholm and Vanier, 1973)
2. chloroform (65) methanol (25) formic acid (10) (Escamilla et al. 1992)
3. chloroform (65) methanol (25) water (4) (Rouser et al. 1967)
4. n-butanol (60) acetic acid (20) water (20) (Rouser et al. 1967)
5. chloroform (25) methanol (13) propan-l-ol (25) potassium chloride 0.25% (9) ethyl 
acetate (25) (Touchstone et al. 1979)
6. chloroform (30) methanol (9) propan-2-ol (25) potassium chloride 0.25% (6) 
triethylamine (18) (Touchstone et al. 1979)
7. methyl acetate (25) propan-2-ol (25) chloroform (25) methanol (10) potassium 
chloride 0.25% (9) (Olsen and Henderson, 1989)
8. chloroform (10) acetone (4) methanol (2) acetic acid (2) water (1) (Rouser et al. 
1967)
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It was decided to use solvent system 2, as when this was scanned using a densitometer, 
the peaks were more distinct than with system 1.
The following methods of phospholipid spot visualisation were assessed.
1. Sulphuric acid 50% in water charred at 180C (Christie, 1982a)
2. Sulphuric acid 50% in water + 0.6% potassium dichromate charred at 180°C (Smith 
and Seakins, 1976)
3. Rhodamine 6G (0.01% w/v) spray viewed under UV light (Christie, 1982a)
4. 0.1% (w/v) 2',7'- dichlorofluorescein in 95% methanol spray viewed under UV light 
(Christie, 1982a)
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6.7.2. HIGH PERFORMANCE TLC (HPTLC)
■’
Two solvent systems were assessed in one dimension using 1 0X 10  HPTLC plates 
(Whatman). :
1. chloroform (25) methanol (13) propan-l-ol (25) potassium chloride 0.25% (9) ethyl 
acetate (25) (Touchstone et al. 1979)
2. methyl acetate (10), propan-2-ol (10), chloroform (10), methanol (4) and 0.25% 
potassium chloride (3.6) (Olsen and Henderson, 1989)
,1
The HPTLC methods proved to be superior to other TLC methods tested, in terms of 
clear and repeatable separation, and sensitivity of visualisation at low levels of 
phospholipid. Additionally, the time taken to complete a run was short, and up to 7 
samples could be loaded per plate.
6.7.3. VISUALISATION OF PHOSPHOLIPIDS ON CHROMATOGRAPHY 
PLATES
5. Molybdenum blue spray (Sigma Chemical Co) Diluted 1:1 with 4.2M sulphuric acid 
heated at 1OOC for 1 hour
6. Molybdenum blue spray (Sigma Chemical Co)
7. Iodine vapour (Christie, 1982a)
8. Sulphuric acid 10% in ethanol (Smith and Seakins, 1976)
9. Bromothymol blue 0.1% in 10% aqueous ethanol with pH 6.8 (by adding conc. 
Ammonia) (Smith and Seakins, 1976)
10. Molybdenum Blue Reagent (Dittmer and Lester, 1964)
11. Modified Molybdenum Blue Reagent (Ryu and MacCoss, 1979)
12. 3% cupric acetate and 8% orthophosphoric acid spray and charring at 180°C 
(Olsen and Henderson, 1989)
The last method was adopted, as it gave the clearest and most sensitive visualisation of 
lipid spots.
6.7.4. ENZYMATIC ASSAY
It was intended to use the enzymatic assay developed by Farquharson et al (1988) to 
quantify PC and PG in BAL fluid. The reactions involved in this assay are shown 
below.
   ^
phosphatidylglycerol phosphoiipase c glycerol phosphate + diglyceride
phosphatidylcholine phosphoiipase c choline phosphate + diglyceride
glycerol phosphate alkaline phosphatase glycerol + phosphate anion
choline phosphate alkaline phosphatase choline + phosphate anion
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glycerol + ATP giycerokinase glycerol phosphate + ADP
choline + ATP choline kinase choline phosphate + ADP
ADP + phosphoenolpyruvate pyruvate kinase pyruvate +ATP
pyruvate + NADH 4- H+ lactate dehydrogenase lactate + NAD
A chloroform-methanol extract o f BAL fluid was used for measurement in this assay. 
The change in optical density produced by degradation o f NADH to NAD in the last 
reaction was measured at 340nm in a spectrophotometer. In this manner, PG was 
measured by first adding giycerokinase, and measuring the conversion o f NADH to 
NAD produced by the pyruvate generated. Then PC was measured in the same sample 
by adding choline kinase and measuring the conversion of NADH to NAD resulting 
from the pyruvate generated in this second reaction.
The buffers, choline kinase and a reagent containing NADH, ATP and 
phosphoenolpyruvate used in this assay were provided in the 'Lecithin UV' kit 
produced by Boelminger Mannheim. Unfortunately, this kit ceased to be produced 
during the course o f this study. When the NADH / ATP / phosphoenolpyruvate 
reagent was reconstituted from separate components in the proportions used in the kit, 
NADH was found to undergo spontaneous degradation, as measured by a steadily 
decreasing optical density at 340nm. It was not possible to ascertain from the 
manufacturers whether the combined reagent used in the kit was in any way different in 
composition from the reconstituted reagent. Further work in investigating this matter 
was precluded by illness and subsequent time constraints.
144
6.7.5. QUANTIFICATION OF SURFACTANT PHOSPHOLIPID CLASSES 
"Bartlett' phosphate assay
Initially, it was intended to quantify phosphorus in spots which had been scraped off 
TLC plates.
It was not possible to obtain COSHH clearance to use perchloric acid to digest 
phospholipids as recommended by Bottcher et al (1961). Therefore, the method of 
Bartlett (1959) was used, with the initial digestion step carried out by heating the 
sample at 160°C for 2 hours in ION sulphuric acid, adding 30% hydrogen peroxide, 
and then heating for a forther 2 hours. The optical density change produced by adding 
ammonium molybdate and Fiske and Subba Row reagent was measured as described 
by Bartlett in 50pg standards of PC, PG, PE, PS, PI and S. A standard curve 
constructed with inorganic phosphate standards (1 to 3pg) was linear with an r 
squared value o f 0.98. Recovery o f phospholipid was calculated from the ratio of 
molecular weight o f each phospholipid standard to phosphorus. The phosphoius 
detected was read from the standard curve and phospholipid recovery calculated. This 
recovery varied from 85.5% for PG, through 77% for PC to 57.6% for PI.
Five separate determinations of phosphate by the above method were performed on 
50pg of PC, PG, PE, PS, PI and S both as pure standards and after running on TLC 
and scraping from the plate. The '%TLC recovery' for each phospholipid was 
calculated as optical density change produced from TLC spot / optical density change 
produced from pure standard. The '% TLC recovery' varied widely between lipids from 
a mean o f 90.6% for PC (sd 13.1) to 55.2% for PS (sd 16.3), The coefficients of
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variation between runs for each lipid were also high (13.1 for PC to 56.6 for PE). It 
was decided that this system had several significant disadvantages;
1. Recoveries when measuring pure standards were fairly low
2. The recovery from TLC scrapings tended to be variable and low.
3. The procedure was time consuming (about 5 V2 hours per sample)
4. Sensitivity was likely to be a problem. If a 0.5ml sample of BAL fluid contained 
lOpg o f phospholipid, and 1/10 o f this was PG (as might be the case in a BAL 
extract), then it was calculated that this would produce a change in optical density of 
around only 0.010, without taking into account analytical losses.
Other spectrophotometric methods of phospholipid quantification
The method o f VanGent and Rosleur (1974) which utilises an ammonium molybdate 
reagent for quantification o f phospholipids was assessed. When lOOpg standards of 
phospholipids were subjected to the assay procedure, the change in optical density 
produced by PS, PI and PG were less than that produced by PC by at least a factor of
10.
The assay procedure of Stewart et al (1980), which uses ammonium hexacyanoferrate 
to produce a colour change was assessed. Again, this assay produced a great variation 
in changes in optical density, with PG, PE, PI and PS producing canges in OD of less 
than a fifth of that of PC, and S being about half that o f PC.
These two methods were rejected due to the variable changes in optical density 
produced by each phospholipid.
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Charring and émulsification
Phospholipid classes may be charred on TLC plates, and the bands thus produced may 
then be suspended in an emulsifier-scintillator, and the amount of phospholipid 
quantified by scintillation counting (Christie, 1982a). This method is said to have an 
accuracy down to lOpg of lipid, which was thought not to be sensitive enough to 
detect the small amounts of individual lipid classes likely to be present in BAL fluid. 
Additionally, the equipment required for this method was not readily available.
Charring and scanning densitometry
The method using HPTLC and charring followed by scanning densitometry as 
described in the methods section was assessed. Intra-plate repeatability was assessed 
by running 5 extracts of an equal volume of the same sample in separate lanes on one 
plate and inter-plate repeatability by running 5 equal extracts of the same sample on 
separate plates. The results are summarised in Table 7. These inter- and intra-run c.v.’s 
are fairly high, however, they are, in general lower than those obtained in the Bartlett 
phosphate assay.
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Table 7, Repeatability of HPTLC/densitometry measurements.
Phospholipid species
Inter-ruu coefficient of 
variation (%)
Intra-run coefficient of 
variation (%)
PC&S 9.5 4.5
PS 19.9 11.6
PI 18.3 12.0
PG 6.6 13.7
Five equal aliquots o f the same sample were tested for inter-run repeatability. Five 
equal aliquots of the same sample were used for intra-run repeatability. Different 
samples were used for assessment o f inter- and intra-run repeatability respectively.
Initially, an attempt was made to introduce a correction factor to compensate for the 
different charring characteristics o f phospholipid classes. A commercial standard 
containing LPC, S, PC, PS, PI, PG and PE was run on plates along with samples. It
§■
became evident from inspection, however, that the charring characteristics of the 
phospholipids in the standard were both less uniform and different from those in the 
human samples. As Olsen and Henderson (1989) suggested, it was necessary to 
assume that all lipid classes had the same response factors, and the percentage 
composition was derived directly from the densitometer. It is unlikely that all
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phosphoiipid classes in lavage fluid chaned to the same degree, and this, undoubtedly 
introduces errors.
Mixtures of phospholipid standards from 4 to 25 [xg of total lipid were assessed by the 
HPTLC / charring / densitometry method, in an attempt to assess the effect of loading 
on the relative proportions given by this method. Variations in measured proportions 
were compatible with intra-run variation as assessed earlier, and in this range, there 
didi not appear to bea relationship between relative proportion measured and loading. 
Therefore, the amount o f sample used was adjusted if necessary to bring them within 
this range before spotting.
The use of HPTLC and scanning densitometry as a method to determine the relative 
proportions of phospholipid classes has significant limitations and the method should 
be regarded as semi-quantitative. Despite these considerable problems, the method of 
HPTLC, charring and densitometry was used in this study, as it was the best available 
at the time. Use of high performance liquid chromatography (HPLC) would have been 
preferable to the TLC method used, and HPLC methods have been used extensively to 
separate and quantify the proportions o f surfactant phospholipids (Bernhard et al. 
1994; Bruch et al. 1994; Pison et al. 1986; Dethloff et al. 1986; Bonnano et al. 1992). 
However, the facilities for this analysis were not available on site, and financial 
constraints prevented outside facilities from being used.
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6.7.6. SPECIES OF FATTY ACIDS AND PHOSPHOLIPIDS 
High performance liquid chromatography (HPLC)
Individual PC species have been separated by HPLC and quantified fluorimetrically by
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.Postle (1987) and this method has subsequently been used in clinical studies (Hunt et 
al. 1991; Ashton et al. 1994). However, neither the equipment nor the expertise 
necessary for this technique was available on site.
Disaturated species
Phospholipid-containing samples can be treated with osmium tetroxide which oxidises 
unsaturated acyl groups. The unaffected disaturated molecules are then isolated 
chromatographically and quantified colorimetrically. Several authors have used this 
method to quantify the surface active DPPC species in BAL fluid (Clercx et al. 1989; 
Gibson and McMurchie, 1986; Neumann et al. 1990). However, Holm et al (1996) 
found recently that palmitoyl oleoyl PC (POPC) oxidised with osmium tetroxide gave a 
51% recovery, where theoretically, there should have been none. This implies that the 
technique for quantifying disaturated species which uses osmium tetroxide gives falsely 
elevated values for DPPC due to the presence of POPC and perhaps other mono­
unsaturated species. In confinnation o f this, these authors performed gas 
chromatography on calf lung surfactant extract, and found the sn2 chain of PC to have 
41% palmitic acid putting an upper limit of 41% on DPPC content. Osmium tetroxide 
assay of the same sample gave a value of 69% DSPC.
Baughman et al. 1993; Gunnison and Finkelstein, 1997; Guthmann et al. 1995). This 
method was chosen for use in this study, as the equipment for HPLC was not available, 
and the osmium tetroxide method was considered to have limitations which precluded 
its use. Additionally, equipment for gas liquid chromatography was available on site. It 
was decided to use gas-chromatography mass spectrometry rather than GLC with 
flame ionisation detection, as an automated method for the former was in use. Also, 
due to problems with previous damage to septa and syringes, departmental policy 
confined use o f the latter method to a limited number o f staff members.
Samples were processed by the method o f Ip (1977) which produces a relatively 
selective extraction of phospholipids into propan-2-ol. As described in section 6.6., this 
method only provides a relatively selective and incomplete extraction, and this will 
introduce an error. In retrospect, preparative TLC to isolate phospholipids prior to 
fatty acid analysis may have produced a more complete separation o f phospholipids.
The high temperature used for derivatisation prompted concern that more fatty acid 
degradation might be taking place than in methods which used a lower temperature for
151
Silver nitrate chromatography
This method has been widely used in the past to separate fatty acid methyl esters on 
the basis of the number, configuration and position of double bonds (Christie, 1982b). ^
This method was not in use locally, and was not investigated due to time constraints.
Gas-liquid chromatography mass spectrometry
Gas liquid chromatography has been widely used to separate fatty acid species in 
human and animal studies of BAL fluid (Shelley et al. 1979; King et al. 1986;
ji
1
longer. In order to investigate this, one sample was split after extraction. One fraction 
was derivatised by the method o f Ip; the other by refluxing with boron trifluoride 
methanol for 2 hours (Christie et al. 1970). Analysis o f the variation between the 
samples showed it to be compatible with intra-run variation. It was therefore 
concluded that gross degradation of fatty acids was not taking place. Although the 
temperature used is high, the time of derivatisation is short, and this probably prevents 
excessive damage to fatty acids. Whether more subtle degradative effects were in fact 
occurring would require investigation of larger numbers of samples derivatised by the 
two methods.
Repeatability and standardisation of fatty acid measurements
The inter and intra batch coefficients of variation (c.v.) for each fatty acid species 
percentage determined by this method were assessed by extracting, derivatising and 
running five aliquots of the same sample (a different sample was used for inter and 
intra run assessments respectively). The results are shown in Table 8.
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Table 8. Repeatability of fatty acid measurements.
Fatty acid 
species 14:0 16:0 16:1 18:0 18:1 18:2 20:4
inter­
batch
coefficient
of
variation
(%)
* 2.6 8.6 5.6 3.6 9.5
intra­
batch
coefficient
of
variation
(%)
24.8 1.7 3.1 4.3 2.9 3.5 2.6
* detectable amounts o f the species not present in sample
Five equal aliquots of the same sample were tested for inter-run repeatability. Five 
equal aliquots o f the same sample were used for intra-mn repeatability. Different 
samples were used for assessment o f inter- and intra-run repeatability respectively.
A standard containing an equal mass of each fatty acid methyl ester measured was run 
at the beginning and end of each batch o f samples. The inclusion of these standards 
allowed a numerical correction to be made for non-uniform detector response between 
species.
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6.7.7. PHOSPHOLIPID QUANTIFICATION 
Background
As described above, problems were encountered in assessing an enzymatic assay, 
phosphate assay and other spectrophotometric methods used to quantify the surfactant 
phospholipids. In the method finally adopted, phospholipids were extracted into 
propan-2-ol and quantified by comparison with an internal standard in GC-MS. This 
method only gives an approximation o f the total phospholipid content in BAL fluid for 
two reasons. Firstly, as described in section 6.6., the partition of phospholipids in the 
propan-2-ol layer is not complete. Secondly, the correction factor used is a general one 
derived from the molecular weights o f the heptadecanoic acid species of phospholipid 
and fatty acid methyl ester (Christie et al. 1970). It is, therefore, not tailored to the 
contents of each individual BAL sample.
Despite these problems, the agreement between gravimetry and this method of 
quantification (shown in Table 9) was reasonable. However, it can be seen that the 
analytic recovery compared to gravimetry is in two cases over 100%. This is at 
variance with Ip's finding of an incomplete extraction of phospholipid into the propan- 
2-ol. This may be due to errors in gravimetry which could have been induced by 
vibration due to intermittent building work in the vicinity o f laboratory. Although the 
balances were recalibrated regularly, it is possible that this may have caused 
inaccuracies in weighing phospholipids. Also, evaporation o f the chloroform used to 
dilute the lipid standards may have resulted in a more concentrated standard being 
measured and giving a higher value. Alternatively, a lipid contaminant on the glassware 
or column could have led to more fatty acid methyl ester being measured than was 
added to the tubes. To minimise this, glassware was thoroughly cleaned, separate
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glassware was used for BAL studies and blanks were run frequently. However, large 
amounts o f lipid (from brain, liver, blood and food) were analysed routinely in the 
same laboratory and a small degree of contamination cannot be ruled out.
Heptadecanoic acid was used as an internal standard, as this was used in Christie's 
method, and was in use at the Scottish Agricultural College, Auchincruive where the 
method is currently being used in quantification of phospholipids. However, use of the 
diheptadecanoyl species of PC as an internal standard would have been more 
appropriate.
Table 9. Phospholipid quantification
Phospholipid 
added(pg)
8.25 16.5 33.0
Phospholipid 
measured (pg)
8.0 18.4 33.8
A mixture o f phospholipids (PC,PG,PS,PI,PE,S in the ratio 10:2:1:1:1:1) in 
chloroform was quantified by the method of section 5.4.4.
Illness, financial and time constraints precluded further assessment of other methods, 
and other locations in which phospholipids could be evaluated. Ideally, this method 
should have been assessed further before use, and, a more up to date and reliable
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method used. Further investigation may have found a laboratory where it was possible 
to carry out perchloric acid digestion of phospholipids, and allowed subsequent 
phosphate assay to be carried out. Also, another enzymatic assay is available (Furlong 
et al. 1992), and this may have proved more reliable than the method used.
Derivatisation
Ip and colleagues (1977), who described the extraction and derivatisation method 
used, reported large losses which they attributed to losses at the derivatisation stage. In 
order to investigate any losses which may have occurred due to this particular 
derivatisation method, a sample of lavage fluid was extracted and then the extract split 
into two equal aliquots. One aliquot was derivatised by the method of Ip, and the 
other, by refluxing for two hours with boron trifluoride methanol (Christie et al. 1970). 
The difference in recoveries of phospholipid between the aliquots was within 95% 
confidence limits for intra run variation. It is possible that the low recoveries obtained 
by Ip et al on adding DPPC to amniotic fluid are due to their use o f linoleic acid (which 
may be present in amniotic fluid) as an internal standard. If endogenous linoleic acid 
was present in amniotic fluid, as well as that added as an internal standard, this would 
have increased the ratio of linoleic to palmitic acid measured, and hence led to an 
underestimation of the amount of DPPC present. Also, the chromatogram illustrated in 
Ip’s paper shows a small broad peak for linoleic acid as opposed to that for palmitic 
acid (the most abundant species present). The large discrepancy between the peaks, 
and the lack of definition of the linoleic acid peak could have led to inaccuracies. A 
typical chromatogram obtained in this study using heptadecanoic acid as an internal
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standard is shown in Figure 13. It can be seen that the internal standard peak is clearly 
defined.
16:0
18:1
18:017:016:1
18:2
^ —I -f—
1 0 . 0 0  1 2 . 0 08 . 0 0
Figure 13. A typical printout from gas chromatography- 
spectrometiy of fatty acids.
Reproducibility of phospholipid quantification
Intra-batch and inter-batch c.v. were assessed by analysing 5 aliquots of the same 
sample. Different samples were used for intra- and inter- batch evaluation respectively,
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as sample volumes did not permit use of the same sample for both determinations. 
Intra and inter batch c.v. were 4.5% and 6.8% respectively.
6.8. MALONDIALDEHYDE
Various methods exist to measure MDA including spectrophotometry of MDA 
complexes, TLC, HPLC or GC. The most commonly used of these is formation of a 
thiobarbituric acid adduct of MDA or MDA-like substances, and subsequent 
quantification of this spectrophotometrically at 432nm. However, many substances 
other than MDA also form complexes with TEA which have a significant absorbance 
at around 532nm. These include other lipid peroxidation products, sugars, amino acids, 
biliverdin and urea. In order to eliminate the interference from these substances, prior 
separation of the MDA-TBA adduct may be performed by HPLC. This has two 
advantages in the measurement of BAL lipid peroxidation products. 1. Inteifering 
substances are removed and 2. Sensitivity is increased. Initially, the spectrophotometric 
method without HPLC separation was assessed, and the treated BAL samples scanned 
through the 430-600nm range as recommended by Esterbauer (1991). No colour 
change was detected, and it was concluded that the levels in BAL were too low for 
detection by this method. For reasons o f sensitivity and specificity, the HPLC method 
was adopted.
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6.9. PULSATING BUBBLE SURFACTOMETER 
STUDIES
Surface film 'creep*
A problem which has received attention in recent years is the expansion of surface film 
from the bubble up the capillary inlet tube o f the sample chamber of the pulsating 
bubble surfactometer (PBS) (Putz et al. 1994b). Putz and colleagues calculated that 
this reduces the percentage compression of the film to 13% during pulsation. They 
studied surfactant preparations in an unmodified PBS, in a PBS in which the capillary 
tube had been kept dry during filling, and in a captive bubble surfactometer (CBS). In 
the CBS, a bubble is formed in an aqueous medium under an agarose ceiling 
(circumventing the need for a capillary inlet tube) (Putz et al. 1994a).
Putz et al found that in the unmodified PBS, adsorption times were longer, for example 
requiring 30 compressions for 1.25mg/ml Survanta to reach minimum surface tensions 
around 5mN/m (surfactant in the modified PBS and the CBS took only one or two 
compressions to reach this surface tension). They suggested that 13% compression did 
not provide enough reduction in surface area to squeeze out high compressibility 
components o f the film early and allow rapid adsorption. However, with repeated 
cycling it was proposed that the monolayer became enriched in low-compressibility 
components (specifically DPPC), and that the nature o f the coating on the capillary 
changed.
In the present study, to circumvent the problem of surface film ‘creeping’ up the 
capillary inlet tube in the surfactometer sample chamber, initial attempts were made to 
plug the outlet of the tube to keep it dry during filling. This procedure, however, was
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difficult to implement repeatably in practice, and was not used. Surface tension 
measurements were taken at 10 minutes (200 cycles), and it was felt that this would 
give adequate time for adsorption. A commercial model of the CBS was not available 
at the time of this study.
Adsorption data were not recorded in this study due to software and computer 
hardware difficulties. Perhaps, in the light of Putz et al.'s work such data would have 
been difficult to interpret, as the spreading characteristics of each sample in the 
capillary tube were not known.
Centrifugation
Several studies have investigated the influence of centrifugation speed on the fraction 
of surfactant phospholipids which sediment. Oulton and colleagues (1979) re- 
centrifuged the supernatant obtained by spinning amniotic fluid at 33,000 x g for one 
hour. When the supernatant o f this fraction was spun again, at 40,000 x g for 1 hour, 
negligible amounts o f phospholipid sedimented. Guthmann et al (1995) found that a 
mean 81.8% of phospholipids in BAL from rats sedimented when spun at 60,000 x g 
for 60 minutes. Ruiz-Budria and colleagues (1992) spun amniotic fluid at 65,000xg for 
60 min and found 69.4% of PC in the pellet.
The results found from centrifugation of BAL fluid from RSV and surgical patients in 
this study are in broad agreement with other work on the proportion of phospholipid 
which sediments on centrifugation. In selected samples, the 40,000g supernatant was 
extracted, derivatised and run with an internal standard (as described in section 6.7.7.) 
to ascertain the amount o f phospholipid which was not pelleted. From these samples,
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the mean phospholipid recovery in the pellet after centrifugation was calculated to be 
79.6% (standard deviation 5.14).
Density gradient centrifugation
Several authors have utilised density gradient centrifugation to separate plasma 
proteins in BAL from the surfactant fraction, and thus to assess the surface activity of 
surfactant in the absence o f interfering proteins.
In BAL fluid from dogs with NNMU lung injury, surfactant purified by density 
gradient centrifugation had a similar phospholipid composition to a 27,000 x g pellet 
which has not been density gradient centrifuged. The latter fraction contained 20-25% 
protein by weight, whereas the former contained 10-15% protein by weight. Perhaps 
surprisingly, the fraction separated by density gradient centrifugation had similar 
surface properties to the 27,000g pellet in injured dogs (Liau et al. 1987). In another 
study, centrifugation of rabbit BAL fluid at different speeds (100 x g for 20 min,
60,000 X g for 60 min and 100,000 x g for 16h) revealed that all subfractions contained 
serum proteins which were probably albumin and subunits of IgG. All the subfractions 
contained secretory IgA. The 100,000 x g pellet contained most secretory IgA per 
microgram of protein (Wright et al. 1984).
Molecular species analysis o f PC composition o f lavage surfactant purified by sucrose 
density gradient centrifugation and that o f cell-free lavage supernatant have been found 
by Hunt and colleagues (1991) to be very similar. Shelley et al (1977),using density 
gradient centrifugation found the fatty acid composition of lung surfactant washings to 
differ only slightly from that purified by density gradient centrifugation.
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The centrifugation speeds used in previous studies for density gradient centrifugation 
were above those available to the author, and there appears still to be protein in 
surfactant fractions after this purification process has been performed. For these 
reasons, it was decided to spin the BAL sample at 40,000 x g (the highest speed 
available on site), and then to perform an organic extraction to remove interfering 
plasma proteins. This has the disadvantage of removing surfactant protein A. However, 
it was felt that, as this protein has a limited role in surface activity o f surfactant this 
was an acceptable loss.
Dilution of surfactant
Whit sett and colleagues (1986) studied calf lung surfactant extract in a pulsating 
bubble surfactometer, and found that concentrations down to 0,5mg/ml reached a 
surface tension of less than 1 dynes/cm (mN/m) in a pulsating bubble surfactometer. 
Concentrations of 2, 0.75 and 0.5 mg/ml phospholipid reached this minimum surface 
tension in 5, 7 and 12 minutes respectively.
Kobayashi and colleagues (1990) studied a lyophilised and resuspended acetone 
precipitable fi*action of a lipid extract o f a pellet from 2,000 x g centrifugation of 
porcine BAL Study of this preparation in a pulsating bubble surfactometer revealed a 
minimum surface tension of less than 1.8mN/m at 5 minutes only at concentrations of 
over 3mg/ml. Unlike Whitsett and colleagues, this group did not study the surface 
tension of their surfactant preparation in the pulsating bubble surfactometer after 5 
minutes. It may be that if a longer time for adsorption had been left, lower surface 
tensions could have been reached. Also, Kobayashi's preparation is quite different from
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the CLSE preparation used by Whitsett and colleagues, as the latter is prepared with a 
higher centrifugation speed, and the acetone precipitation step is omitted. It is 
therefore possible that the two preparations would have different surface properties.
Dargaville and colleagues (1996), in their recent study of surfactant in viral 
bronchiolitis used a concentration o f ImMol phospholipid (750pg/ml DSPC) for 
assessment in a pulsating bubble surfactometer.
It was decided to adopt a concentration of 750pg/ml phospholipid for use in this study, 
as it was felt that this would allow comparison between this study and that of 
Dargaville, and use o f a low concentration of phospholipid would allow the maximum 
possible number of samples (some of which contained little phospholipid) to be 
assessed. Also, Whitsett's work (1986) suggested that this concentration would be 
adequate for adsorption in the PBS if pulsated for a sufficient time. However, it must 
be acknowledged that the low surfactant concentration used may not in fact have been 
enough to allow adequate adsorption in all samples.
6.10. TOTAL PROTEIN
Lipids have been shown to interfere with the Lowiy protein assay (Kessler and 
Fanestil, 1986; Eichberg and Mokrasch, 1969). Kessler et al. (1986) demonstrated that 
the bicinchoninic acid-based protein assay was more sensitive to phospholipid 
inhibition than was the Lowry assay, and a procedure for eliminating interference with 
the latter has been developed (Rodriguez-Vico et al. 1989). Many published studies of 
BAL fluid have used Lowry's original method, and this was the method used in the
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7. RESULTS - SURFACTANT FUNCTION
7.1. INTRODUCTION
As described in the introduction to this thesis, there is evidence of reduced surfactant 
function in inflammatory lung disease. Studies of BAL fluid from patients with ARDS 
have found increased minimum surface tension in both crude surfactant pellets and in 
surfactant purified by density gradient centrifugation to remove inhibitory plasma 
proteins. Animal models o f lung injury provide further evidence of surfactant 
dysfunction in pulmonary inflammation. In severe RSV infection, there is an 
inflammatory infiltrate, an alveolar capillary leak, and, in some cases, viral invasion of 
type II cells. Additionally, the lung histology of advanced infection is similar to that 
seen in ARDS. This would suggest that in RSV infection, surfactant may be 
dysfunctional due to several mechanisms. Surfactant may be damaged by products 
released from cells in the inflammatory infiltrate, deficient or abnormal in composition 
as a result of disturbed synthesis or inhibited by plasma proteins. Surfactant function 
was therefore investigated by performing click and shake tests on whole BAL fluid, 
and pulsating bubble studies on a lipid extract of BAL fluid.
The shake and click tests were performed in order to give an overall estimate of the 
functional status o f pulmonary surfactant in cell-free supernatant of BAL fluid. These 
tests give no indication of the reason for surfactant dysfunction: they merely provide a 
'positive' result with good surfactant function and a 'negative' result with poor 
surfactant function. No adjustment was made for the concentration of surfactant
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present in BAL fluid, and no attempt was made to remove surfactant inhibitory 
proteins from the fluid. Previous studies (Skelton et al. 1996; Skelton and Jeffrey, 
1994) have investigated the results of click and shake tests performed on tracheal 
aspirates. The results described below illustrate that these procedures can also be used 
in assessment of BAL fluid.
In order to assess surfactant frmction in isolation from the effects o f inhibitoiy proteins 
or alterations in phospholipid concentration, a lipid extract of BAL fluid adjusted to a 
concentration of ImMol (750pg/ml) phospholipid was studied in the pulsating bubble 
surfactometer. This allowed the effects o f surfactant damage and change in 
phospholipid composition on surface activity to be studied.
7.2. RESULTS
7.2.1. THE SHAKE AND CLICK TESTS
Shake and click tests were performed on 66 samples of BAL fluid from 18 patients 
with RSV infection, and 28 BAL samples from 13 surgical patients. (It was not 
possible to assess surfactant function in all samples due to limited sample size.)
The shake test
The shake test for surface activity was positive in 90% of samples in the surgical group 
compared to 8% of samples in the RSV group (%^  = 64.69; d.f. = 1 ; p < 0.000).
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No relationship was seen between disease severity (as measured by arterial alveolar 
oxygen ratio) and surface activity as assessed by the shake and click tests.
The click test
The click test for surface activity was positive in 96% of samples in the surgical group, 
compared to 11% of samples in the RSV group (%^  = 62.72; d.f. = 1; p < 0.000).
The proportion of positive click and shake tests on the first and last days o f ventilation 
in samples from children with RSV infection are shown in Figure 14. The proportion of 
patients showing a positive click test on the final day of ventilation was greater than on 
the first day. However, this difference was not statistically significant (%^ = 3.022; d.f.
= l ;p  = 0.082)
£
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First day o f ventilation Last day of ventilation
f
negative shake test 
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Figure 14. Click and shake tests on the first and last days of ventilation 
in children with RSV infection who were ventilated for more than one day.
It was not possible to assess all 16 children ventilated for more than 1 day due 
to insufficient sample size.
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7.2.2. SURFACTOMETER STUDIES OF LIPID EXTRACTS OF BAL FLUID
Evaluation o f the surface activity o f an organic extract of BAL fluid adjusted to ImM 
phosphoiipid in the pulsating bubble surfactometer showed no significant difference in 
minimum or maximum surface tension attained in a 10 minute period between RSV 
and control groups (Table 10).
Table 10. Surfactometer studies on lipid extract from BAL fluid.
No. of 
patients
(samples)
min. surface tension 
mN/m
median (range)
(95% C l for median)
max. surface tension 
mN/m
median (range)
(95% C l for median)
Children 15 21.4 47.3
with RSV (34t) (19.1-27.5) (35.2-67.8)
infection (20.6-21.7) (44.0-50.0)
Surgical 8 20.6 54.1
patients (19t) (17.2-24.0) (37.8-68.3)
(19.0-21.8) (46.1 -56.3)
p value* 0.1295 0.0704
* Mann Whitney U test
Surfactant from BAL fluid was subjected to an organic extraction to remove 
interfering proteins, and adjusted to ImM to compensate for variations in sample 
dilution. When tested in the surfactometer, surfactant adjusted in this way showed no 
difference in surface activity between RSV and control groups.
t  It was not possible to assess all 71 samples in the RSV group and all 31 samples in 
the control group due to limited sample size and to insufficient amount of phospholipid 
present in some samples.
169
7.3. DISCUSSION
In this study, the click and shake tests of surfactant function, performed on whole BAL 
samples were found to be negative in the majority of patients with RSV infection, and 
positive in the majority of controls. These simple tests of whole surfactant function 
provide evidence that surfactant is not fully functional in severe RSV infection.
When potential inhibiting proteins were removed from the lipid fraction of BAL fluid 
by organic extraction, and phospholipid concentration was adjusted to the same level 
in all samples, no significant difference was found in surface activity of lavaged 
surfactant between RSV and surgical groups. Also, no significant difference in surface 
activity o f the lipid extract was found between first and final days o f ventilation. This 
implies that the surfactant which is present in RSV infection is functionally normal in 
the absence of inhibitors irrespective of disease progress. However, the method used to 
study the lipid extract has some limitations which are discussed below, and these make 
it difficult to conclude whether or not the hydrophobic fraction of surfactant is 
functionally normal in RSV infection.
The principal problem is that the values for maximum and minimum surface tension are 
high in both RSV and control groups in this study. The minimum surface tensions 
reported here are very similar to those found by Dargaville and colleagues (1996) in 
their study of ventilated infants with severe viral bronchiolitis and surgical controls. 
They studied crude 25,000 g surfactant pellets from tracheal aspirates resuspended at 
ImM (750pg/ml DSPC) in the pulsating bubble surfactometer.
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The maximum and minimum surface tensions reported in the current study are also 
very similar to those reported by Raymondos and colleagues (1996). In Raymondos's 
study, surfactant from tracheobronchial aspirates of ventilated infants and children was 
resuspended at 3mg/ml after density gradient centrifugation at 116,000 x g and 
assessed in the pulsating bubble surfactometer. Using this method, mean minimum 
surface tension was found to be 17.4 mN/m and maximum surface tension was 53.9 
mN/m .
However, the findings of Gregory and colleagues (1991) who studied crude 48,000 g 
surfactant pellets resuspended to l.SmM phospholipid from adults with and without 
ARDS were somewhat different from the results described in the present study. 
Gregory's group found that, in the control group, the mean minimum surface tension 
was 7.44 dynes/cm (mN/m), and that the mean maximum surface tension was 35.76 
dynes/cm. These values are considerably lower than the control values in this study.
The reasons for resuspension of surfactant lipid extract to ImM phospholipid are 
explained in section 6.9. However, in view o f the relatively high maximum and 
minimum surface tensions obtained, this concentration may not have been great 
enough to allow adsorption to the air-liquid interface in the pulsating bubble 
surfactometer. This might explain why the results differ from those of Gregory. On the 
other hand, the concentration of surfactant which Gregory used was still quite low, and 
may have even contained inhibitory proteins which could have sedimented with the 
surfactant pellet. Also, Raymondos and colleagues used a higher concentration of 
surfactant, and obtained higher surface tensions. Interestingly, the surfactant used in
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Gregory's measurements was derived from adults, whereas the surfactant measured in 
the present study and those of Raymondos and of Dargaville was derived from 
children. The reasons for these variations are not clear, and it is difficult to compare 
results unless a standardised method is used.
It is interesting to note that the three studies on BAL from children produced fairly 
consistent results. The possible limitations of the surfactant concentration used in the 
present study should be acknowledged. However, the similarity of the surface tensions 
in this study with those found in other studies o f children prompts speculation that 
BAL surfactant may be functionally normal in RSV infection compared to control in 
the absence of inhibitors.
Acute respiratory distress syndrome tends to increase the proportion o f small 
aggregates present in BAL fluid (Lewis et al. 1997). If the small/large aggregate ratio 
was also increased due to lung injury in RSV, this would have led to less surfactant 
sedimenting at 40,000 x g. In this case, an assumption of 79.6% recovery would have 
led to an over-dilution o f the pellet before assessment in the surfactometer, and, if 
anything, an apparently reduced surface activity of the lipid pellet in the RSV group.
No attempt was made to study surfactant small/large aggregate ratio in BAL fluid from 
the two groups in this study. If different aggregate ratios were present in different BAL 
samples, this would have altered the proportion o f phospholipid which pelleted at
40,000 X g. The assumption of a 79.6% recovery (derived from measuring recoveiy in 
a small number of samples) would then have introduced an error in the final 
concentration of surfactant assessed in the surfactometer. If this was the case, then a 
more accurate dilution volume for the surfactant pellet would have been obtained by
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measuring the percentage of phospholipid pelleted in each individual sample. 
Unfortunately, total phospholipid amounts in the BAL sample and/or volumes of 
supernatant were, in many cases, too small to allow this measurement.
While acknowledging the above limitations, the data provide evidence of surfactant 
dysfunction in RSV infection, and perhaps suggest that abnormality of the hydrophobic 
fraction of surfactant may not be the origin o f this dysfunction.
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8. RESULTS - SURFACTANT 
COMPOSITION
8.1. INTRODUCTION
8.1.1. SURFACTANT PROTEINS A, B AND D
Variable alterations in surfactant proteins A and B have been shown in two major 
inflammatory lung diseases - ARDS and pneumonia. Reduced levels of surfactant 
protein A have been found in patients with ARDS (Gunther et al. 1996; Gregory et al. 
1991), while SPB in ARDS was found to be reduced in one study (Gregory et al.
1991) and normal in another (Gunther et al. 1996). Surfactant protein A has also been 
found to be reduced in bacterial pneumonia which was not associated with HIV 
infection (Gunther et al. 1996; Baughman et al. 1984), and increased in AIDS-related 
pneumonia (Phelps and Rose, 1991). Two groups (LeVine at al. 1996; Dargaville et al. 
1996) have found reduced surfactant protein A in tracheal aspirates from ventilated 
children with viral lower respiratory tract infection. Le Vine's group also studied SPB, 
and found it not to be reduced in children with viral pneumonitis. No studies have 
hitherto investigated the levels o f SPD in pneumonia, RSV infection or ARDS.
As described, in severe RSV infection there is a pulmonary inflammatory infiltrate. 
Surfactant proteins A and D play a role in the immune defense mounted by the lung 
against microorganisms, and consumption of these proteins during opsonisation could 
lead to reduced quantities being present in BAL fluid. Severe infection is also
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associated with viral invasion of pulmonary cells including, in some cases, type II 
pneumocytes. Theoretically, this could lead to disruption of surfactant protein 
synthesis.
In the light of these pathological features, and the similarities with ARDS and 
pneumonia, SPA, SPB and SPD were measured by ELISA of BAL fluid.
8.1.2. SURFACTANT PHOSPHOLIPIDS
It is not clear how ARDS and pneumonia affect the concentration o f phospholipids in 
BAL fluid. Several studies have found surfactant phospholipid levels in BAL fluid not 
to be different from control in ARDS (Jacobson et al. 1993; Gunther et al. 1996; Pison 
et al. 1990; Spragg and Hallman, 1983; Hallman et al. 1982), however, there are also 
studies which demonstrate increased (Offenstadt et al. 1981) and decreased (Gregory 
et al. 1991) phospholipid levels in this condition.
In the AIDS-related pneumocystis pneumonia, too, the picture is not clear, with two 
studies finding a reduced lipid concentration in BAL (Escamilla et al. 1992; Hofrman et 
al. 1992), and one study finding no reduction in total phospholipid in AIDS-related 
lung disease (including pneumocystis pneumonia) (Rose et al. 1994).
A recent study of tracheal aspirates from neonates with nosocomial pneumonia found a 
reduction in phospholipid concentration (Griese et al. 1996). Also, Dargaville and 
colleagues (1996) found reduced DSPC in tracheal aspirates from ventilated infants 
with severe viral bronchiolitis. As discussed above, viral invasion of type II
175
pneumocytes can occur in severe RSV infection, and this may affect the synthesis of 
phospholipids. In order to investigate these possibilities, phospholipids in BAL fluid 
were quantified.
8.2. RESULTS
8.2.1. SURFACTANT PROTEINS A, B AND D
Concentrations of SPA, SPB and SPD measured in lavage fluid were significantly 
lower in the group with severe RSV infection than in the group without RSV infection. 
This difference was present irrespective o f whether surfactant protein levels were 
expressed per ml lavage fluid or per mg total protein (Tables 11 and 12, Figure 15). 
Table 11. Surfactant proteins in BAL fluid.
No. of patients
(samples)
SPA pg/ml
median (range)
(95% Cl for median)
SPB ng/ml
median (range)
(95% Cl for median)
SPD ng/ml
median (range)
(95% C l for median)
Children with 18 5.6 12.0 130.3
RSV infection (71) (0.6-151.9) (0.0-60.8) (0.0-1486.0)
(3.8- 7.6) (7.3- 13.6) (71.0 - 270.0)
Surgical 16 9.0 118.1 600.4
patients (31) (0.5-139.6) (0-778.2) (0.0-1869.0)
(6.1-22.5) (63.8- 171.7) (367.0 - 679.0)
p value* 0.0368 < 0.0000 < 0.0000
* Mann Whitney U test
Surfactant proteins A B and D were found to be significantly reduced in RSV infection
compared to control.
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Table 12. Surfactant proteins in BAL fluid expressed per mg total protein.
no. of 
patients
(samples)
S P A  M-g/mg
protein
median (range) 
(95% Cl for 
median)
SP B  ng/mg 
protein
median (range) 
(95% C l for median)
SP D  ng/mg 
protein
median (range) 
(95% C l for 
median)
protein mg/ml
median (range) 
(95% Cl for  
median)
Children with 
RSV infection 18(71)
10.4
(0.6-173.1)
(6.9- 16.3)
14.0
(0.0-190.0)
( 7.8-24. 1)
242.8
(0.0-5680.0)
(98. 0- 450. 0)
0.49
(0.13-2.46)
(0.44 - 0.70)
Surgical
patients 16(31)
33.3
(0.5-654.4)
(10. 1-80.8)
342.0
(0.0-1441.1)
(136. 0- 476.0)
1607.3
(0.0-88575.0)
(916. 0-3140. 0)
0.36
(0.07-1.65)
(0.2 J - 0.59)
p value'* 0.0011 <0.0000 <0.0000 0.0079
* Mann Whitney U test
As a consequence o f the high levels of total protein seen in the RSV group,expression 
of surfactant protein values per mg total protein magnified the differences between the 
two groups.
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Figure 15. Surfactant proteins A, B and D in BAL fluid (95% Cl for median shown)
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Sequential changes in patients with RSV infection
Surfactant protein levels were higher on the last day of ventilation than on the first in 
12 of the 16 patients with RSV who were ventilated for more than one day. The 
median SPA level was 2.3|ig/ml on the first day compared with 6.0p,g/ml on the last 
day (p = 0.0135 Mann Whitney) (Figure 16). No significant difference was found 
between first and last days of ventilation in SPB and SPD levels (Figures 17 and 18). 
There was no clear relationship between sequential surfactant protein levels and 
disease severity (as measured by arterial alveolar oxygen ratio). Surfactant protein 
levels were highly variable throughout the course of ventilation (Figure 19).
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Figure 16. Surfactant protein A concentration on first and last days of 
ventilation in children with RSV infection ventilated for more than 1 day 
(n=16). The median value o f  SPA on the final day o f ventilation (6.0pg/ml) was 
significantly higher than that on the first day (2.3|ig/ml)(p = 0.0135 Mann 
Whitney).
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Figure 17. Surfactant protein B concentration on fîrst and last days of 
ventilation in children with RSV infection ventilated for more than 1 day 
(n = 16). There was no significant difference between median initial and 
final levels o f SPB.
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Figure 18. Surfactant protein D concentration on first and last days of 
ventilation in children with RSV infection ventilated for more than 1 day
(n = 16. In six of these children, SPD level was Ong/ml on first and last days). 
There was no significant difiference between median initial and final levels 
of SPD.
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Figure 19. Surfactant protein levels in three children with RSV infection 
who were ventilated for more than 5 days. Levels of SPA, SPB and SPD are highly variable.
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8.2.2. TOTAL PHOSPHOLIPID
Total phospholipid in patients with and without RSV infection
The median total phospholipid level in the RSV group was significantly lower than that 
in the surgical group (Figure 20).
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Figure 20. Phospholipid levels in BAL fluid (95% C l for median shown)
The median level for children wilh RSV infection was 28.6 (range 0.9-177.5)|Lig/ml.
In surgical patients, the median was 82.6 (range 2.1 - 386.1) pg/ml p<0.000. It was not 
possible to assess all 71 samples from the RSV group due to insufficient sample size.
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Sequential changes in patients with RSV infection
In patients with RSV infection who were ventilated for more than 3 days, no consistent 
pattern o f change in phospholipid level was found throughout the period o f ventilation 
and no correlation was found with the arterial alveolar oxygen ratio. In patients who 
were ventilated for more than one day, no significant difference was found between 
median phospholipid level on the first day o f ventilation and on the last day (Figure 
21 ).
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Figure 21. Phospholipid concentration on first and last days of 
ventilation in children with RSV infection ventilated for more 
than 1 day (n = 13). It was not possible to plot values for all 16 
children ventilated for more than one day due to insufficient 
sample size. There was no significant difference between median 
initial and final phospholipid concentrations.
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8.2.3. THE RELATIONSHIP BETWEEN PHOSPHOLIPIDS AND PROTEINS
When surfactant proteins were expressed per p,g o f phospholipid, there was no 
significant difference in SPA or SPD levels between the groups, but the level of SPB 
was significantly lower in the RSV group than in the surgical group (Table 13).
Linear regression analysis was performed in RSV and in control groups to ascertain 
any correlation between surfactant protein and phospholipid levels. In the control 
group, both SPA and SPB were positively correlated with BAL phospholipid (r- 
squared values: SPA 0.344 p=0.001, SPB 0.489 p<0.000), and these significant 
correlations were not present in the RSV group. In neither the RSV nor the control 
group was SPD correlated with phospholipid level.
Table 13. Surfactant proteins in BAL fluid expressed per pg phospholipid.
No. of patients
(samples)
SPA fxg/pg
phospholipid
median (range)
(95% C l for median)
SPB ng/pg 
phospholipid
median (range)
(95% C l for median)
SPD ng/pg 
phospholipid
median (range)
(95% Cl for median)
Children with 
RSV infection
18
(68)
0.23
(0 .0 2 -9 .1 1 )
(OJ 2-0.33)
0.27
(0 .0 0 -3 .8 7 )
(0.11-0.38)
5.51
(0 .0 0 -2 0 0 .3 2 )
(1.92-10.01)
Surgical
patients
16
(31)
0.15
(0 .0 1 -1 .3 6 )
(0.10-0.24)
1.29
(0 .0 0 -6 .4 7 )
(0.83-1.70)
5.60
(0 .0 0 -3 3 7 .4 3 )
(3.59-15.16)
p value* 0.1323 <  0 .0000 0.2551
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8.3. DISCUSSION
8.3.1. SURFACTANT PROTEINS A, B AND D
The median level of SPA in the control group in this study (9.0pg/ml) was similar to 
the levels found by Rat)en et al (1996) in their study of BAL fluid from children 
without bronchopulmonary disease aged 3-15 years (mean 6.9 ± s.d. 9.2 pg/ml).
The finding that the SPA concentration is reduced in BAL fluid from children with 
RSV infection is similar to the reports o f Dargaville and co-workers (1996) and 
Le Vine and colleagues (1996) who studied tracheal aspirates from ventilated children 
with viral pneumonitis. Interestingly, Dargaville et al (1995) in earlier preliminary data 
reported no significant difference in SPA in viral bronchiolitis compared to control 
when BAL samples rather than tracheal aspirates were studied. Indeed, consideration 
of confidence intervals suggests that the reduction in SPA in severe RSV infection is 
relatively modest.
In agreement with Dargaville and Le Vine, it was found that SPA tended to increase 
between the first and last days of ventilation (Figure 16). However, in the present 
study, where sequential daily samples were taken, no consistent pattern of day to day 
change throughout the disease process could be discerned.
Surfactant protein B was found to be reduced in ventilated children with RSV 
infection. A previous study of tracheal aspirates from children with viral pneumonitis 
(LeVine et al. 1996) did not demonstrate this reduction. Two possible explanations for 
the difference spring to mind - sampling method and age distribution. In the present
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study, sequential daily samples o f BAL fluid were taken, whereas Le Vine’s group 
collected tracheal aspirates on selected days. Also in the present study, the ages of 
patients in the RSV and control groups are similar (Figure 6). In contrast, in Le Vine’s 
study, the mean age o f the control group was 1.89 years (± 2.37 SD), while the mean 
age in the group with viral pneumonitis was 0.37 years (± 0.42 SD). The effect of age 
on SPB is not known, but surfactant phospholipid concentration in BAL fluid is known 
to decrease with increasing age (Rat)en et al. 1996). If SPB also decreases in the same 
manner, this could have masked any difference between the groups in Le Vine’s study.
Limitations of surfactant protein measurements, and standardisation with other 
BAL components
The possibility o f damage (by the disease process) to the tertiary structure of any of 
the surfactant proteins and consequent altered immunoreactivity should be 
acknowledged as a factor which may affect the results of ELIS As. Equally, the disease 
process could damage the functional properties of surfactant proteins, leaving 
immunogenic epitopes intact.
There has been concern about quantification of extracellular lung fluid proteins in BAL 
fluid, and debate about the most appropriate method of standardising alveolar protein 
levels to take account of possible variations in lavage dilution (Grigg and Venge,
1996). This concern could indeed be extended beyond the quantification of proteins to 
the quantification of any lavageable material.
It was found in this study that the total protein content of lavage fluid from patients
with RSV infection was higher than that in the control group, reflecting the pulmonary
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inflammation occurring with infection. In these circumstances, and, in fact, in any 
inflammatory lung disease with a ‘protein leak’ into the alveoli, expression of BAL 
constituent concentrations per mg of total protein potentially introduces an error.
Dargaville and colleagues (1996) used urea as a marker in their studies of viral 
pneumonitis, and expressed surfactant constituents per ml of 'epithelial lining fluid' as 
well as reporting values per ml o f lavage fluid. However, the urea method is also 
known to be problematic due to the tendency for urea to enter the alveolus very 
rapidly on lavage (van de Graaf et al. 1991; Ward et al. 1992).
Due to the problems involved in using either urea or protein to standardise values, the 
concentrations o f surfactant constituents were expressed per ml of lavage fluid in this 
study. Surfactant proteins were also expressed per jig of phospholipid. A standard 
collection technique was used by one investigator (MK), and lavage dwell time was 
very short in all lavages performed. There was no significant difference in percentage 
return of BAL fluid between controls and RSV patients (Table 14), indicating that 
lavage dynamics were similar in both groups. It should be noted that the reduction in 
surfactant proteins found in this study was present regardless of whether the values 
were expressed in mg/ml or mg/mg protein. However, when expressed with reference 
to phospholipid, only SPB was reduced in RSV relative to control, suggesting a global 
reduction in secretion o f surfactant lipids and proteins, with a more profound reduction 
in SPB compared to other components.
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Table 14. Percentage return on BAL.
no. of patients
(samples)
% return on BAL
median (range)
(95% Cl for median)
Children with RSV 18 44.7 (22.0-60.7)
infection (71) (41.3-46.7)
Surgical patients 16 46.7 (30.0-70.0)
(31) (41.3-56.7)
p value* 0.1342
* Mann Whitney U test
There was no significant difference in percentage return on bronchoalveolar lavage 
between patients with RSV and with surgical conditions, indicating that lavage 
dynamics were similar in the two groups.
8.3.2, PHOSPHOLIPIDS
Phospholipids in BAL fluid from patients with RSV infection
In this study, a reduction in surfactant phospholipid was found in patients with RSV 
infection compared to controls. This supports the findings of Dargaville (1996).
It is interesting to note that in this study, no significant difference was found in median 
levels o f phospholipid between the initial and final days of ventilation. This finding 
differs from that of Dargaville and colleagues (1996) who found that ‘epithelial lining 
fluid DPPC’ increased between the first and last days of ventilation. However, it is
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difficult to compare these results, as Dargaville’s group studied DPPC in tracheal 
aspirates, and expressed the result corrected for the amount of urea in the sample. In 
this study, total phospholipid was measured in BAL fluid, and the results expressed in 
|ag/ml. Any or all of these three factors - sampling method, phospholipid species 
measured, or method of standardisation might contribute to the differences between 
studies.
Limitations of the method to quantify phospholipids, and comparison with 
published data
The similarity of the phospholipid amounts obtained in this study to those measured by 
Dargaville (1996) suggests that the method used in the present study gives a 
reasonable estimate of phospholipid quantity.
It is interesting to note that the total phospholipid values obtained in the control group 
in the present study (median 82.6 pg/ml) are higher than those obtained by Ratjen et 
al (1996) in normal children over 3 years old. The mean value o f phospholipid obtained 
by Ratjen et al was 35,2 pg/ml, and they found that the quantity o f phospholipid 
present rises with decreasing age. If surfactant phospholipid continues to rise with 
decreasing age in children under 3 years old, it would be likely that the phospholipid 
values found in the control group in the present study (a younger age group) would be 
higher than those in Ratjen’s study.
While acknowledging the limitations o f the method used to obtain an approximation of 
phospholipid levels in this study, it should be noted that the results are in broad 
agreement with other similar studies.
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8.3.3. PHOSPHOLIPIDS AND PROTEINS
Interestingly, SPA and SPB were positively correlated with phospholipid levels in the 
control groups, but SPD showed no correlation with phospholipids. Surfactant 
proteins A, B and phospholipids are found in lamellar bodies, while SPD is not, and the 
correlation of SPA and SPB with phospholipids suggests that the secretion of these 
lamellar body products is linked. In the RSV group, this correlation disappears, 
possibly suggesting that synthesis or secretion of SPA, SPB and phospholipids is 
disrupted by the disease.
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9. RESULTS - SURFACTANT 
COMPOSITION
9.1. INTRODUCTION
9.1.1. PHOSPHOLIPID CLASSES
Several studies have investigated the proportions o f phospholipid classes present in 
BAL fluid from people with ARDS. From these studies has emerged a picture of 
reduced PC and PG, and increased sphingomyelin. Also, in studies of animal models of 
lung injury, reduction in PC and PG are the main changes seen. In tracheal aspirates 
from neonates with nosocomial pneumonia, no changes were found in phospholipid 
composition (Griese et al. 1996). Skelton and colleagues (1976) found reduced PG in 
tracheal aspirates from infants with viral bronchiolitis.
In the light o f the findings described above, and in order to investigate the proportions 
of phospholipid classes present in BAL from children with severe RSV infection, a 
lipid extract of BAL fluid was separated by HPTLC, and the lipid classes quantified by 
charring and scanning densitometry.
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9.1.2. FATTY ACID SPECIES
Studies of the fatty acid profile o f BAL fluid in ARDS have found a reduction in 
phospholipid palmitic acid and increases in oleic (Baughman et al. 1984) and linoleic 
acids (Hallman et al. 1982; Spragg and Hallman, 1983). An animal study of dogs with 
acute lung injury, however, found increased palmitic acid and decreased oleic acid. The 
findings in human studies are consistent with contamination of BAL surfactant 
phospholipids by fragments of cell membrane which could have been damaged by the 
disease process. In this study, BAL samples were centrifuged at 250 x g in an attempt 
to remove cell debris before GC-MS analysis to ascertain relative proportions of 
phospholipid fatty acids. However, it is likely, given the nature of the pathological 
changes seen in severe RSV infection that some contamination from membrane 
fragments of necrotic cells was present, and this was supported by the results of fatty 
acid analysis.
9.2. RESULTS
9.2.1. PHOSPHOLIPID CLASSES
Examination of HPTLC plates revealed that the large phosphatidylcholine band and the 
small sphingomyelin band were not easily distinguished separately by scanning 
densitometry, and PC and S were therefore reported as a combined peak. Also, in the 
RSV group, PE co-migrated with a double glycolipid band (identified as described in 
section 5.4.2. (Siakotos and Rouser, 1965)), so that proportion of PE could not be 
reliably reported (Figures 11 and 12).
Phospholipid proportions were reported as percentages o f the total (excluding PE).
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Proportions of phospholipid classes
The combined PC & S fraction was significantly lower in the RSV group than in the 
control group, while PG accounted for a significantly higher proportion in the RSV 
group compared to control. However, the differences were small and the 95% 
confidence intervals for the medians overlapped. The proportion of PS was 
significantly increased in the RSV group. There was no significant difference between 
groups in the values for PI. (Table 15).
Sequential changes in patients with RSV infection
The PG fraction and the PI fraction tended to follow a pattern o f reciprocal change 
throughout the period of ventilation, with one fraction increasing as the other 
decreased (Figure 22). There was no consistent association of phospholipid 
proportions with disease severity as measured by arterial alveolar oxygen ratio. No 
predictable pattern o f change was observed between the first and last days of 
ventilation. The pattern o f change seen in the S&PC fraction and PS is shown in Figure 
23.
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Table 15. Phospholipid classes in BAL fluid.
No.of
patients
(samples)
S&PC % 
median 
(range)
(95% Cl for 
median)
PS %
median
(range)
(95% Cl for 
median)
P l%
median
(range)
(95%CIfor
median)
PG%
median
(range)
(95% C l for 
median)
Children 18 58.2 5.9 11.3 21.3
with RSV (69t) (40.4-72.9) (2.2-11.4) (1.3-23.7) (8.3-49.3)
infection (56.3 - 60.4) (5.3-6.7) (10.3-14.0) (19.9-23.3)
Surgical 14 62.3 4.0 12.3 18.7
patients (29?) (51.2-80.2)
(57.2-66.3)
(0.5-9.3)
(2.8-4.7)
(2.8-25.8)
(9.9- 18.2)
(12.2-32.9)
(16.4-20.8)
p value* 0.0317 0.0001 0.4404 0.0240
* Marm Whitney U test
The proportion of PS in the RSV group was increased. Although statistically 
significant, differences in proportions o f the S & PC fraction and the PG fraction 
between patients with RSV and controls were small as indicated by overlapping 
confidence intervals.
t  It was not possible to assess all 71 samples in the RSV group and all 31 samples in 
the control group due to insufficient sample size.
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Figure 23. Sequential changes in the S&PC and PS fractions in 10 
ventilated children with RSV infection
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9.2,2. PHOSPHOLIPID FATTY ACID PROFILE 
Fatty acid species in RSV and control groups
The median weight percent o f the 14:0, 16:0 and 16:1 species of fatty acids was 
significantly reduced in the RSV group compared to the surgical group. Conversely, 
the median weight percent of the 18:0 and 18:1 species was significantly increased in 
the RSV group compared to control. There was no significant difference between 
groups in the proportions of 18:2 and 20:4 (Figure 24).
Sequential changes in children with RSV infection.
The pattern of variation o f 16:0 and 16:1 (Figure 25) and o f 18:0, 18:1 and 18:2 
(Figure 26) is shown in 10 children with RSV infection ventilated for more than three 
days. There was no consistent relationship with disease seventy as measured by arterial 
alveolar oxygen ratio.
The median percentage o f the 18:2 species was greater on the first day of ventilation 
(median 8.0%; range 2.4 - 18.3%) than on the last (median 5.6%; range 0.0 - 9.7%) (p 
= 0.0159 Mann Whitney). No other species showed a significant change between the 
first and last days of ventilation.
199
14:0 18:0
50
30
%20
10
0
16:0
70
60
40
30
10
18:1
35
25
20
15
16:1 18:2
18
12
10
RSVsurgical controls
20
15
0
RSVsurgical controls
F igu re  24 . F a tty  acid  sp ecies in  B A L  flu id  (95%  C l  fo r  th e  m ed ians show n )
The median (and range) percentages of fatty acid species were as follows: 14:0 0.0(0.0-6.7) RSV 
2.0 (0.0-6.4) surgical p=0.0003. 16:0 42.8 (18.7-60.1) RSV; 52.6 (41.1-65.1) surgical p<0.0000. 16:1 8.0 (0.0-13.2) RSV; 
13.8 (6.2-17.0) surgical p<0.0000. 18:0 13.7 (5.9-46.0) RSV; 6.0 (0.0-15.8) surgical p<0.0000. 18:1 23.1 (9.9-35.9) RSV; 
14.1 (10.9-30.5) surgical p<0.0000. 18:2 and 20:4 - no significant difference.
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9.3. DISCUSSION
9.3.1. PHOSPHOLIPID CLASSES
Sui*factant phospholipid classes in RSV and surgical patients
A statistically significant reduction was found in the combined S & PC class (p = 
0.0317) and an increase in PG (p = 0.0240) in the RSV group. However, examination 
of confidence intervals reveals an overlap in both cases. This, taken with the relatively 
high p values would suggest caution in interpreting these results as biologically 
significant. An increased proportion of PS was found in children with RSV infection 
compared to control. The mechanism for and consequences of this finding are 
uncertain.
Unfortunately, when all the BAL samples were run, although PC and S could often be 
distinguished by the naked eye (Figure 11), h was not possible to make an adequate 
distinction for reporting when the scanning densitometer was used. The reporting o f S 
and PC as a combined peak undoubtedly introduces an incomplete interpretation of the 
facts. It was also impossible to report the proportion of PE, due to its co-migration 
with glycolipid fractions in samples from patients with RSV infection (Figures 11 and 
12). Additionally, as described before, charring characteristics of different phospholipid 
classes may vary. This makes it difficult to compare the results obtained from the 
control group in this study with published normal values. Also no normal data are 
available for children under 3 years of age, the age group o f patients who were 
controls in this study.
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The findings in the present study contrast with some preliminary data in viral 
bronchiolitis from Skelton and colleagues (1996). Skelton reports a qualitative 
deficiency of PG early in the course o f ventilation, which recovered by extubation. She 
studied 18 infants with bronchiolitis, and found that ‘surfactant activity [by the click 
test] and PG were present in only 6/18 at intubation, but reappeared in all 18 by 
extubation’. In the present study, this pattern was not found and PG was seen to be 
present in all patients at all times. When the patients who were ventilated for more than 
1 day were studied, PG rose from the first to the last day in 50% of patients and fell 
from the first to the last day in 50% of patients (Figure 27). It is not clear what method 
was used by Skelton et al for qualitative analysis of PG, and methodological 
differences along with sampling differences (tracheal aspirates vs BAL) may account 
for the divergence of these findings. Skelton’s data are only available in abstract form 
at present, so it is not possible to comment in more detail.
Values of PS, PG and PI in the control group in this study are all high compared to 
other published normal data (as reviewed by Ratjen et al (1996)). As described earlier, 
the method of HPTLC and scanning densitometry used in the present study has 
significant limitations in terms of accuracy, and as several phospholipid classes were 
not clearly distinguished by densitometry, it is difficult to compare proportions found 
in this study with other published data.
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Figure 27. Phosphatidylglycerol on the first and last days of ventilation in 
children with RSV infection (n = 14). Levels o f PG could not be plotted for 
all 16 children due to insufficient sample volume. In 50% o f  children, 
there was a decrease from first to last days, and in 50%, an increase.
In order to investigate further whether the high PG levels found in this study were 
artifactual due to methodological problems, or whether, indeed they represented a true 
indication o f  PG in BAL, PG proportion was compared to fatty acid species 
proportion. As can be seen from Tables 2 and 3, the PG fraction o f  surfactant contains 
a higher proportion o f  18:0 and 18:1 species and a relatively lower proportion o f  16:0 
species than PC. Regression analysis o f  results from samples in the control group 
showed significant positive correlations between both 18:0 and 18:1 species and PG 
fraction, and a significant negative correlation between 16:0 and PG. In the RSV
2 0 5
group, similar correlations were found with the exception of 18:1 which was not 
significantly correlated to PG. This gives somewhat greater validity to the proportions 
of PG found in this study. However, due to the limitations of the method, and 
differences from published values, their potential inaccuracy should be acknowledged.
The microsomal and mitochondrial fractions o f adult human lung tissue have less PC, 
less PG, more PE and more S than the surfactant fraction (Post et al. 1982). Due to 
comigration of S and PE with other fractions on HPTLC in this study, it is difficult to 
assess the effect of any possible contamination of BAL fluid with membrane fragments 
from the organelles of damaged cells on the profile of phospholipid classes.
The finding that PI and PG increased and decreased in a reciprocal manner is 
consistent with the literature reviewed in section 1.2.3. The concentrations of these 
phospholipids are linked in a reciprocal manner both during lung development and in 
disease states (Akino, 1992). Although global variations in PG/PI ratio have been 
demonstrated before in other diseases, it is interesting to note the reciprocal day to day 
variation between these two phospholipids in some ventilated patients with RSV 
throughout the disease process (Figure 22).
9.3.2, PROPORTIONS OF PHOSPHOLIPID FATTY ACIDS IN BAL FLUID
The pattern found in this study was that of a reduction in myristic (14:0), palmitic 
(16:0), and palmitoleic (16:1) acids, and an increase in stearic (18:0) and oleic (18:1)
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acids in patients with RSV infection compared to controls. Linoleic (18:2) and 
arachidonic (20:4) acids were not significantly different between the groups.
This pattern of shift is reminiscent of that found by Baughman and colleagues (1984) in 
adult intensive care patients with bacterial pneumonia. They found a reduction in the 
16:0 species and an increase in the 18:0, 18:1 and 18:2 species in BAL fluid of patients 
with pneumonia compared to controls. A similar pattern was also seen in patients with 
ARDS, and, in this group, the 16:0 species was reduced, and the 18:0 and 18:1 species 
were increased compared to control. Hallman et al (1982) found reduced 16:0 and 
increased 18:0 and 18:2 in BAL from patients with ARDS.
High levels of inspired oxygen - comparable to those sometimes used in ventilated 
patients with RSV- can cause decreases in DPPC levels in experimental animals (King 
et al. 1989). Therefore, it is possible that the high inspired oxygen fraction needed in 
treatment of RSV infection could have been a contributory factor to the decrease in the 
palmitic acid fi-action seen in the RSV group.
Phosphatidylcholine from microsomal membrane fragments and lung tissue contains 
more 18:0, 18:1 and 18:2 and less 16:0 species than surfactant (Rooney et al. 1975; 
Hunt et al. 1991; Schlame et al. 1988). Athough centrifugation at 250 x g was 
performed before sample analysis to pellet cells and cell debris, it is likely that small 
intracellular membrane fragments contaminated analysed BAL fluid in this study. 
Membrane contamination could account for the pattern o f fatty acid species seen in 
BAL from patients with RSV. According to the histological picture in severe 
infection, there is likely to be more breakdown of cells in the RSV group, and this was
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the group with higher levels of 18:0 and 18:1 species, and lower levels of 16:0. It is 
interesting to note that in this study the other fatty acid species which is present 
predominantly in membrane fragments, 18:2, showed a reduction on the last day of 
ventilation compared to the first, and this may have been due to a reduction in cell 
necrosis with disease resolution.
Therefore, the changes in BAL fatty acid proportions seen in children with severe RSV 
infection are highly suggestive o f the presence o f membrane fragments in lavage fluid. 
The presence of similar changes in ARDS and pneumonia supports this, as pulmonary 
cellular necrosis can also occur in these conditions. However, the influence on 
surfactant synthesis o f hyperoxia, or o f other unknown effects of viral infection in type 
II pneumocytes cannot be mled out.
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10. RESULTS - INDICES OF SURFACTANT 
DAMAGE
10.1. INTRODUCTION
Peroxynitrite is a reactive molecule formed by combination of nitric oxide and 
superoxide, which are released during the inflammatory response. There are no known 
specific scavenging mechanisms in the alveolar lining fluid which would offset 
peroxynitrite damage. Therefore this molecule may cause cellular and molecular
,.j
damage during inflammatory lung disease (Haddad et al. 1993; Royall et al. 1995).
Nitrotyrosine is a specific marker for damage to proteins by peroxynitrite 
(Ischiropoulos and A-Mehdi, 1995). Evidence o f peroxynitrite damage is seen from 
the presence of increased nitrotyrosine in lung sections from patients who have died of 
ARDS (Royall et al. 1995; Haddad et al. 1994). Peroxynitrite has been shown, in vitro, 
to damage pulmonary surfactant phospholipids and proteins (Haddad et al. 1993). As 
this reactive molecule may be released during the pulmonary inflammatory response in 
severe RSV infection, in this study, BAL nitrotyrosine was measured, as a marker of 
damage to alveolar proteins.
As a non-specific marker of oxidant damage to lipids, BAL malondialdehyde (MDA) 
was also studied. Malondialdehyde is thought to originate in vivo mainly from oxidised 
linolenic, arachidonic and docosahexanoic acids and from certain prostaglandins via the
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action of platelet thromboxane synthetase. Linoleic acid is regarded as a weak 
precursor of MDA (Esterbauer et al. 1991). Malondialdehyde has been detected after 
in vitro exposure of calf lung surfactant extract to peroxynitrite (Haddad et al. 1993). 
Other indicators of lung lipid peroxidation have been measured in ARDS (Baldwin et 
al. 1986; Sznadjer et al. 1989; Cochrane et al. 1983), and MDA has been measured in 
BAL fluid in rats (Petruska et al. 1990). However, to the author's knowledge, no 
measurements of MDA have hitherto been made in human BAL fluid.
Glycolipids and lysophosphatidylcholine have been found on chromatographic analysis 
of BAL fluid in ARDS (Hallman et al. 1982; Rauvala and Hallman, 1984; Gregory et 
al. 1991). Glycolipids are found on cell surfaces and can act as receptors for viruses 
and bacteria and mediate interactions between cells. They are also known to bind SPA 
and Momoeda and colleagues (1996) identified them as receptors for SPA in the 
murine lung. Lysophosphatidylcholine is a breakdown product of PC resulting from 
phospholipase action. It is likely that the presence of these lipids in BAL fluid in 
inflammatory lung disease indicates damage to cellular and surfactant lipids. 
Lysophosphospatidylcholine and glycolipids were sought on HPTLC analysis of BAL 
fluid in this study.
10.2. RESULTS
10.2.1. MALONDIALDEHYDE
Contrary to expectation, significantly lower amounts of malondialdehyde were found in 
lavage fluid from patients in the RSV group than in the control group (Figure 28).
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Further, no correlation was evident with severity of illness or with duration of 
ventilation.
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Figure 28. Malondialdehyde levels in BAL fluid (95% Cl for median shown)
Values for M DA from patients in the control group who had not had surgery 
are shown as yellow  dots. The median level in patients with RSV was O.OOpmol/l 
(range 0.00-0.65). In surgical patients, the median level was also O.OOpmol/l 
(range 0.00-3.38) p=0.0005 Mann Whitney.
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10.2.2. NITROTYROSINE
Levels o f nitrotyrosine per mg of total protein in BAL fluid were significantly higher in 
the RSV group (Figure 29). No clear relationship could be determined between 
nitrotyrosine level and disease progress. In particular, there was no significant 
difference between median values of nitrotyrosine on the initial and final days of 
ventilation (Figure 30).
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Figure 29. Nitrotyrosine levels in BAL fluid (95% C l for median shown)
Values for nitrotyrosine from patients who had not had surgery are shown 
as yellowdots. The median value in patients with RSV was 107.9ng/mg protein 
(range 0.0-11500.0). The median value in surgical patients was O.Ong/mg protein 
(range 0.0-338.9). p<0.0000 Mann Whitney.
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Figure 30. Nitrotyrosine levels on first and last days of ventilation in children 
with RSV infection ventilated for more than 1 day (n = 14). No significant 
difference was found between the median values on initial and final days 
(p = 0.1207 Mann Whitney).
10.2.3. EVIDENCE FOR SURFACTANT AND CELLULAR DAMAGE ON 
HPTLC
High performance thin layer chromatography was performed on 69 BAL fluid samples 
from 18 RSV patients, and 29 BAL fluid samples from 14 surgical patients (It was not 
possible to perform HPTLC on all samples due to insufficient sample volume).
Lysophosphatidylcholine
A lysophosphatidylcholine band on HPTLC plates (Figure 9) was detected in 87% of 
samples from patients with RSV infection, and in 10% of controls (%^ = 52.198; d.f. =
21 5
1; p< 0.000). No clear relationship was found between duration o f ventilation and the 
presence of LPC.
Glycolipids
Glycolipids were detected in 88% of samples from RSV patients, and in none of the 
control samples (Figures 9 and 10) (%^^ 67.905; d.f. = 1; p< 0.000 Chi Square). No 
clear relationship was found between duration o f ventilation and the presence of 
glycolipids.
103. DISCUSSION
10.3.1. NITROTYROSINE
Nitrotyrosine levels were found to be increased in lavage fluid from children with RSV 
infection. Low levels of nitrotyrosine were found in some control patients. There was 
no apparent distinction between nitrotyrosine levels in patients in the control group 
who had had surgery and those who had not (Figure 29).
Although the level of nitrotyrosine can be seen to fall sharply between the first and last 
days o f ventilation in some patients (Figure 30), this was not a consistent finding, and 
there was no significant difference in the median levels on first and final days.
Because it is likely that nitrotyrosine concentrations are linked to the amount o f protein 
present in the alveolus, nitrotyrosine levels were expressed per mg of protein in this 
study.
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Neutrophils and macrophages which invade the lung in RSV infection produce nitric 
oxide and superoxide (Rosen et al. 1995), the majority of which is probably converted 
to peroxynitrite (Iscliiropoulos et al. 1992). Peroxynitrite is known to cause nitration 
of tyrosine residues in SPA and in other proteins (Haddad et al. 1993). The finding that 
nitrotyrosine is elevated in RSV infection, therefore, is consistent with the 
inflammatory infiltrate seen in this condition and concords well with the presence of 
increased nitrotyrosine in immunocytochemical studies o f lung sections from patients 
with other inflammatory lung diseases (Haddad et al. 1994; Royall et al. 1995).
10.3.2. MALONDIALDEHYDE
The finding that malondialdehyde is present in significantly lesser amounts in the lavage 
fluid o f patients with RSV infection than in surgical patients appears at first 
contradictory, in the light of the raised amounts of nitrotyrosine (the other indicator of 
fi'ee radical damage) found in the RSV group. The presence of raised nitrotyrosine 
levels and reduced MDA levels in RSV would suggest that peroxynitrite is present in 
this condition, but, for some reason is not causing significant lipid peroxidation.
Potentially, there may be three reasons for the decreased appearance of MDA in lavage 
fluid from children with RSV compared to controls: less substrate, increased 
scavenging and an increase in MDA in the control group due to the effects of surgery.
As stated earlier, the main substrates for MDA formation are long chain unsaturated 
fatty acids. It is not possible to tell whether the proportions o f fatty acids found on
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analysis of BAL fluid in this study have been altered due to lipid peroxidation. The 
proportionate amounts of arachidonic and linoleic acids did not differ significantly 
between the two groups, and docosahexanoic acid was not found in detectable 
amounts in any samples. Linolenic acid was found in small amounts in 4 members of 
the control group, and three o f these had undetectable levels of MDA. It should not be 
overlooked that, although the percentages of arachidonic and linolenic acids did not 
differ between groups, the absolute amount of phospholipid was less in the RSV 
group. This could theoretically have led to less lipid substrate being available for lipid 
peroxidation. However, when amounts of MDA were expressed per p,g phospholipid, 
MDA was still significantly lower in the RSV group (p = 0.0057 Mann Whitney). Also, 
free fatty acids and triglycerides were not quantified in the two groups, and these may 
have provided potential substrates. Additionally, the amounts of prostaglandins present 
in the two groups may differ.
Alveolar lining fluid is known to contain catalase, superoxide dismutase and reduced 
glutathione, all o f which act to mop up the three participants in the Haber-Weiss 
reaction (O2 , Hi 0% and Fe  ^) (Figure 4) while leaving peroxynitrite untouched. As 
discussed in the introduction, the free radical scavenging capacity o f lavage fluid from 
patients with ARDS is greater than that of controls. Perhaps the situation is similar in 
RSV infection which, like ARDS, is an inflammatoiy lung condition. It may be that 
while nitrotyrosine formation by peroxynitrite is increased in the patients with RSV, 
superoxide and hydrogen peroxide (the other reactive molecules capable of lipid 
peroxidation) are more efficiently scavenged in these patients, leading to less formation 
of MDA
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Plasma proteins are also known to act as free radical scavengers, and these are present
I
in greater amounts in the lavage fluid of children with RSV infection. It is possible that S
proteins absorb the m^ority o f damage by peroxynitrite (as evidenced by increased 
nitrotyrosine) and effectively shield lipids from harm. In vitro studies of the free radical 
scavenging properties of BAL fluid from patients with and without RSV will cast more 
light on this area.
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Surgery inevitably results in tissue damage, and, as such is likely to cause a release of 
free radicals and prostaglandins. Both these factors could increase the levels of MDA 
in the circulation, and this might be transferred from the pulmonary capillaries to the 
fluid collected in bronchoalveolar lavage. The levels of MDA in eight samples from 
patients in the control group who had not had surgery are identified in Figure 28. It 
can be seen that values for 7 out of these 8 samples fall within the 95% confidence 
interval for the median in the control group. This would suggest that surgery did not 
have a significant impact on MDA levels.
10.3,3. LYSOPHOSPHATIDYLCHOLINE AND GLYCOLIPIDS 
Lysophosphatidylcholine
In this study, qualitative analysis of HPTLC plates showed a spot migrating between 
the origin and the sphingomyelin band. By comparison with the relative migration o f a 
commercial standard, and from Olsen and Henderson's (1989) original description of 
the method, this spot was assumed to be lysophosphitidyIcholine (LPC). This 
lysophospholipid was found to be present in BAL from significantly more patients with 
RSV infection than from surgical controls.
i
The finding of increased LPC in BAL from ventilated children with severe RSV 
infection is in accordance with other human and animal studies of inflammatory lung 
disease. Gregory and colleagues (1991) found increased LPC in BAL fi*om patients 
with ARDS, and Casals and co-workers (1989) found that LPC was increased in 
rabbits with lung injury.
The increased levels o f LPC seen in lung inflammation may be due to action of 
phospholipases on PC. In one study o f adults with ARDS and pneumonia, 
phospholipase A2 activity was found to be lower in ARDS than control, however, 
when expressed on the basis o f total phospholipid, normal controls had lower activities 
of this enzyme than patients with pneumonia or ARDS. Additionally, LPC levels were 
increased compared to controls, but this increase did not reach statistical significance 
(Hallman et al. 1982; Spragg and Hallman, 1983). In a study of oleic-acid injured 
rabbits, Casals group demonstrated significantly higher LPC and Phospholipase A 
activity in BAL and whole lung in injured animals (Casals et al. 1989).
Glycolipids
An unexpected finding in this study was the presence, on qualitative analysis of 
HPTLC, of two bands corresponding to glycolipids in the majority of BAL samples 
from patients with RSV infection, but in none from controls (Figure 12).
Glycolipids have also been found in BAL fi-om patients with ARDS (Hallman et al. 
1982; Rauvala and Hallman, 1984). Examination of BAL fluid in one study revealed on
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TLC two doublet bands identified as paragloboside and lactosylceramide (Rauvala and 
Hallman, 1984).
Neutrophils, erythrocytes and normal lung tissue contain glycolipids, including 
paragloboside (Yoda et al. 1982; Narasimhan and Murray, 1979; Macher and Klock, 
1980; Vance and Sweeley, 1967).
It may be that the glycolipids found in lavage fluid from patients with RSV are simply 
an index of cellular damage. As discussed earlier, cellular damage is likely to be a 
feature of severe RSV infection (section 9.3.2.). It is also possible, however, that they 
are engaged in some more complex interaction with the virus or with surfactant 
proteins as SPA is thought to compete with microorganisms for glycolipid receptors 
on cell surfaces (Kuroki et ah 1992). More detailed studies will be needed to elucidate 
the exact nature of these glycolipids and to define the contribution made by glycolipids 
to the overall pathological picture in RSV infection.
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11. RESULTS - INDICES OF SURFACTANT 
INHIBITION AND POTENTIAL INHIBITORS
11.1. INTRODUCTION
Pulmonary inflammation leads to an alteration in capillary permeability, and leakage of 
oedema fluid and plasma proteins into the alveolus. One study of BAL fluid in ARDS 
study showed a coiTelation between the percentage of neutrophils in BAL and BAL 
protein (Weiland et al. 1986). Plasma proteins and oedema fluid have been shown, in 
vitro, to inhibit the surface activity of pulmonary surfactant. It was considered likely 
fi'om the histological picture o f fibrinous alveolar exudates in severe RSV infection that 
surfactant inhibition would be present in this condition. Therefore, the inhibitory 
potential o f lyophilised proteins from BAL was assessed by mixing these proteins at 
1 mg/ml with a bovine lipid surfactant preparation, and studying the mixture in the 
pulsating bubble surfactometer.
Total protein and the surfactant inhibitors albumin, fibrinogen, fibrin degradation 
products and c-reactive protein were quantified in BAL fluid. These substances were 
the 'main suspects' for inhibition of surfactant in RSV infection. However, other 
substances such as globulins and haemoglobin were not quantified, and these may also 
have played a part in surfactant inhibition.
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11.2. RESULTS
11.2.1. TOTAL PROTEIN
Total protein levels were significantly higher in lavage fluid from patients with RSV 
than in surgical patients (Figure 31, Table 12). Total protein levels showed no 
consistent relationship either to disease severity as measured by arterial alveolar 
oxygen ratio or to duration of ventilation.
11.2.2. C-REACTIVE PROTEIN
C-reactive protein was not detected in any o f the BAL samples assayed.
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Figure 31, Total protein and fibrin degradation products in BAL fluid 
(95% C l for median shown). Values for FDP's from patients in the 
control group who had not had surgery are shown as yellow dots.
In patients with RSV, the median FDP level was 47ng/ml (range 1-1252) 
In surgical patients, median FDP level was 1 Ing/ml (range 1-108)
Values for total protein are shown in table 12.
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11.2.3. ALBUMIN
Levels of albumin were not significantly different between RS V and control groups 
(Table 16).
Table 16. Albumin levels in BAL fluid.
No. of patients
(samples)
albumin gg/ml 
median (range)
(95% Clfor median)
Children with RSV 18 69 (7-420)
infection (63f) (55-117)
Surgical patients 11 86 (17-388)
(24f) (35-114)
p value* 0,6349
* Mann Whitney U test
There was no significant difference in the level of albumin detected between RSV and 
control groups.
t  It was not possible to assess all 71 samples in the RSV group and all 31 samples in 
the control group due to insufficient sample size.
11.2.4. FIBRIN DEGRADATION PRODUCTS
Fibrin degradation products (FDP) were significantly increased in lavage fluid from 
RSV patients compared to control (Figure 31). Levels of FDP showed no consistent
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relationship either to disease severity as measured by arterial alveolar oxygen ratio or 
to duration of ventilation (Figure 32).
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Figure 32. FDP concentration on first and last days of ventilation in 
children with RSV infection ventilated for more than 1 day.
Although there was a dramatic fall in FDP concentration between the 
first and last days of ventilation in some patients, there was overall no 
significant difference between median FDP levels on the initial and 
final days of ventilation.
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11.2.5. SURFACTOMETER STUDIES OF SURFACTANT INHIBITORS IN 
BAL FLUID
When proteins from the 40,000g supernatant of BAL fluid were resuspended to a 
concentration of 1 mg/ml in suspension buffer containing 2.5mg/ml Survanta and tested 
in the surfactometer, minimum surface tensions achieved within a 10 minute period 
were significantly higher in the RSV group than in the control group (Table 17), 
indicating greater inhibition of surfactant function. There was no significant difference 
in the median level of inhibition (as assessed by minimum surface tension) between the 
first and last days of ventilation.
Table 17. Surface tension values achieved with Img/ml supernatant protein and 
2.5ing/ml Survanta.
No. of 
patients
(samples)
min. surface 
tension mN/m
median (range)
(95Vo Cl for median)
max. surface 
tension mN/m
median (range)
(95% Cl for median)
Children 16 21.0 46^
with RSV (53f) (1.1-35.5) (35.2-59.4)
infection 0 9 3 -2 3 .3 ) (45.2-47.3)
Surgical 10 13.9 47.6
patients (20t) (3.4-27.9) (33.6-55.8)
(8.4- 18.2) (44.7-48.8)
p value* 0.0086 0.6920
Survanta 5 3.8 52 0
alone (3.0-3.8) (51.5-57.3)
* Mann Whitney U test
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Inhibition of Survanta, an animal surfactant was greater when Img/ml supernatant 
protein was added from BAL fluid of patients with RSV infection than when the 
protein was derived from BAL fluid of controls.
t  It was not possible to assess all 71 samples in the RSV group and all 31 samples in 
the control group due to insufficient sample size or to insufficient amounts of protein 
in some samples.
11.3. DISCUSSION
11.3.1. TOTAL PROTEIN
The total protein content of BAL fluid from children with RSV infection was found to 
be increased compared to control. This is likely to be due to leakage of protein rich 
fluid from pulmonary capillaries in the inflammatory response and is in keeping with 
the histological evidence o f an alveolar exudate in RSV infection. To give a better 
picture of the molecules involved in this exudate, potential surfactant inhibitors were 
quantified in BAL fluid.
11.3.2. FIBRINOGEN AND C-REACTIVE PROTEIN (CRP)
The concentration of CRP was assessed by immunoturbimetry, and fibrinogen by the 
thrombin time method (which uses the fact that the thrombin clotting time is inversely 
proportional to the amount o f fibrinogen present) (Clauss, 1957; Alving and Bell,
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11.3.3. ALBUMIN
Albumin levels, assessed by immunoturbimetry, were not significantly different 
between RSV and control groups. The levels of albumin found in the BAL in this study 
were similar to those found elsewhere in healthy adult human volunteers (Low et al. 
1978). This suggests that albumin, an inhibitor of surfactant at relatively high levels of 
protein, does not have a specific role in the inhibition of surfactant in patients with 
RSV.
11.3.4. FIBRIN DEGRADATION PRODUCTS (FDP)
The D-dimer FDP was found to be elevated in samples of BAL from children with 
RSV infection - a finding consistent with the histological picture of an alveolar 
fibrinous exudate. The D fibrin degradation product has been shown to be an extremely
229
-
1976). CRP was assessed in all patients and fibrinogen in selected samples from RSV 
and control patients. Neither CRP nor fibrinogen was detected in any samples. The
lower limit of detection in the CRP assay (2.5 pg/ml) was within the range of the low 
amounts of CRP found in control patients in Li’s study (1989) of BAL from ARDS 
patients, and would certainly have allowed detection of the levels elevated to the 
degree found in Li’s ARDS group.
These results suggest that CRP and fibrinogen, known inhibitors o f surfactant function, 
are unlikely to play a significant role in the inhibition of surfactant in RSV infection.
11.3.5. SURFACTOMETER STUDIES OF SURFACTANT INHIBITORS M  
BAL FLUID
When the inhibitory capacity of BAL proteins was assessed, it was found that proteins 
from patients with RSV infection inhibited a bovine surfactant replacement preparation 
(Survanta) more strongly than those from control patients. This is consistent with the 
finding that a strongly inhibitory FDP was found in increased amounts in BAL from 
patients with RSV infection. It is also possible that other proteins which were not 
studied played a part in the inhibition of surfactant in these patients. Whatever the 
cause, this study provides clear evidence that surfactant inhibitors are present and are 
contributing to the observed surfactant dysfunction in RSV infection.
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potent inhibitor of surfactant in vitro - more potent than either fibrinogen or the E 
fibrin degradation product (O'Brodovich et al. 1990; Seeger et al. 1993).
As surgery increases the action of the clotting and fibrinolytic systems, patients in the 
control group who had not had surgery were identified on the graph of FDPs shown in 
Figure 31. From this, it appears that surgery does not have a substantial effect on FDP 
levels in BAL fluid and whether preoperative or post operative samples are considered, 
the conclusion that FDP’s are raised in RSV infection remains.
It can be seen from Figure 32 that the level of FDP detected in BAL fluid fell 
dramatically between the first and last days o f ventilation in some patients. The 
implication of this finding for surface activity is uncertain, as this fall in FDP was not I
reliably associated with the appearance of a positive click test.
12. DISCUSSION
12.1. SURFACTANT FUNCTION - SURFACE ACTIVITY
12.1.1. SURFACTANT DYSFUNCTION AND DEFICIENCY OF 
SURFACTANT PHOSPHOLIPID AND SPB
In agreement with other authors (Dargaville et al. 1996; Skelton et al. 1996), 
surfactant function was found, in this study, to be reduced in whole BAL fluid. The 
factors contributing to the surfactant dysfunction in severe RSV infection emerged as 
complex.
Ill contrast to most studies o f ARDS (Jacobson et al. 1993; Offenstadt et al. 1981; 
Gunther et al. 1996; Hallman et al. 1982; Spragg and Hallman, 1983; Pison et al.
1990), and in keeping with Dargaville's (1996) finding of reduced DSPC in viral 
bronchiolitis, the amount of surfactant phospholipid in BAL fluid was found in this 
study to be decreased in severe RSV infection.
There are histological clues to the underlying mechanism of the decrease in 
phospholipids. The first comes firom the finding, in an immunohistochemical study, of 
RSV in type II pneumocytes, the cells which synthesise and secrete surfactant 
phospholipid (Wright et al. 1997). It is possible that the virus, once in the cells, 
reduces their surfactant output. Secondly, areas of lung may become necrotic in viral 
pneumonia (Aheme et al. 1970), and this would reduce surfactant production simply 
by wholesale cellular destruction. These particular features are in marked contrast to
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the situation in ARDS, where there is hyperplasia of type II pneumocytes in the early |
stage of the disease, probably leading to normal or even increased surfactant j
phospholipid production.
In this study it was found that SPA and SPB but not SPD were positively correlated 
with phospholipid levels in the control groups. However, in the RSV group, this 
correlation disappears. This would support the hypothesis that the disease has a 
disruptive effect on the synthesis of surfactant components in type II pneumocytes.
As well as the effects of viral invasion on type II pneumocytes, indirect effects of RSV 
infection in the shape of the release o f peroxynitrite and nitric oxide in the 
inflammatory response could affect metabolism and surfactant processing in these cells.
Evidence for increased peroxynitrite production in RSV infection is seen in increased 
nitrotyrosine in BAL fluid and peroxynitrite has been shown to inhibit oxygen
ÿconsumption and sodium transport in alveolar type II cells in vitro (Hu et al. 1994).
A so nitric oxide, which is released from alveolar macrophages in the inflammatory 
response, has been shown to reduce synthesis o f PC in vitro by 60% (Haddad et al.
1996). There is indirect evidence, from the presence of nitrotyrosine, that nitric oxide 
production is increased in severe RSV infection, and this mechanism may also act to 
reduce alveolar phospholipids.
The high oxygen levels used in treatment of severe RSV infection (Fig 33) could also 
be partly responsible for the reduction in surface active phospholipids in the infected 
infants in this study. Similar levels o f oxygen have been shown to cause decreases in 
DPPC and surface activity in experimental animals (King et al. 1989). No significant
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correlation was found in this study between inspired oxygen level and phospholipid 
level at time o f  sampling. However, the effect o f  increased fractional oxygen  
concentration on phospholipid level is a delayed one (King et al. 1989). It is not 
possible to disentangle the effect o f  increased oxygen in RSV infection from the other 
factors which may be responsible for a reduced phospholipid level, as oxygen is an 
integral part o f  the therapy o f  respiratory failure.
^ 10
Z  6  -
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% inspired oxygen
Figure 33. Inspired oxygen concentrations in patients ventilated for RSV infection.
Inspired oxygen concentration is shown on the day that each sample was taken in the 
group o f patients with RSV infection.
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Surfactant protein B was also found to be reduced in severe RSV infection. This 
contrasts with Levine's (1996) finding of normal levels of SPB (per ml o f BAL and per 
mg of total protein) in viral pneumonitis. The potential reasons for this divergence of 
findings are discussed in section 8.3.1. It is interesting to note that in severe RSV 
infection, the positive correlation between SPB and phospholipids is lost. This supports 
the idea that surfactant synthesis is in some way disrupted. Surfactant protein B is 
found in lamellar bodies of type II pneumocytes, and is thought to be secreted along 
with surfactant phospholipids. It is as though there is an 'uncoupling' o f SPB and 
phospholipid levels in RSV, with both falling, but not to the same degree. The amount 
of SPB produced in the lung is increased, in animal models, by high inspired oxygen 
(Nogee et al. 1991). It may be that the high oxygen concentrations used in severe RSV 
infection offset some decrease in SPB in these patients. However, it is not possible to 
go beyond speculation in this matter.
Both surfactant phospholipids and SPB are important for surfactant fimction, and it is 
likely that some of the surfactant dysfunction observed in this study may be due to 
deficiency of these components.
12.1.2. COMPOSITION AND FUNCTION OF THE SURFACTANT LIPID 
FRACTION OF BAL
In agreement with Skelton at al (1996), and with studies of ARDS (Pison et al. 1990; 
Pison et al. 1987; Veldhuizen et al. 1995; Hallman et al. 1990; Gregory et al. 1991), 
the fraction of PC was found to be reduced in this study. However, a small increase 
was found in the PG fraction in patients with severe RSV infection. This is at variance 
with Skelton's (1996) finding o f absent PG in infants with viral bronchiolitis. Aso,
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studies of ARDS (Pison et al. 1990; Pison et al. 1987; Veldhuizen et al. 1995; Hallman 
et al. 1990; Gregory et al. 1991) and infant RDS (Obladen, 1978; Bose et al. 1984), 
conditions which have pathological similarities to RSV, have shown a reduction in PG. 
The small degree of the increase in PG, and the inaccuracy of the HPTLC method used 
in this study, along with the fact that this finding is at variance with other studies 
makes it unlikely that an increase in PG is a significant contributor to the pathology of 
RSV. However, it should be said, in defense of this result, that the proportion of fatty 
acids which are found predominantly in PG increased with increasing levels of this 
lipid. A so, a PG spot was clearly visible on each HPTLC run in this study, and this 
does not support Skelton's finding that PG is at times absent in viral bronchiolitis. 
Further work with a more reliable method o f quantification would be necessary to 
elucidate this matter. The uncertainty o f this conclusion means that it is not possible to 
determine whether or not the phospholipid composition of surfactant adversely affects 
surface activity in severe RSV infection. Certainly, the surface activity of a lipid extract 
of surfactant in this study did not appear to be adversely affected by the presence of 
RSV infection. However, concerns about the surfactant extract tested being too dilute 
to adsorb fully to the air liquid interface must prompt caution in interpreting this as 
proof of a normally active lipid fraction.
The presence of glycolipids in the lipid fraction o f surfactant from children with RSV 
infection is consistent with the finding of glycolipids in two studies of ARDS (Hallman 
et al. 1982; Rauvala and Hallman, 1984). In one of these studies, the glycolipids found 
were shown to reduce surface activity of BAL surfactant purified by density gradient 
centrifugation when tested in the pulsating bubble surfactometer (Rauvala and 
Hallman, 1984). Glycolipids may be influencing surface activity of surfactant in RSV
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infection. However, from the PBS studies performed in this study, it is not possible to 
draw any firm conclusions.
The presence o f LPC in a large number o f BAL samples from children with severe 
RSV infection corresponds with the finding of this lipid in ARDS. 
Lysophosphatidylcholine on its own appears to inhibit the surface activity o f a lipid 
mixture, but when LPC combined with palmitic acid is added to a lipid mixture, this 
effect is reversed (Cockshutt et al. 1991), and surface activity may even be improved 
(Lema and Enhoming, 1997). As free palmitic acid was not measured in this study, it is 
not possible to say whether the presence of LPC in the sample could have been 
detrimental to surface activity.
Surfactant protein B participates in the lowering of surface tension of a phospholipid 
mixture. It is also co-extracted with surfactant lipids in a chloroform-methanol 
extraction. In order to investigate whether the reduction in SPB seen in whole BAL 
fluid affected surface tension of the lipid extract o f BAL in this study, regression 
analysis was performed. No significant correlation was found between SPB 
concentration in a sample (expressed per ml o f BAL fluid and per pg o f phospholipid) 
and minimum or maximum surface tensions achieved by a lipid extract of that sample.
In conclusion, several changes in the composition of the hydrophobic fraction of BAL 
fluid were found in this study. There were minor alterations in phospholipid class and 
phospholipid fatty acid proportions, lysophosphatidylcholine and glycolipids were 
increased and SPB was reduced. Any o f these changes could, in theory, adversely 
affect the surface activity of a lipid extract of surfactant. This study provides no
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evidence of a detrimental effect o f any o f these changes on surfactant function. 
However, the concentration of BAL lipid extract used in surfactometer studies was at 
the low end of the range used in other studies, and therefore this conclusion should be 
interpreted with caution.
12.1.3. INHIBITION OF SURFACTANT BY PROTEINS
The concentration of total protein found in BAL fluid was increased in children with 
severe RSV infection. A similar picture occurs in ARDS, and lavage protein has been 
shown to correlate positively with the percentage of neutrophils in BAL fluid (Weiland 
et al. 1986). Neutrophils release free radicals in the inflammatory response, and are 
present in large numbers in BAL fluid from ventilated infants with RSV infection 
(Everard et al. 1994). It is likely that the integrity o f the alveolar and pulmonary 
capillary endothelium is breached by free radical damage, and that proteins leak from 
the plasma into the alveolus in both ARDS and RSV.
The increase in fibrin degradation products found in this study is consistent with the 
fibrinous exudate seen in histological sections of the lung in severe RSV infection. 
Fibrinogen was not detected in the small numbers of exploratory samples from infants 
with RSV studied, therefore it was decided not to pursue this line of investigation 
further. It is possible, though unlikely that substantial amounts o f fibrinogen were 
present in some but not others o f the samples from children with RSV. It is more likely 
that fibrinogen in the inflammatory exudate was converted into the insoluble fibrin 
which was then deposited in the aveolus, and subsequently degraded by proteolytic 
enzymes. Jacobson and colleagues (1993) found fibrin/fibrinogen in BAL fluid from
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patients with ARDS, and there can be little doubt that the fibrin/fibrinogen/FDP system 
is active in lung inflammation.
The finding of FDP in BAL fluid has implications for surfactactant inhibition, as fibrin 
degradation products are known to be potent inhibitors of surfactant function, 
however, the effect o f FDP is difficult to separate from other proteins which might be 
causing surfactant inhibition. The minimum and maximum surface tensions of Suiwanta 
produced when Img/ml o f BAL protein was mixed with the lipid did not correlate with 
levels o f FDP/mg protein. A so  albumin, another known inhibitor of surfactant activity 
was not elevated in the RSV group, and CRP, which has been shown to inhibit 
surfactant in ARDS (Li et al. 1989) was not detectable in any of the samples in this 
study. Therefore, it seems that some other proteinaceous surfactant inhibitor is at work 
in severe RSV infection.
Immunoglobulins, haemoglobin, elastin and fibrin monomer were not measured in this 
study, and all these substances are known surfactant inhibitors. Additionally, viral 
proteins were not quantified, and, although no work has been done in this area, it is 
possible that they may have surfactant inhibitory properties. Quantification of these 
other potential inhibitors in BAL in RSV infection would provide a clearer picture.
The BAL proteins tested for inhibitory capacity in this study were derived fi*om a 
40,000 X g supernatant of lavage fluid. This centrifugation procedure would have 
removed most SPA and SPB. However, some SPD may have been present in the 
supernatant. Both surfactant proteins A and B protect surfactant from inhibition by 
plasma proteins but it is not known whether SPD has a similar role. Theoretically, if
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SPD did act to protect surfactant phospholipids from inhibition, and there was less of 
this protein in the supernatant from patients with RSV infection, the increased 
inhibitory capacity of total protein found in these samples could have been partly due 
to this reduced protection.
The reduction in SPB found in this study was still present when concentations of these 
surfactant proteins were expressed per mg o f phospholipid. However SPA/pg 
phospholipid was not reduced in the RSV group compared to control. This suggests 
that in vivo, there would be less protection from SPB available to surfactant 
phospholipids against protein inhibition in severe RSV infection. However, as the full 
spectrum of potentially inhibitory proteins has not been studied in this condition, it is 
not possible to say whether the reduction in SPB exacerbates the problem or not. It is 
known that SPB offsets the inhibition o f lipid mixtures by fibrinogen. However, it is 
not known whether this is also the case with PDFs. Surfactometer studies o f FDP's 
and other plasma proteins, lipid mixtures and surfactant proteins would shed more light 
on this issue.
Finally, LPC was found in increased numbers o f infants with severe RSV infection. The 
presence of lysophosphatidylcholine produced by phospholipase digestion o f 
phospholipids in lipid extract surfactant has been shown to sensitize this extract to 
inhibition by fibrinogen (Cockshutt and Possmayer, 1991). Perhaps LPC also increases 
the sensitivity of surfactant phospholipids in RSV infection to inhibition by FDPs and 
plasma proteins which enter the alveolus during the inflammatory response.
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12.2. SURFACTANT AND THE ALVEOLAR IMMUNE 
RESPONSE
Surfactant proteins A and D were found to be significantly reduced in patients with 
RSV infection. Surfactant proteins A and D are known to participate in local 
inflammatory mechanisms in the lung, and it is possible that these proteins opsonise 
RSV, and are subsequently phagocytosed in the inflammatory response to the virus. If 
this happens the concentration of SPA and SPD in the alveolus would be reduced.
A reduction in SPA or SPD during pulmonary infection could have several important 
consequences for the local immunological defenses in the lung. Both have been shown 
to bind to microorganisms and alveolar macrophages, enhancing the cytotoxic 
properties o f these phagocytic cells (Hartshorn et al. 1994; Malhotra et al. 1994; Van 
Iwaarden et al. 1991; Anonymous1995; van Iwaarden et al. 1990; Van Golde, 1995). 
Additionally, SPA enhances phagocytosis by alveolar macrophages. This prompts us to 
ask : does RSV infection increase phagocytosis of surfactant proteins and 
microorganisms, which, in turn reduces the stimulation of alveolar macrophages to 
phagocytose and kill the infective agent, leading to a downward spiral o f worsening 
infection? This is not likely to be the full picture, as severe RSV infection is not usually 
fatal, and spontaneous recovery occurs if the infant is supported through the most 
difficult days of the disease.
In vitro studies of the binding of surfactant proteins to the virus, and the effect of the 
virus on phagocytosis o f these proteins would be useful as a preliminary attempt to 
elucidate the fate of SPA and SPD in RSV infection, As well as phagocytosis, it is 
possible that viral invasion of type II pneumocytes or damage to these cells by
240
peroxynitrite could reduce SPA synthesis in this disease. In animal models, an elevated 
inspired oxygen concentration increases the amount o f SPA produced in the lung 
(Nogee et al. 1991). Patients in the RSV group were subjected to over 50% inspired 
oxygen throughout most of the period of ventilation (Figure 33) and it may be that the 
reductions seen in SPA would have been more dramatic had this not been the case.
12.3. MARKERS OF FREE RADICAL ACTIVITY
The finding that nitrotyrosine is elevated in RSV infection is consistent with previous 
immunohistochemical studies o f ARDS and pneumonia (Haddad et al. 1994; Royall et 
al. 1995). The presence of nitrotyrosine in all these conditions suggests increased 
peroxynitrite activity, as a result of invasion by neutrophils and macrophages.
The reactivity o f peroxynitrite is affected by pH. At low pH, formation of the reactive 
trans peroxynitrite anion is favoured. In lung disease, the alveolar environment may be 
more acidic due to retention o f C 02 behind partially occluded airways. The level of 
C 02 present in the alveolus is indicated by arterial C02 (Riley and Cournand, 1949). 
The median arterial C02 level was higher in the RSV group (48.1 - range 14.6-144.0 
mmHg) than in the post-operative patients in the control group (30.6 - range 18.3-57.1 
mmHg) (p<0.0001 Mann Whitney), leading to a lower median alveolar pH in the RSV 
group, which may have favoured peroxynitrite damage. However, when linear 
regression analysis was performed, no correlation was found between arterial C 02 and 
nitrotyrosine level.
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Haddad and colleagues (1993) showed nitration of tyrosine residues in SPA to occur 
as a result o f in vitro exposure to peroxynitrite. The findings of this study provide no 
evidence of damage specifically to SPA, but this might be inferred from the increased 
nitrotyrosine per mg o f total protein. The functional consequences o f this structural 
alteration have not been fully characterised. However, SPA exposed to peroxynitrite 
has been shown to have a reduced ability to cause lipid aggregation (Haddad et al. 
1993), and tyrosine nitration is known to adversely affect the function of IgG (McCall 
and Easterbrook-Smith, 1989) and cytochrome P-450 (Janing et al. 1987). This 
prompts speculation that the functional properties o f SPA may be compromised in 
RSV infection. Perhaps the stimulatory effects on alveolar macrophages are lost, 
reducing the cytotoxic activity and phagocytic ability of these cells during infection. 
Surfactant protein A might then no longer offer protection to surfactant phospholipids 
from the inhibitory effects of plasma proteins which flood into the alveolus in the 
inflammatory response. Surfactometer studies and in vitro studies of macrophage 
activity in the presence of peroxynitrite-exposed SPA would provide useful 
information in clarifying the functional effects of tyrosine nitration on SPA.
Three potential reasons for the reduced amount o f MDA seen in RSV infection have 
been discussed earlier : reduced substrate, increased scavenging and the effects of 
surgery in the control group. The results of this study provide no evidence for a 
reduction in substrate as a causal factor, although this cannot be ruled out, as some 
substrates for MDA formation eg. prostaglandins and free fatty acids were not studied. 
A so  it is impossible to tell whether the concentrations of fatty acids measured in RSV 
and control groups were affected by lipid peroxidation. The effects of surgery on MDA 
level do not appear to be significant, although the number of patients in the control
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group who had and had not been operated upon were relatively small. A larger study 
might show some effect of surgical tissue damage on BAL MDA, although it is 
difficult to imagine under what circumstances such a study would be performed. 
Probably the most likely explanation for the reduced concentration of MDA seen in 
BAL from patients with RSV is increased scavenging of oxidants by plasma proteins or 
surfactant proteins. Support is lent to the importance of this last mechanism by the 
finding of increased nitrotyrosine and increased total protein in BAL fluid fr om patients 
with RSV infection.
A fourth potential reason for the reduction in MDA in ptients with RSV infection is 
also suggested by the presence of nitrotyrosine in this group. It is interesting to note 
that the presence of nitric oxide, depending on its concentration, can either stimulate or 
inhibit lipid peroxidation in phosphatidylcholine liposomes in vitro (Rubbo et al. 1994). 
Increased nitric oxide production in children with RSV infection is inferred by the 
presence of increased nitrotyrosine in BAL. Nitric oxide may actually act in a defensive 
manner in patients with RSV, offering a potential explanation for the reduced amounts 
of MDA- However, it is not possible to go beyond speculation in this matter, as nitric 
oxide levels could not be directly measured.
12.4. SURFACTANT AND THE CLINICAL PICTURE
12.4.L ARTERIAL ALVEOLAR OXYGEN RATIO AND SURFACTANT 
LEVELS
The arterial arteriolar (a-A) oxygen ratio was used as an index of clinical condition in 
this study, and as such provided a relatively non invasive measurement of shunt
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fraction. It would have been preferable to have measured pulmonary function tests in 
addition to a-A ratio and to have combined these measurements to produce an index of 
disease progress which encompassed lung mechanics and gas exchange.
In this study no correlation was found between a-A ratio and parameters measured in 
BAL fluid. From a review of the literature it appears that alterations in the pulmonary 
surfactant system are not reflected by indices o f oxygenation alone. In a study of adults 
recieving artificial surfactant after cardiopulmonary bypass, Macnaughton and 
colleagues (1994) found that A-a gradient, FRC and respiratory system compliance 
were not affected by administration o f exogenous surfactant, however T lco was 
improved. Pison and colleagues studied surfactant phospholipid classes in patients with 
ARDS secondary to multiple trauma, and found that the proportion of PC was 
inversely correlated with the respiratory failure score. This score was found by the 
following formula: 0.108 + (chest radiographic score x 0.1512) + (oxygenation index x 
0.6208) 4- (mean PAP x 0.00725) - (respiratory system compliance x 0.00416), a 
complex score composed o f radiographic, oxygenation, ventilatory and lung 
mechanical measurements. Survival or severity of trauma did not correlate with any 
surfactant data (Pison et al. 1989; Pison et al. 1990). In another study, reduction of PG 
showed little relation to the time of sampling during ARDS (Spragg and Hallman, 
1983).
A so, in patients with idiopathic pulmonary fibrosis, phospholipid content in BAL was 
correlated with improvement in %FVC but arterial alveolar oxygen difference was not 
coiTelated with phospholipid content o f BAL or with PG/PI ratio (Robinson et al. 
1988). In study of neonates with RDS the percentage of tracheal wash palmitate rose
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in concert with a clinical grading score which reflected the amount of ventilatory 
support required (Balint et al. 1978). In another study, infants given dexamethasone, 
logPC concentration in epithelial lining fluid was correlated with the degree of 
respiratory failure as measured by mean airway pressure x Fi02. However, among 
placebo treated infants, the association was not significant (Kari et al. 1995).
These studies suggest that measurement of arterial alveolar oxygen ratio alone, or, 
indeed pulmonary function tests alone provides a very inaccurate indication of the 
totality of clinical progress with relevance to changes in the pulmonary surfactant 
system.
12.4.2. SURFACTANT AND DISEASE PROGRESS IN RSV INFECTION
It can be seen from the results in this study that, surfactant function did not recover in 
all patients with RSV by the time ventilation was discontinued (Figure 14). Nor, with 
the exception of surfactant protein A, did surfactant components change in a consistent 
pattern between the first and last days of ventilation. Equally, the pattern seen in 
indices of surfactant damage or inhibition was highly variable from day to day. These 
findings prompt the question - if respiratory failure in RSV infection is due to 
surfactant dysfunction, why did that dysfunction and the factors contributing to it not 
resolve by the last day of ventilation?
There are several possible answers, all o f which underline the complex nature of the 
disease. When ventilation is discontinued in RSV infection, the effects of the virus are 
still present, and the child often requires respiratory support eg. continuous positive
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airways pressure or oxygen via nasal cannulae after extubation, so recovery is by no 
means immediate or complete at extubation. Some indication of this is given by the fact 
that 13 out of the 18 patients with RSV infection were still being ventilated with 50% 
or more oxygen on the day when the last sample was taken before coming off 
ventilation. It may be that children with resolving infection still have a surfactant 
dysfunction, however, this cannot be easily studied as BAL fluid is only available in the 
ventilated group.
Several types of RSV are known to cause respiratory failure, and the variable pattern 
of change seen in surfactant components in this study may be due to interactions with 
RSV which are specific to viral type. It is impossible to go beyond speculation in this 
matter, as, at present, viral typing is not performed routinely in children hospitalised 
with RSV.
Surfactant protein A levels were shown to increase between the first and last days of 
ventilation in 12 out o f 16 children with RSV who were ventilated for more than one 
day. As discussed, SPA reduces inhibition of surfactant by proteins, and it may be that 
the presence of this protein is important for disease resolution.
It is likely that factors other than surfactant function, such as regeneration of the 
alveolar epithelium and clearance of mucus, contribute to the improvement in gas 
exchange which eventually allows the ventilated child with RSV to be extubated. This 
emphasises the conclusion that although surfactant abnormalities may contribute to the 
respiratory failure seen in severe RSV infection, they should be viewed in the context 
of the disease as a whole.
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12.5. IMPLICATIONS FOR CLINICAL PRACTICE
12.5.1. SURFACTANT THERAPY IN VENTILATED CHILDREN WITH RSV 
INFECTION
This study provides evidence that surfactant funtion is abnormal, that surfactant 
phospholipids and proteins are deficient and that surfactant inhibition is likely to be a 
part of the pathological picture in severe RSV infection. It backs up previous evidence 
fi-om Dargaville's (1996) and Skelton's (1996) studies of surfactant deficiency and 
dysfirntion in viral bronchiolitis. A so, two recent case reports point to an improvement 
in clinical condition following intratracheal instillation of surfactant in ventilated 
children with severe RSV infection (Vos et al. 1996). As discussed earlier, there is no 
satisfactory animal model for severe RSV infection, therefore surfactant replacement 
studies in animals with RSV would not be useful. In light o f the evidence provided by 
the present study and other studies, it must be considered whether the next step is to 
replace surfactant in ventilated patients with RSV infection.
As described in the introduction to this thesis, surfactant replacement in ARDS, a 
condition with many similarities to severe RSV infection, has met with limited success. 
When considering the viability o f surfactant replacement in RSV, several factors 
should be taken into account. These are the method of delivery, the type of surfactant 
used, cost effectiveness, and other potential therapies for RSV infection in the 
intensive care unit.
Exogenous surfactant can be delivered to the lungs either by nébulisation or by 
intratracheal instillation. Nebulised surfactant is preferentially distributed to normally
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ventilated parts o f the lung (Macnaughton and Evans, 1994), and therefore may not 
reach the most severely affected alveolar units which are collapsed or lie behind 
narrowed airways in RSV infection. This is also true to a lesser extent of surfactant 
delivered by intratracheal instillation. However, Enhoming's work on surfactant 
function in the small airways (1995; 1991) suggests that surfactant might, in fact, 
improve airway narrowing in RSV, and lead to not only better small airway function 
and consequently improved gas exchange, but also better delivery of exogenous 
surfactant to the alveoli.
It is interesting to note that in a study o f rabbits injured with NNMU (Lewis et al.
1991) supplementation with nebulised surfactant produced a modest physiological 
improvement, whereas intratracheal surfactant was not beneficial. In this study, only 
3.6 ± 0.5% of the amount o f nebulised surfactant was recovered from the lung. In 
contrast, a trial of nebulised Exosurf produced no significant clinical improvement in 
patients with ARDS (Anzueto et al. 1996). However, another pilot study of 
intratracheally delivered natural surfactant produced a reduction in mortality from 
ARDS (Gregory et al. 1997). It is not possible to separate the influence of mode of 
delivery from the type of surfactant used in these two studies of ARDS. Natural 
surfactant has certain advantages over Exosurf which are considered below.
Natural surfactants (eg, Curosurf, Infasurf, Survanta) are manufactured by retrieval of 
surfactant from the lungs of slaughtered animals (pigs or cows) by bronchoalveolar 
lavage. An organic extraction is then performed on this fluid to obtain the clinical 
preparation. This results in this type o f exogenous surfactant conatining all surfactant 
lipids and SPB and SPC. Exosurf, on the other hand, contains only phosphatidylcholine
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solubilised in alcohol. As plasma proteins are present in the alveolus in ARDS, and 
SPB and SPC have been shown to protect surfactant phospholipids from inhibition by 
these proteins, it would seem that a natural surfactant replacement would be a more 
logical choice in this condition. The same arguement applies in RSV infection, where 
inhibition of surfactant by BAL proteins has been demonstrated in vitro. Additionally, 
SPB deficiency was found in this study. If surfactant were to be replaced 
therapeutically in RSV, it would be sensible to choose a surfactant known to contain 
hydrophobic surfactant proteins.
A so, calf lung surfactant extract (a natural surfactant) has been shown to reduce the 
increased alveolar permeability resulting from hyperoxia (Engstrom et al. 1989), and 
the increased protein in BAL fluid from patients with RSV would suggest that alveolar 
permeability is increased in this condition, and that exogenous natural surfactant might 
be helpful in stopping the leak.
In an ideal world, a surfactant containing phospholipid and proteins A, B and C would 
be the perfect replacement mixture to use in RSV infection or in ARDS. Surfactant 
protein A would be an especially desirable component, as not only does it offer some 
protection against free radical damage to lipid components of surfactant, but also, it 
offsets the inhibitory effects of fibrinogen (Cockshutt et al. 1989). Natural surfactant 
replacements containing surfactant protein A are, unfortunately, not commercially 
available due to purification difficulties. Synthetic analogues o f SPB have been 
produced by genetic engineering in E.coli, however, SPA has more post translational 
modifications and is not suited to production in this way (Benson, 1993).
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12.5.2. SURFACTANT THERAPY IN SPONTANEOUSLY BREATHING 
CHILDREN WITH RSV INFECTION
Surfactant abnormalities may be present in children with resolving RSV infection who
are no longer ventilated or in children with milder disease who have breathing
difficulties but are not ventilated. In this situation, the pathological features of the
disease are likely to be confined to the small airways, where surfactant supplementation
2 5 0
Exogenous surfactant therapy is expensive, but so is a day's stay in the intensive care 
unit. If  administration of surfactant could be shown to shorten the intensive care time 
or offer benefits to the patient's long term wellbeing, it would be accepted as part of 
the inpatient treatment o f severe RSV infection. However, if giving surfactant 
produced only transient clinical improvement, then it could not be considered an 
economically viable treatment.
It is possible that other advances in care o f patients with RSV infection might 
supersede the need for surfactant, even it it does prove to have success in the clinical 
situation. Improved hygiene has reduced nosocomial spread of the virus (Madge et al.
1992) and immunoglobulin therapy has been shown to prevent infection in high risk 
infants (Everard 1995).
In summary, the evidence from this study supports the theory that surfactant is 
dysfonctional and deficient in severe RSV infection. Also case reports have shown a 
clinical improvement after surfactant therapy in this condition. However, there are 
several caveats which must be taken into account when designing a pilot study of the 
efficacy of surfactant replacement in clinical practice.
could theoretically improve luminal patency (Liu et al. 1991; Enhoming et al. 1995; 
Yager et al. 1989). In these patients, the problem of a putative surfactant phospholipid 
deficiency could be addressed by therapy with surfactant in a powder form. To date, 
the only artificial surfactant available in this form is ALEC, and this has the advantage 
of relatively low cost and easy administration to patients who are not intubated and 
ventilated.
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13. CONCLUSIONS
The main conclusions o f this study are summarised in Figure 34.
13.1. SURFACE ACTIVITY OF SURFACTANT
Surfactant is dysfunctional in whole BAL fluid from patients with severe RSV 
infection. The factors involved in producing this dysfunction are complex.
Surfactant function in a lipid extract o f BAL from children with severe RSV infection 
was not different from control, however, the low concentration of phospholipids used 
in this study may have masked differences between the groups.
13.2. DEFICIENCY AND ABNORMAL COMPOSITION 
OF SURFACTANT
In ventilated children with severe RSV infection, there are deficiencies of surfactant 
proteins A, B and D, and o f surfactant phospholipids. It is likely that the surface 
tension-lowering and immunological frinctions of surfactant, and the protection offered 
against surfactant inhibition by plasma proteins are compromised in RSV infection by 
these deficiencies.
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Surfactant fatty acid composition is altered in RSV infection, in a pattern similar to 
that seen in ARDS. This is likely to be due to contamination of BAL fluid by 
membrane fragments.
13.4.INHIBITION OF SURFACTANT
Increased amounts of protein and fibrin degradation products are present in BAL fluid 
from ventilated children with severe RSV infection. Plasma proteins and PDFs are 
potent inhibitors of surfactant, and the conclusion that surfactant inhibition is present in 
severe RSV infection is supported by the finding that BAL proteins from children with 
RSV have a strong inhibitory effect on bovine surfactant.
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13.3. DAMAGE TO SURFACTANT COMPONENTS
There is evidence of alveolar protein damage by the peroxynitrite free radical in severe 
RSV infection. However, lipid peroxidation by free radicals is minimal. It is possible 
that the presence of proteins or other free radical scavengers in the alveolus offset 
damage to surfactant lipids by reactive molecules released in the inflammatoiy 
response.
Evidence for damage to phosphatidylcholine and pulmonary cells in severe RSV 
infection is present in the form of increased lysophosphatidylcholine and glycolipids in
BAL fluid.
I
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Figure 34. Surfactant abnormalities in severe RSV infection
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15. APPENDICES
APPENDIX 1. CONSENT AND INFORMATION FORMS
INFORMED CONSENT FOR PARTICIPATION IN A STUDY OF THE 
EFFECTS OF VIRAL PNEUMONIA ON SURFACTANT 
An investigation of the pulmonary surfactant system in infants with viral 
pneumonia
We are studying how viruses affect the lungs of small children. To do this we want to 
look at samples of a natural chemical, surfactant, that stabilises the lungs and prevents 
the small air spaces from collapsing when someone breathes out.
To study surfactant in the lungs, we need to pass a fine suction tube into the small 
airways (via the breathing tube). The tiny samples which we get in this way will be 
taken to the laboratory and measured. The amount we remove is so small that it does 
not affect the working of the lungs. Usually, we will combine the collecting of samples 
with the suction that the nurses need to do to keep your child’s airway free of 
secretions.
This technique has been tried and tested, and your child will be closely monitored all 
the time. If our study shows that sufractant is lacking in the lungs o f children with 
pneumonia, this would pave the way for a trial o f giving artificial surfactants such as 
are used in very small babies. This could help other children in the future recover more 
quickly from their pneumonia.
Confidentiality
The medical history, the results of treatment, laboratory results and X rays may be 
published for scientific purposes, but neither your child’s nor your identity will be 
disclosed, and confidentiality will be maintained at all times. You are free to withdraw 
from this project at any time without any penalty, and treatment will otherwise be the 
same as that given to other children with pneumonia.
I,____________________________(Parent/Guardian) agree that my child may
participate in the study as detailed above. I understand that I may withdraw consent at 
any time.
Signed________________________ (Parent)
_________________(Investigator)
________________________ (Witness)  (Date)
2 7 5
INFORMED CONSENT FOR PARTICIPATION IN A STUDY OF 
SURFACTANT IN NORM AL INTUBATED CHILDREN
An investigation of the pulm onaiy surfactant system in normal intubated 
children
We want to look at samples o f the natural chemical, surfactant, that stabilises the lungs 
and prevents the small air spaces from collapsing when someone breathes out. Very 
little is known about this chemical in children with healthy lungs.
In operations such as the one your child is having, the anaesthetist always puts a 
breathing tube into the mouth. This tube goes down into the windpipe and helps your 
child breathe more easily while they are anaesthetised. The fact that this tube is already 
there makes it easy for us to take small samples of natural chemicals from the lungs.
To study surfactant in the lungs, we need to pass a fine suction tube into the small 
airways (via the breathing tube). The tiny samples which we get in this way will be 
taken to the laboratory and measured. The amount we remove is so small that it does 
not affect the working of the lungs. Usually, we will combine the collecting of samples 
with the suction that the nurses need to do to keep your child’s airway free of 
secretions.
This technique has been tried and tested, and your child will be closely monitored all 
the time. Looking at surfactant in children with healthy lungs will help give us clues as 
to how surfactant works. It will also help us to understand what happens when it goes 
wrong, eg. in the lungs of children with lung disease.
Confidentiality
The medical history, the results of treatment, laboratory results and X rays may be 
published for scientific purposes, but neither your child’s nor your identity will be 
disclosed, and confidentiality will be maintained at all times. You are free to withdraw 
from this project at any time without any penalty.
I,____________________________(Parent/Guardian) agree that my child may
participate in the study as detailed above. I understand that I may withdraw consent at 
any time.
Signed________________________ (Parent)
_________________ (Investigator)
________________________ (Witness)  (Date)
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APPENDIX 2. CLINICAL DATA FORM
Name
D.O.B.
Diagnosis
Hosp.no.
DATE
Sample no.
Fi02
Sa02
Bar. press.
H20 press.
Pa02
PaC02
R
PA 02
Pa/PA 0 2
Drugs
Comments
2 7 7
APPENDIX 3. CALCULATION OF IDEAL ALVEOLAR 
GAS
The concept of “ideal alveolar” gas was first introduced in 1949 by Riley and 
Coumand . In a patient with lung disease, samples of expired gas give a very poor 
estimate of the composition of alveolar gas, due to the asynchronous emptying of 
alveoli with different time constants and different oxygen concentrations. Calculation 
of ideal alveolar gas circumvents this problem. The alveolar air equation allows 
estimation of an alveolar oxygen tension for the lung as a whole. The alveolar air 
equation can be derived with respiratory quotient (R) as a starting point.
Where
V= volume of gas per unit time
P = partial pressure of gas
F = fractional concentration of gas
R = respiratory quotient
Pm= barometric pressure
Ph20 ~ partial pressure of water vapour, assumed to be 47mmHg
A = alveolar
2 7 8
i = inspired
e = expired
O2 = oxygen CO2 = carbon dioxide = nitrogen
j^^VCOlV02 (1)
VC02 ~ VeA X FaCOI
V02 = {ViA X FiOl) — (VeA X FaOI)
therefore, equation 1 becomes: R VeA x  F a c o i(Vu X F02) — (VeA X FaOi)
K c o 2 ( 2 )
( ^ x F i O l ) - F a O 2
As the amount o f nitrogen in inspired and expired gas is the same.
N2e A A VeA(\-FA02-FAC02) = 1 therefore, assuming that inspired 0,  = 1
V iA FaOI—FaCO.VeA 1 — Fi02
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Equation 2 may now be rewritten as; R = ^   T—
This allows Fao2 to be determined.
F m , =  E o 2- + F a c o2 x F io, x  T J :R R
This equation can be simplified further to
F a o 2 =  F iO l — F a c o  ï ( F iO i  +  —
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APPENDIX 4, BUFFERS
Where buffers are prepared as concentrated solutions, the proportions given below 
represent the final composition after dilution with deionised water. Liquid additives are 
given as volume/volume percentages. Preservatives are given as weight:volume 
percentages,
82b
sodium chloride 150mM 
Tris pH 7.4 lOmM 
bovine serum albumin 5 mg/ml
(Prepared as a 5 X solution, stored at -20°C and diluted before use)
PBS (phosphate buffered saline)
sodium chloride 137mM
potassium chloride 2.7mM
phosphate (as disodium hydrogen phosphate
and potassium dihydrogen phosphate) lOmM
pH 7.4
(prepared by dissolution of PBS tablets - Sigma Chemical Co)
FBS/NP-40
non ionic detergent NP-40 0.5% (v:v) 
in PBS
Phosphate buffer for MDA assay
sodium hydrogen phosphate 25mM 
pH 6.5
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SPA/SPB dilution buffer
0.05% Tween 20 
in PBS 
p H  7 . 4
SPA/SPB substrate buffer
sodium hydrogen phosphate 65mM 
citric acid 17mM 
merthiolate 0.001% 
pH 6.3
(Prepared as a 10 X solution and diluted before use)
SPA/SPB wash buffer
Tween 20 0.05%
Tris lOmM 
merthiolate 0.001% 
pH 8
(prepared as a 50 X solution and diluted before use)
SPD coating buffer
sodium carbonate 35mM 
sodium bicarbonate 15mM 
sodium azide 0.05% 
pH 9.6
SPD developing buffer
Tris lOOmM
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sodium chloride lOOmM
magnesium chloride hexahydrate 5mM
adjusted to pH 9.6 with IM hydrochloric acid
SPD wash buffer
Tris 20mM
sodium chloride 130mM 
Tween 20 0.05% 
calcium chloride 1 mM 
sodium azide 0.05%
adjusted to pH 7.4 with IM hydrochloric acid
Suspension buffer
sodium chloride ISOmM 
calcium chloride 1.5mM
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APPENDIX 5. ABBREVIATIONS
ARDS acute respiratory distress syndrome
BAL bronchoaiveolar lavage
BSA bovine serum albumin
CBS captive bubble surfactometer
CLSE calf lung surfactant extract
DPPC dipalmitoylphosphatidylcholine
DSPC disaturated phosphatidylcholine
ELISA enzyme linked immunosorbent assay
GC gas chromatography
GLC gas liquid chiomatography
HIV human immunodeficiency virus
HPLC high performance liquid chromatography
HPTLC high performance thin layer chromatography
HRP horseradish peroxidase
IV intravenous
LA large aggregates
LPC lysophosphatidylcholine
MDA malondialdehyde
NKNMU n-nitroso n-methylurethane
P partial pressure
PBS pulsating bubble surfactometer. Phosphate buffered saline
PC phosphatidylcholine
PCP pneumocystis carinii pneumonia
PE phosphatidylethanolamine
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PG phosphatidylglycerol
PI phosphatidylinositol
POPC palmitoyloleoylphosphatidylcholine
PS phosphatidylserine
RDS respiratory distress syndrome
RSV respiratory syncytial virus
S sphgingomyeiin
SA small aggregates
SPA surfactant protein A
SPB surfactant protein B
SPC surfactant protein C
SPD surfactant protein D
TLC thin layer chromatography
